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Abstract 
Atypical haemolytic uraemic syndrome (aHUS) is a life threatening renal disease, 
caused by deregulation of the alternative complement pathway. Several genes 
within this pathway are associated with aHUS. At the outset of this project, the 
genetic cause had been identified in 45% of familial cases in the Newcastle aHUS 
cohort. The aim of this project was to identify the genetic cause of disease in the 
remaining 55%. 
Complement Factor H (CFH) and Complement Factor H-related (CFHRs) are found 
on chromosome 1. This area contains several low copy repeats, the result of 
genomic duplications that occurred early in evolution. This causes genomic 
instability, which can lead to gene conversions or rearrangements. Sanger 
sequencing will not always detect these abnormalities, therefore patients were also 
screened using multiplex ligation-dependent probe amplification and western 
blotting. 
A novel hybrid CFH/CFHR3 gene was described, which arose by microhomology-
mediated end joining. Functional analysis demonstrated that it was defective at 
regulating complement at the cell surface, which was predicted to predispose this 
patient to disease. Review of all patients in the Newcastle aHUS cohort with CFH 
abnormalities, identified a third of patients had a genomic rearrangement between 
CFH and CFHRs. The relative frequency of genomic rearrangements emphasised 
the importance of undertaking copy number analysis in aHUS diagnostic testing, 
because often they are not detected by Sanger sequencing. 
Whole exome sequencing was then undertaken in Newcastle familial cohort with an 
unknown genetic aetiology. Pathogenic sequence variants were identified in genes, 
known to be associated with thrombotic microangiopathies. Sequence variants that 
were predicted to be pathogenic, were found in three genes not previously 
associated with disease. Two of these genes were located outside of the 
complement system, indicating that complement-directed therapies may be 
contraindicated. In this project, a genetic cause of disease was found in 54% of 
familial cases tested. 
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Chapter 1: Introduction 
1.1. Haemolytic uraemic syndrome 
Haemolytic uraemic syndrome (HUS) is a thrombotic microangiopathy (TMA) that is 
characterised by the occurrence of microangiopathic haemolytic anaemia (MAHA), 
thrombocytopenia and acute renal failure in patients (Siegler and Oakes, 2005, 
Kavanagh and Goodship, 2010, Fremeaux-Bacchi et al., 2008, Boyer and Niaudet, 
2011). MAHA refers to the lysis of erythrocytes, which occurs as a result of increased 
shear stress in diseased blood vessels (Barbour et al., 2012). Thrombocytopenia 
describes the decrease in the amount of platelets found in the blood due to their 
sequestration within blood clots. In this condition the kidney is unable to filter the blood 
efficiently, as a result of the thrombi in the microvasculature and consequently, there is 
ischaemia and reduced kidney function (Coppo and Veyradier, 2009). There are two 
subtypes of HUS, the typical and atypical form. 
1.1.1. Typical HUS 
Typical HUS or Shiga toxin Escherichia coli (STEC) HUS is caused by the presence of 
Shiga toxin (Stx)- producing bacteria (Kavanagh et al., 2014). It is the most commonly 
occurring form of HUS, comprising of approximately 90% of cases (Boyer and Niaudet, 
2011). It occurs at a frequency of approximately 2 to 3 per 100,000 in the population, 
most frequently in young children (Tarr et al., 2005). One commonly HUS-associated 
serotype of STEC is the O157:H7 strain (Tarr et al., 2005), although there are other 
Shiga toxin-producing bacteria that can cause HUS such as Shigella dysenteriae 
serotype 1 (Koster et al., 1978). Patients with STEC HUS often present with bloody 
diarrhoea (Barbour et al., 2012).  
1.1.2. Atypical HUS 
Atypical or non-diarrhoeal HUS (aHUS) is a rare form of HUS, found in the remaining 
10% of cases. aHUS occurs at a frequency of approximately 7 per million in children 
and 2 per million in adults (Taylor et al., 2010). This subtype of HUS is defined by the 
absence of STEC in patient stool samples (Scully and Goodship, 2014). It is a severe 
disease with 70% of patients developing End Stage Renal Failure (ESRF) and a 10-15% 
mortality rate (NICE, 2015). 
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A patient with aHUS has a reduced ability to filter waste from the blood due to 
pathology in glomerulus (Kavanagh et al., 2013). The glomerulus is a dense network of 
capillaries that form part of the nephron, the filtering unit of the kidney (Pollak et al., 
2014). There are approximately 1 million nephrons per kidney (Bertram et al., 2011). In 
aHUS the glomerular capillaries become occluded causing a loss of kidney function 
(Pollak et al., 2014). This is the result of narrowing of the glomerular capillaries, as a 
result of endotheliosis (endothelial cell swelling), deposition of material between the 
endothelium and glomerular basement membrane (GBM) and the formation of fibrin 
and platelet-rich thrombi (Kavanagh and Goodship, 2010). Figure 1-1 demonstrates the 
occlusion of the glomerular capillaries in a histological section of a glomerulus from a 
patient with aHUS.  
 
Figure 1-1 Histological sections of glomeruli. 
 Showing normal histology (Kamar et al., 2008) (left) and  aHUS histology (McMahon, 2011) 
(right). 
It has now been well documented that loss of complement regulation and thus 
uncontrolled alternative pathway (AP) activation is the initiating event that leads to 
aHUS (Meri, 2013). This includes the occurrence of activating and inactivating 
mutations in genes that encode proteins found within the complement pathway 
(Kavanagh et al., 2013, Fremeaux-Bacchi et al., 2013, Maga et al., 2010, Noris et al., 
2010). The inheritance pattern of aHUS has been previously reported to be both 
recessive (Thompson and Winterborn, 1981) and dominant (Roodhooft et al., 1990). 
1.1.3. Diagnosis 
HUS is diagnosed by the findings of MAHA, thrombocytopenia and acute renal failure, 
shown in Table 1.  
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Test HUS 
Haemoglobin (Hb) Reduced 
Platelet count Reduced 
Haptoglobin Reduced 
Blood smear Schistocytes  
Coombs test Negative* 
Serum creatinine Elevated 
Lactate dehydrogenase (LDH) Elevated 
 
Table 1 Diagnostic tests for HUS. 
‘*’ Pneumococcal HUS positive. 
Originally aHUS was used to classify any HUS in the absence of Stx-producing bacteria 
(Kavanagh et al., 2013). Primary aHUS had been used to refer to cases with 
complement deregulation caused by complement gene mutations and secondary aHUS 
was used to describe the development of aHUS after a trigger event (Besbas et al., 
2006), shown in Table 2. However this failed to account for the fact that often, patients 
with an underlying complement mutation will still often require a secondary trigger for 
the disease to manifest. Classifications that consider the genetic and environmental 
causes of disease are now being introduced (Besbas et al., 2006). 
Event Reference 
Infections Cochran et al. (2004), Constantinescu et al. 
(2004) 
Drugs Al-Nouri et al. (2015), Eremina et al. (2008), 
Zarifian et al. (1999) 
Autoimmune conditions El-Husseini et al. (2015), Aguiar and Erkan 
(2013) 
Transplants Noris and Remuzzi (2010) 
Pregnancy Fakhouri et al. (2010) 
Metabolic conditions Sharma et al. (2007) 
Table 2 Events that can lead to aHUS. 
Reviewed by Kavanagh et al.  (2013).  
1.2. Complement System 
The complement system is part of the innate immune system, which is involved in 
producing a large, non-specific immune reaction in response to foreign microorganisms 
(Trouw and Daha, 2011). It is composed of three pathways: the classical (CP), lectin 
(LP) and AP, which are initiated by different factors (Campbell et al., 1988). Ultimately 
the pathways combine to produce a common immunological response (Walport, 2001a, 
Walport, 2001b). This includes the release of anaphylatoxins which recruit other 
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immunological cells, leading to amplification of the immune response and the formation 
of a Membrane Attack Complex (MAC) that can destroy targeted cells (Sarma and 
Ward, 2011).   
The AP is unlike the CP and LP as it does not require an initiating step. Instead it 
depends on the natural hydrolysis of a C3 thioester, producing C3(H2O) (Thomas et al., 
1982). C3(H2O) is structurally similar to C3b thus it is able to bind with complement 
factor B (FB) (Isaac and Isenman, 1992). However the CP and LP can also recruit the 
AP, leading to pathway amplification. The AP C3 convertase, a serine protease, is 
formed by a C3b subunit binding to FB to form a pro-convertase enzyme (Zipfel and 
Skerka, 2001). FB contains the serine protease domain of the C3 convertase, which is 
not activated until complement factor D (FD), another serine protease, cleaves FB into a 
Ba and Bb subunits (Sarma and Ward, 2011). The Bb subunit containing the active 
region remains bound to the C3b, producing the active AP C3 convertase (C3bBb 
complex), whilst the anaphylatoxin, Ba subunit, is released (Ricklin et al., 2010). With 
the additional stabilisation effect of Properdin, the C3 convertase is then able to cleave 
more C3 into C3a and C3b. This leads to generation of even more C3 convertase, 
producing a positive feedback loop (Holers, 2014), shown in Figure 1-2. Some C3b 
subunits can complex with the C3 convertase to produce a C5 convertase, which can 
cleave C5 into C5a and C5b (Campbell et al., 1988). C5a is also an anaphylatoxin that 
is released into the circulation whilst C5b forms a complex with complement 
components 6 to 9 to produce a MAC (Hadders et al., 2012). This is able to insert into 
the plasma membrane of pathogens or self cells, leading to lysis of targeted cells 
(Ricklin et al., 2010).  
  
5 
 
 
Figure 1-2 Schematic diagram of the Complement system. 
Adapted from Campbell et al. (1988). 
1.2.1. Complement Regulators 
Regulators of complement activation are molecules that control the complement system 
when it is not required. They include Factor H (FH), Factor I (FI), Complement 
Receptor 1 (CR1), C4b binding protein (C4BP), Membrane Cofactor Protein (MCP), 
CD59 and Decay Accelerating Factor (DAF) (Holers, 2014). There are three methods 
for complement regulation including protein mediated decay acceleration, irreversible 
protein inactivation and reversible competitive inhibition (Hourcade, 1989).  
Firstly protein-mediated decay acceleration occurs when the C3 or C5 convertase 
enzymes dissociate more readily, due to the presence of regulators such as FH (Schmidt 
et al., 2008a) and DAF (Sun et al., 1999). The second mechanism is irreversible 
inactivation, which occurs when a protein is cleaved into smaller non-functioning by-
products (Hourcade, 1989). For example C3b is first cleaved by FI, with fluid phase 
cofactors FH or cell surface cofactors MCP and CR1, to produce a surface bound iC3b 
and a soluble C3f subunit (Davis et al., 1984). C4BP predominately regulates the CP, 
however it has also been shown to act as a cofactor to FI in the inactivation of C3b 
(Blom et al., 2003). The second proteolytic event uses CR1 as a cofactor to cleave iC3b 
into a membrane-bound C3dg and a soluble C3c subunit (Davis et al., 1984, Hourcade, 
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1989). Finally competitive inhibition is the reversible binding of regulators to target 
molecules, so that they are unable to bind to other molecules and carry out their 
function. For example FH can competitively bind with C3b, reducing the amount 
available for FB, for C3 convertase formation (Schmidt et al., 2008a).  
1.3. Known genetic causes of aHUS  
1.3.1. Complement Factor H (CFH) 
The Complement Factor H (CFH) is a gene containing 23 exons, located in the 
Regulators of Complement Activation (RCA) cluster on Chromosome 1q32. It encodes 
FH, a 155kD protein (Morgan et al., 2011) that contains 20 Complement Control 
Protein domains (CCPs) in a folded conformation (Morgan et al., 2011), shown in 
Figure 1-4. FH is a serum glycoprotein produced mainly by the liver, which regulates 
the alternative pathway by several mechanisms. Firstly it competes for the binding site 
on C3b with FB and C5, thus restricting the formation of C3 convertases (C3bBb 
complex) and C5 convertases (C3BbC5a) (Warwicker et al., 1998). The second method 
is to act as a cofactor to FI in order to mediate the proteolysis and thus inactivation of 
C3b (DiScipio, 1992). The final function of FH is to enhance the dissociation of the AP 
C3 convertase by releasing the C3b and Bb subunits (Hourcade et al., 2002). 
Functional analysis of FH has demonstrated that there are 3 regions involved in C3b 
binding. These areas are CCPs 1-4, CCPs 6-8 and CCPs 19-20 (Sharma and Pangburn, 
1996, DiScipio, 1992, Warwicker et al., 1998), although CCPs 1-4 and 19-20 are 
predominantly involved (Schmidt et al., 2008b). FH also has the ability to bind to 
polyanions, such as glycolaminoglycans (GAGs) found on cell membranes, via CCPs 6-
8, 19 and 20 (Ferreira et al., 2009, Blaum et al., 2015, Blackmore et al., 1996). One 
study demonstrated that the removal of GAGs from sheep erythrocytes led to impaired 
complement regulation due to reduced FH-activity (Fearon, 1978). CCPs 1-4 of FH 
have also been demonstrated to mediate cofactor (Gordon et al., 1995, Kuhn et al., 1995, 
Sharma and Pangburn, 1996) and decay acceleration activity of FH (Kuhn and Zipfel, 
1996). Alternative splicing of CFH produces a truncated protein termed FH-like (FHL), 
which contains CCPs 1-7 (Kuhn et al., 1995). The role of FHL is not currently known, 
although the presence of CCPs1-4, suggests that it also binds to C3b and mediates 
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cofactor activity with FI (Zipfel and Skerka, 1999). These binding sites are shown on 
the FH protein in Figure 1-3. 
 
Figure 1-3 Map of FH binding sites 
Adapted from Schmidt et al. (2008b). 
CFH was the first gene to be linked to aHUS (Warwicker et al., 1998), mainly inherited 
in an autosomal dominant mode of inheritance. CFH mutations currently are found in 
approximately 30% of aHUS cases (Caprioli et al., 2006, Loirat and Fremeaux-Bacchi, 
2011, Maga et al., 2010). As a result of these inactivating mutations, there is reduced 
AP control and thus onset of disease. Patients with CFH mutations may have lower C3 
levels due to uncontrolled AP pathway and thus increased C3 consumption (Kavanagh 
et al., 2013). Patients with mutations in CFH have a poor prognosis, with approximately 
60% of cases resulting in death or ESRF (Loirat et al., 2008, Sellier-Leclerc et al., 
2007). In addition patients with CFH mutations are more likely to have recurrence of 
disease after transplantation, with approximately 80% of patients losing the graft within 
2 years (Bresin et al., 2006, Richards et al., 2001). This is due to the presence of FH in 
the circulation, therefore a renal allograft will not correct the underlying genetic defect. 
It has been observed that many disease-associated mutations are located in the C-
terminal portion of the protein, particularly within CCPs domains 19 and 20 (Noris and 
Remuzzi, 2009, Caprioli et al., 2001, Perez-Caballero et al., 2001, Kavanagh et al., 
2013), shown in Figure 1-4. This area is highly important in cell surface binding, 
therefore mutations occurring here can lead to reduced FH-mediated complement 
regulation on the cell surface (Ferreira et al., 2006, Ferreira et al., 2009). Mouse models 
have shown that mice lacking CCPs 16-20 (FHΔ16-20) developed aHUS (Pickering et 
al., 2007). Goicoechea de Jorge et al. (2011) crossed FHΔ16-20 mice with C5 knockout 
mice and found that these mice failed to develop aHUS spontaneously. This indicated 
the importance of the terminal pathway in disease pathogenesis. 
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Figure 1-4 FH protein and mutations 
Schematic diagram showing FH on the cell surface, annotated with point mutations seen in 
aHUS. Adapted from Kavanagh et al. (2013), variants obtained from the literature and from FH 
HUS database (Rodriguez et al., 2014). 
1.3.1.1. CFH risk haplotype 
Additional sequence variants have been found in CFH that do not directly cause aHUS, 
but are thought to give carriers a higher risk of developing aHUS (Pickering et al., 
2007). This haplotype is known as CFH-H3, shown in Table 3. 
SNP Amino acid change dbSNP ID MAF (%) 
-331C>T - rs3753394 26.2 
c.184G>A V62I rs800292 46.8 
c.1204C>T Y402H rs1061170 26.7 
c.2016A>G Q672= rs3753396 20.3 
c.2237-543G>A - rs1410996 49.5 
c.2808G>T E936D rs1065489 20.3 
Table 3 CFH - H3 aHUS risk SNPs. 
Minor allele frequency (MAF) is given as a percentage, based on the 1000g database. 
Caprioli et al. (2003) demonstrated that -331C>T, c.2016A>G and c.2808G>T were 
significantly (c.1204C>T mildly) associated with aHUS in patients, with and without 
additional CFH mutations. However when investigated in the Newcastle cohort, this 
association was only observed in aHUS patients without additional CFH, MCP or CFI 
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sequence variants. In the French cohort an association was found in patients with known 
mutations (in CFH, MCP or CFI) (Fremeaux-Bacchi et al., 2005). These differences 
may be the result of screening small populations. Heurich et al. (2011) and Hocking et 
al. (2008) demonstrated that the polymorphism V62 decreased FH’s affinity to C3b, 
which would cause less C3b inactivation. 
1.3.2. CFH related (CFHRs) genes 
Within the RCA cluster there are several genes upstream of CFH, called Complement 
Factor H related proteins (CFHRs). The CFHRs are thought to have arisen during 
evolution in a series of sequence duplication events (Jozsi and Zipfel, 2008). As a result 
there are areas of very high sequence similarity, called low copy repeats (LCRs) 
between CFH and CFHRs (Bailey et al., 2002), shown in Figure 1-5.  
 
Figure 1-5 Position of CFH and CFHRs on Chromosome 1. 
A diagram showing region of Chromosome 1 that encodes CFH and CFHRs. LCRs are colour 
coded and labelled A-D and exons are shown as vertical lines. Adapted from Heinen et al. 
(2006). 
Currently there have been 5 FHRs described, labelled 1-5. They share similar features to 
FH in that they are mainly secreted by the liver and they are composed of CCPs 
domains. Figure 1-6 shows the percentage amino acid homology of the FHRs compared 
to FH. Overall, the CCPs of all 5 FHRs range from approximately 30-100% sequence 
identity to FH. FHR1 has the highest sequence identity to FH, particularly CCPs 3-5, 
which are between 95-100% similar to CCPs 18-20 of FH. Due to the lack of protein 
domains that correspond to CCPs 1-4 of FH, it is expected that the FHRs do not display 
cofactor or decay acceleration activity (Jozsi and Zipfel, 2008). This is true for all FHRs 
except for FHR3, 4 and 5 which display some cofactor activity (Hellwage et al., 1999, 
McRae et al., 2005). The high sequence identity of the FHRs 1,2 and 5 N-terminal 
CCPs allowed them to dimerise and compete with FH, leading to reduced complement 
regulation at the cell surface (Goicoechea de Jorge et al., 2013). Although alternative 
hypotheses have suggested that they may have a protective effect by regulating 
complement in addition to FH (Jozsi and Zipfel, 2008).  
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Figure 1-6 FH and FHRs amino acid sequence identity. 
Light grey indicates the CCPs that are homologous to CCPs 6-9 of FH and dark grey indicates 
CCPs that are homologous to CCPs 18-20 of FH. Amino acid identity to FH is given as a 
percentage. Adapted from Jozsi and Zipfel (2008). 
Studies have shown that copy number variation (CNV) of CFHRs, which is the loss or 
gain of approximately ≥1kb genetic material (Chen et al., 2010), is associated with the 
presence of anti-FH autoantibodies that bind to and inhibit the C-terminus of FH 
(Dragon-Durey et al., 2009, Zipfel et al., 2007, Moore et al., 2010, Jozsi et al., 2008, 
Abarrategui-Garrido et al., 2009). These studies identified that homozygous CFHR1/3 
or CFHR1/4 deficiency was higher in aHUS patients than in control populations, 
especially in those patients with anti-FH autoantibodies (Zipfel et al., 2007, Jozsi et al., 
2008, Dragon-Durey et al., 2009, Abarrategui-Garrido et al., 2009, Moore et al., 2010). 
It is unclear whether it is the deletion and the loss of FHR protein that alters 
complement regulation and that the autoantibody is an epiphenomenon or that it is the 
deletion that allows the development of autoantibodies and these cause disease. CNVs 
can occur as a result of structural rearrangements in the DNA, discussed below. 
1.3.2.1. DNA repair mechanisms 
1.3.2.1.1. Homologous Recombination (HR) 
When a double strand break (DSB) has occurred during meiosis, there are several 
mechanisms used to repair the DNA. Homologous recombination (HR) is one that 
utilizes homologous sequences to act as a template, allowing polymerases to restore the 
missing sequences(McVey and Lee, 2008). Here the 5’ end of the strands are shortened 
to form single-stranded DNA (Szostak et al., 1983). These hybridise with a nearby 
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sequence displaying a high degree of homology, creating a displacement (D)-loop 
where they are then extended by DNA synthesis. The other 3’ single-stranded DNA 
(ssDNA) undergoes DNA synthesis, using the D-loop as a template sequence (Chen et 
al., 2010). This can lead to non-allelic homologous recombination (NAHR) or gene 
conversions, which can cause CNVs. It can lead to the formation of hybrid genes, 
several of which have been reported in association with aHUS (Heinen et al., 2006, 
Venables et al., 2006, Eyler et al., 2013, Valoti et al., 2015, Francis et al., 2012). These 
hybrid genes will be discussed in Chapter 3. 
Once the D-loop has formed there are two possible pathways that lead to either NAHR 
or gene conversion. The first uses the Holliday Junctions (HJ) model, where DNA 
synthesis of the 5’ strand occurs and double HJs are formed due to ligation of the strand 
break (Holliday, 2007). HJs are intermediate structures occurring between all 4 strands, 
which are then cleaved by endonucleases (Chen et al., 2010). This can occur in two 
possible orientations, reviewed by Liu and West (2004). It can occur on the strand that 
is complementary to the strand break, indicated by the solid grey arrows in Figure 1-7, 
which leads to crossing over and thus NAHR. The alternative mechanism is that the 
other set of strands are cleaved, shown by the hashed grey arrows, where there is no 
crossing over and leads to a gene conversion. 
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Figure 1-7 Schematic diagram showing DSB repair by HR. 
DSB repair starts with a common mechanism, before using either HJ or SDSA repair model. HJ 
leads to both NAHR and gene conversions, whereas SDSA leads only to gene conversions. 
Adapted from Szostak et al.(1983) and Chen et al. (2007).  
Gene conversions can also occur via another mechanism, termed the synthesis-
dependent strand-annealing (SDSA) pathway, where after D-loop formation and 5’ 
extension, the strand becomes displaced (Chen et al., 2007). It then anneals to the 
3’strand, where DNA synthesis continues, shown in Figure 1-7. 
1.3.2.1.2. Microhomology-mediated End Joining (MMEJ) 
Microhomology-mediated end joining (MMEJ) is a distinct subtype of non-homologous 
end joining (NHEJ). Unlike HR, NHEJ mechanisms repair DSBs without the use of 
homologous sequences, with the exception of MMEJ (McVey and Lee, 2008). MMEJ 
take places less frequently, occurring when microhomologies of 5-25bp are found next 
to DSBs (Sharma et al., 2015). Similar to HR, after the occurrence of a DSB the 5’ ends 
are resected to reveal microhomologous sequences that then align and anneal. DNA 
synthesis and ligation then restores the gaps in the sequences. 
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Figure 1-8  Schematic diagram showing DSB repair by MMEJ 
Blue lines represent DNA strands and black squares demonstrate regions of sequence homology. 
Adapted from McVey and Lee (2008). 
1.3.3. Complement Factor I (FI) 
Complement Factor I (FI) is a component of complement that regulates C3 convertase 
formation (Kavanagh et al., 2008, Fremeaux-Bacchi et al., 2004). It is a serine protease 
and together with a cofactor, it is able to inactivate C3b and C4b by removing their 
alpha chains (Kavanagh et al., 2005). This inhibits the formation of C3 and C5 
convertases (Caprioli et al., 2006) and in doing so regulates the complement pathway by 
preventing over activation.  
CFI is found on chromosome 4 (Goldberger et al., 1987) and contains 13 exons and 
encodes the protein FI, an 88kD glycoprotein that is mainly produced by the liver (Vyse 
et al., 1994). FI is composed of a heavy and light chain joined by a disulphide bond 
(Roversi et al., 2011). The light chain contains the catalytic serine protease domain 
(Campbell et al., 1988). The heavy chain does not have catalytic activity, instead was 
hypothesised to mediate the interaction of FI with cofactors and C3b (Sanchez-Gallego 
et al., 2012) or be responsible for producing an inactive conformation when FI is 
circulating in the blood stream (DiScipio, 1992). This modulates the protein activity by 
‘hiding’ the catalytic site, which can then be exposed upon interaction with cofactors 
(Morgan et al., 2011).  
Fremeaux-Bacchi et al. (2004) and Kavanagh et al. (2005) reported mutations in exons 
11 and 13 of CFI, which encode the catalytic site of the protein’s light chain. Both 
studies found two mutations that created a premature stop codon, causing truncation of 
the light chain and thus absence of the serine protease domain. This led to lower FI 
levels in patients, either due to a reduction in protein secretion or the half-life of the 
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protein. This consequently led to decreased complement regulation and onset of disease. 
Other mutations have been reported patients with normal FI levels in the serum, 
suggesting that they affect function (Caprioli et al., 2006). Nilsson et al. (2010) and  
Kavanagh et al. (2008) demonstrated that these mutants have abrogated protease 
activity and were unable to inactivate C3b and C4b.  
 
Figure 1-9 FI protein with mutations. 
Structure adapted from Sanchez-Gallego et al. (2012). Mutations obtained from aHUS database 
(Rodriguez et al., 2014) and from Kavanagh et al. (2013). 
The frequency of CFI mutations is lower than compared with CFH. Sellier-Leclerc et al. 
(2007), Kavanagh et al. (2005) and Caprioli et al. (2006) found that mutations occurred 
with a frequency of approximately 5% in their respective cohorts. It is attributed to a 
poor prognosis in patients, with early onset of disease, disease recurrence and in 50% of 
cases leading to ESRF or death (Caprioli et al., 2006).  
1.3.4. Membrane Cofactor Protein (MCP) 
Membrane Cofactor Protein (MCP), also known as CD46, is a cell surface protein that 
is involved in regulating the complement pathway (Liszewski et al., 2000). The 
extracellular structure of MCP comprises of 4 N-terminal CCP domains, followed by a 
serine-threonine-proline rich region (STPR) (Lublin et al., 1988). Then there is a 
transmembrane domain that anchors MCP onto the cell surface and a cytoplasmic tail 
(Liszewski et al., 1991). It is found as multiple isoforms, depending on alternative 
splicing of the C-terminal STPR and cytoplasmic tail (Post, 1991). MCP acts as a 
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cofactor to FI in the cleavage of C3b and C4b, but unlike FH, MCP does not accelerate 
the decay of the AP convertase (Seya et al., 1986). Studies have identified that CCPs 1 
and 2 are important for C4b binding (Liszewski et al. 2000) and CCPs 3-4 were 
involved in C3b and C4b binding (Adams et al., 1991). Impaired ligand binding reduces 
cofactor activity, but not vice versa (Barilla-LaBarca et al., 2002). MCP is expressed on 
many surfaces including platelets (Yu et al., 1986) and endothelial cells (McNearney et 
al., 1989). 
MCP is located within the RCA cluster on chromosome 1 (Lublin et al., 1988). MCP 
mutations have been reported in several cohorts with a frequency of approximately 5-15% 
(Loirat and Fremeaux-Bacchi, 2011, Sellier-Leclerc et al., 2007). MCP mutations are 
less severe with fewer patients developing ESRF. Patients that do develop ESRF are 
less likely to have disease recurrence after transplantation because the underlying defect 
in the kidney has been corrected (Caprioli et al., 2006).  
 
Figure 1-10 MCP protein with mutations. 
Protein structure adapted from Lublin et al. (1988). Mutations obtained from aHUS database 
(Rodriguez et al., 2014) and Kavanagh et al. (2013). 
The vast majority of sequence variants identified in MCP, approximately 75%, result in 
the loss of protein expression on the cell surface, whilst the other 25% lead to the 
formation of a non-functional protein (Kavanagh et al., 2013).  
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1.3.4.1. MCP risk haplotype 
Several Single Nucleotide Polymorphisms (SNPs) were found within the MCP gene, 
termed MCPggaac and this haplotype was significantly associated with aHUS (Esparza-
Gordillo et al., 2005). These variants are shown in Table 4.  
SNP dbSNP ID MAF (%) 
-652A>G rs2796267 39.1 
-366A>G rs2796268 36.4 
c.989-78G>A rs1962149 29.3 
c.1127+638A rs859705 31.7 
c.*897T>C rs7144 34.7 
Table 4 MCP aHUS risk SNPs. 
Minor allele frequency (MAF) is given as a percentage, based on the 1000g database. ‘*’ 
indicated that the substitution occurred 3’ of the translation termination codon. 
Esparza-Gordillo et al. (2005) found that the frequency of this haplotype was 2 fold 
higher in aHUS patients than in controls. This was also replicated in French and 
Newcastle aHUS cohorts (Fremeaux-Bacchi et al., 2005). There were various 
observations in the significance of the association seen in aHUS patients with and 
without additional complement mutations, such as in CFH, MCP or CFI. Some cohorts 
found patients with no additional complement gene mutation had a risk of disease, 
comparable to that of controls (Esparza-Gordillo et al., 2005), whilst in another cohort 
these patients had an increased risk of aHUS (Fremeaux-Bacchi et al., 2005). These 
differences may be the result of small sample sizes. In vitro experiments have suggested 
that this haplotype reduced transcriptional activity by approximately 25% (Esparza-
Gordillo et al., 2005). However no change in the surface expression of MCP was seen 
in human umbilical vein endothelial cells (HUVECs) in vivo (Frimat et al., 2012). 
1.3.5. Complement Factor B (FB) 
Factor B (FB) is one subunit of the AP C3 convertase enzyme, produced by the liver 
(Maga et al., 2010). CFB is located in the Major Histocompatibility Complex (MHC) 
class III region 6p 21.3 and is composed of 18 exons (Campbell, 1987). It has three 
CCP domains, one von Willebrand (vWA) type A domain and a serine protease domain 
(Milder et al., 2007). FB binds to C3b to form a pro-C3 convertase, which is activated 
when FB is fragmented by FD (Forneris et al., 2010). FD cleaves the linker region 
between the CCPs and VWA allowing the Ba subunit, containing the CCPs, to be 
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liberated (Torreira et al., 2009). The active Bb subunit containing the serine protease 
and vWA domains, remains attached to C3b to form the active C3 convertase 
(Campbell and Porter, 1983).  
CFB mutations are rare, accounting for approximately 1-5% of aHUS cohorts (Maga et 
al., 2010, Fremeaux-Bacchi et al., 2013). Mutations that occur in this gene lead to 
enhanced enzyme activity, faster convertase formation or reduced sensitivity to decay. 
These activating mutations are associated with lower serum C3 levels in patients, due to 
up regulated complement activity. 
 
Figure 1-11 FB protein with mutations. 
Disease-associated mutations were obtained from the literature and FB protein structure was 
adapted from Milder et al. (2007). 
Two mutations (F286L and K323E) were found in the C3b binding site on the vWA 
domain and are thought to lead to enhanced C3b:Bb binding and thus faster convertase 
assembly, with a potentially longer half life (Goicoechea de Jorge et al., 2007). In 
addition they were less sensitive to decay in the presence of FH and DAF. Another 
aHUS case reported a K533R located in the serine-protease domain (Tawadrous et al., 
2010). This was shown to enhance convertase activity, breaking down even more C3 
(Tawadrous et al., 2010). Hourcade et al. (2002) mapped DAF binding sites on FB by 
generating mutant FB proteins. They found that there is an area on the vWA domain 
that is important in DAF interaction, which would explain why these mutations are 
more resistant to decay in the presence of DAF. 
1.3.6. Complement component 3 (C3) 
Complement component 3 (C3) is a serum protein produced by the liver and plays a 
critical role in the complement system (Fearon et al., 1976, Maga et al., 2010).  It is 
186kD in size until it is cleaved by C3 convertases, when it forms a 9kD (C3a) and 
177kD (C3b) fragments (Janssen et al., 2006). C3b can then interact with FB to form 
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the AP pro-C3 convertase, producing a positive feedback loop. To prevent deregulation, 
C3b is rapidly degraded by FI along with a cofactor, such as FH, CR1 and MCP 
(Lambris et al., 1988).  
C3 is positioned on chromosome 19p13.3 (Shaw et al., 1986). It encodes a protein 
consisting of an α (amino acids 650-1641) and β (amino acids 1-645) chain (Janssen et 
al., 2005), linked by disulphide bridges (Thomas et al., 1982). Cleavage of C3 into C3b 
results in the removal of the ANA domain, which forms the C3a fragment (Janssen et 
al., 2005). The side chains of amino acids C988 and Q991 form a thioester bond, which 
maintains the conformation of the protein (Thomas et al., 1982). Hydrolysis of this 
thioester bond produces C3(H2O), which is similar in conformation to C3b and can also 
bind to FB (Isaac and Isenman, 1992). Residues 727-767 of the N-terminus of cleaved α 
-chain (α’NT) domain have been demonstrated to be involved in C3 binding to FB, FH 
and CR1 (Oran and Isenman, 1999). 
Similar to CFB mutations in C3 are activating, causing enhanced C3 convertase activity 
and faster convertase formation. Mutations in C3 account for an estimated 4-8% of 
aHUS cases (Maga et al., 2010, Fremeaux-Bacchi et al., 2013, Noris et al., 2010), 
summarised in Figure 1-12.  
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Figure 1-12 C3 protein with mutations. 
MG= macroglobulin domain, LNK= linker domain, ANA= anaphylatoxin domain, α’NT= N-
terminus of cleaved α-chain, CUB= complement C1r/C1s, Uegf, Bmp1 domain, TED= 
thioester-containing domain. Mutations were compiled from the literature (Schramm et al., 
2015, Rodriguez et al., 2014, Kavanagh et al., 2013). Protein structure adapted from Janssen et 
al. (2005). 
Fremeaux-Bacchi et al. (2008) found 5 heterozygous mutations (R570Q, R570W, 
A1072V, D1093N and Q1139K) that affected the interaction of C3 with MCP. When 
compared to wild type C3, these mutants had reduced binding with MCP, but normal 
FB binding (Fremeaux-Bacchi et al., 2008). As a result mutant AP convertases were 
formed normally but due to decreased cofactor activity of MCP, had longer half lives. 
This would result in more C3b generation, leading to increased complement activity. 
1.3.7. Thrombomodulin (THBD) 
Thrombomodulin (THBD) is a cell surface bound protein that can inhibit the activity of 
thrombin and enhance the activity of protein C, reducing coagulation (Anastasiou et al., 
2012). THBD is located on chromosome 20p11.2 (Maglott et al., 1996) and found to 
lack introns (Jackman et al., 1987). THBD is composed of an N-terminal Lectin-like 
domain, 6 tandemly repeated epidermal growth factor-like (EGF) domains, 
serine/threonine rich segment, transmembrane region and a cytoplasmic tail (Wen et al., 
1987). EGF4, 5 and 6 are critical for protein C cofactor activity (Gale and Griffin, 2004). 
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Figure 1-13 THBD protein with mutations. 
L= Lectin-like domain, EGF= epidermal growth factor- like domain, STR= serine/threonine 
rich segment, TM= transmembrane region and CYT= cytoplasmic tail. Adapted from Tsiang et 
al. (1992). Mutations obtained from the literature. 
Autosomal dominant THBD sequence variants have been previously reported in aHUS 
patients by Delvaeye et al. (2009) and Maga et al. (2010). The frequency of a known 
SNP (A473V) was not significantly different between the aHUS and control cohort 
(Delvaeye et al., 2009). Functional analysis of THBD (Delvaeye et al., 2009) 
demonstrated that THBD acted as a cofactor to FI in the presence of C4BP and FH, 
leading to increased inactivation of C3b. They established that mutant THBD was less 
able to convert C3b into iC3b, despite increased binding to FH and C3.  
1.3.8. MMACHC 
Cobalamin C disease is a disorder of cobalamin (Cbl), or vitamin B12, metabolism 
(Sharma et al., 2007, Martinelli et al., 2011). It can occur as a result of autosomal 
recessive sequence variants in methylmalonic aciduria cblC type with homocystinuria 
(MMACHC) gene (Lerner-Ellis et al., 2006). MMACHC is involved in reducing the 
cobalt atom of Cbl and transporting Cbl within the cell (Green, 2010). Loss of 
MMACHC leads to the accumulation of homocysteine, increasing the risk of TMA 
(Cattaneo, 1999, Morel et al., 2006). Generally this disease occurs in infancy, although 
there has been a reported case of an adult developing cobalamin C- associated HUS, 
who failed to respond to eculizumab (Cornec-Le Gall et al., 2014). It is diagnosed by 
high levels of homocysteine in the blood and methylmalonic aciduria (Loirat et al., 
2012).  
1.4. Two hit hypothesis 
It is now known that aHUS is caused by deregulation of the complement pathway, due 
to mutations in genes encoding complement proteins (Kavanagh et al., 2013, Fremeaux-
Bacchi et al., 2013, Maga et al., 2010, Noris et al., 2010). However it has been 
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proposed that to acquire aHUS, an initiating environmental event is required to activate 
the complement system (Caprioli et al., 2006). The complement system then becomes 
deregulated as a result of a genetic defect, leading to the onset of disease.  
One study found that 70% of aHUS patients with a CFH mutation had an infection prior 
to disease onset, whilst 4% had either been pregnant or taking certain prescribed drugs 
(Abarrategui-Garrido et al., 2008). In the case of patients with CFI mutations, they 
established that 40% individuals were pregnant and 40% had an infection prior to aHUS 
onset (Abarrategui-Garrido et al., 2008). This is also seen in French and Italian 
paediatric cohorts, where aHUS was preceded by an infection in 63% and 85% of cases, 
respectively (Loirat et al., 2008). This could explain how within a family, individuals 
can acquire the disease at any point within their lives, with varying severity. Fakhouri et 
al. (2010) identified pregnancy as a trigger for aHUS, with 20% of the females having 
disease onset during pregnancy.  
Roumenina et al. (2012) also noted that 70% of patients with a sequence variant in C3 
had aHUS after a trigger event and that penetrance was incomplete. In affected 
individuals the presence of additional risk haplotypes such as MCPggaac and CFH-H3 
were higher than in healthy carriers. This suggested that several factors may be required 
to lead to disease onset.  
1.5.  Treatment 
Eculizumab is a humanized monoclonal antibody against C5, a component of MAC 
(Rother et al., 2007). This antibody binds to C5 and thus prevents the formation of the 
MAC, reducing the activation of prothrombotic and proinflammatory pathways (Meri, 
2013). Failure to respond to eculizumab may suggest that complement is not involved in 
disease pathogenesis or that treatment was initiated too late to be effective (Wong et al., 
2013). The exception to this is that there is a known sequence variant in C5, p.R885H, 
which has been shown to reduce drug efficacy (Nishimura et al., 2014). Therefore all 
patients who will receive this treatment by the national aHUS service are routinely 
tested for this sequence variant (Sheerin et al., 2015).  
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1.6. Whole Exome Sequencing (WES)  
Next Generation Sequencing (NGS) is becoming an increasingly common method of 
genetic analysis for Mendelian diseases (Botstein and Risch, 2003), particularly Whole 
Exome Sequencing (WES). This was first used to successfully identify the genetic cause 
of Freeman-Sheldon syndrome (Ng et al., 2009). It has since been used to discover 
novel genetic causes of many diseases. The method of exome capture was first 
described by Hodges et al. (2007), which when combined with next generation 
sequencing, produced a very rapid approach to sequencing large areas of DNA. 
Traditional methods for candidate gene identification were to use Sanger sequencing 
(Ku et al., 2012), linkage analysis (Kerem et al., 1989, Riordan et al., 1989), 
homozygosity mapping (Lander and Botstein, 1987) or Genome-wide association 
studies (GWAS) (McCarthy et al., 2008). However these techniques have limitations 
which are described in section 5.1. 
1.6.1. Advantages 
WES utilizes the sequence data from the exonic regions of DNA only, approximately 1% 
of the entire genome. Despite this, the exome is estimated to contain 85% of disease 
causing mutations (Choi et al., 2009). Therefore it has the benefit of being more cost 
effective than targeted resequencing and much faster than whole genome sequencing 
(WGS). 
WES is an unbiased approach to finding candidate variants and allows for the screening 
of genes that may not be within a pathway of interest (Boycott et al., 2013). This is 
useful for screening genes that have associations with alternative diseases, which may 
be important if patients have atypical presentation of disease or have been misdiagnosed 
(Bamshad et al., 2011). WES has also been demonstrated to be able to detect 
mosaicisms, where the ratio of variant alleles compared to reference alleles is lower and 
tissue-specific (Riviere et al., 2012).  
1.6.2. Disadvantages 
There are several potential disadvantages to WES. Firstly it excludes intronic data, 
which comprises approximately 99% of the genome. This could lead to potentially 
important mutations being missed. There are also some technical issues such as it 
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poorly sequences areas that are CG-rich or highly repetitive (Aird et al., 2011, 
Kozarewa et al., 2009) and generally tends to favour the wild type allele (Meynert et al., 
2014).  
Secondly WES generates a huge number of variants and it can be difficult to determine 
which are pathogenic and which are bystanders (Bamshad et al., 2011). Examining 
variants that are not in the general population, or are rare, is one method to select 
candidates. However it is thought that each person can have around 30 de novo variants, 
which can make this strategy more complicated (Marian, 2012). Variants of unknown 
significance (VUSs) are another major problem of next generation sequencing, 
particularly if they occur in a gene with limited functional information (Goldstein et al., 
2013). The use of prediction software can help to prioritise sequence variants, however 
they are only a prediction and can often be non-concordant (Tennessen et al., 2012).  
Finally this analysis assumes that this disease is a monogenic disorder and that the 
occurrence of one causative gene defect leads to disease. However it may be that there 
are additional genetic variations that contribute to disease or additional environmental 
factors, which have been previously reported in aHUS (Caprioli et al., 2006). 
1.7. Aim of project 
At the time the project commenced (2010) approximately 45% of aHUS cases in the 
Newcastle familial cohort had a known genetic cause of disease, shown in Figure 1-14. 
This is comparable to what has been described in other studies (Noris et al., 2010, Maga 
et al., 2010, Fremeaux-Bacchi et al., 2013). Currently 7 genes have been associated 
with aHUS (CFH, MCP, CFI, CFB, C3, THBD and MMACHC). The largest proportion 
of patients have mutations in CFH, followed by C3 and MCP, with CFI mutations were 
seen less frequently. No familial cases have been identified with genetic abnormalities 
in CFB, THBD or MMACHC. However there have been reports of sequence variants 
occurring in CFB in the sporadic cohort.  
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Figure 1-14 Percentage of gene mutations in 2010. 
Percentage of gene mutations observed in the Newcastle familial aHUS cohort in 2010, before 
the start of this project. 
The aim of this project is to elucidate the genetic cause of disease in familial aHUS 
cases, in whom no genetic cause had previously been identified. Initially CNVs 
occurring in known aHUS-associated genes were identified using Multiplex Ligation-
dependent Probe Amplification (MLPA) and Western Blotting, with complement assays 
used to establish their functional significance. Subsequently WES was used to identify 
candidate genes using a filtering strategy based on different inheritance patterns, minor 
allele frequency (MAF), in silico analysis of functional significance and conservation 
and known phenotypic information. 
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Chapter 2: Methods 
2.1. Patient selection 
The study was approved by Newcastle and North Tyneside 1 Research Ethics 
Committee and informed consent was obtained in accordance with the Declaration of 
Helsinki. Patients in Newcastle aHUS cohort were chosen if there was a family history 
of disease. It should be noted that some families were referred from outside of the UK. 
2.2. DNA and RNA extraction 
Performed by the Northern Genetics Service. DNA was isolated from peripheral blood 
leukocytes using QIAamp DNA mini kit (QIAGEN). RNA was extracted from 
peripheral blood leukocytes using RNAeasy mini kit (QIAGEN). 
2.3. DNA quantification 
DNA was quantified using a NanoDrop 8000 (Thermo Scientific) at 260nm. 
2.4. Serum preparation 
Performed by the NHS. Serum was prepared using a standard method (Whaley and 
North, 1997). Blood was allowed to clot by incubating at 37°C for 30 minutes. This was 
then chilled on ice for 1 hour and the serum separated by centrifugation at 2000xg for 5 
minutes at 4°C. Serum was removed and stored at -70°C until use. 
2.5. PCR protocols 
2.5.1. CFH/CFHR3 break point analysis 
To confirm the position of the breakpoint that caused the formation of the CFH/CFHR3 
hybrid gene, genomic DNA was amplified using a forward primer specific for CFH in 
exon 20 (GTAACTGTTATCAGTTGATTTGC) and a reverse primer in CFH 3’UTR 
(ACGGATTGCATGTATAAGTG), shown in Figure 3-4. This was performed by the 
Northern Genetics Service.  
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2.5.2. CFH/CFHR3 cDNA amplification 
Complementary DNA (cDNA) was synthesised by the Northern Genetics Service with 
SuperScript III First-Strand Synthesis System (Invitrogen) using random hexamers and 
the extracted patient Ribonucleic acid (RNA) as a template. cDNA was used as a 
template in a polymerase chain reaction (PCR) reaction with a forward primer in CFH 
exon 20 (TGGATGGAGCCAGTAATGTAAC ATGCAT) and a reverse primer in 
CFHR3 exon 2 (GAAATAGACCTCCATGTTTA ATGTCTG). 
2.5.3. Primer design 
Genomic sequences for genes were downloaded from UCSC Genome Browser (Kent et 
al., 2002, Karolchik et al., 2014). Sequences of approximately 18-20 nucleotides were 
then selected either side of the region of interest. The reverse primer was reverse 
complemented. These sequences were then run through the UCSC in silico PCR 
software , which determined the primer specificity. All primers were tagged with a 17bp 
sequence that is specific for sequencing primers. This allows the PCR products to be 
sequenced. The sequences for the forward and reverse primers were 
‘GTAGCGCGACGGCCAGT’ and ‘CAGGGCGCAGCGATGAC’ respectively. 
2.5.4. Polymerase chain reaction (PCR) 
PCR was carried out to generate enough DNA transcripts for subsequent Sanger 
sequencing. 50-250ng/µL of genomic DNA was amplified by PCR comprising of 10µL 
Immomix Red (Bioline, BIO-25021), 1µL forward primer (10µM), 1µL reverse primer 
(10µM) and sufficient H2O to make a final volume of 20µL. PCR was then carried out 
on a Bio-Rad T100 Thermal Cycler (186-1096). 
Cycle conditions: 
1. 95 °C for 10 minutes 
2. 94 °C for 1 minute 
3. Annealing temperature* for 1 minute 
4. 72 °C for 2 minutes. Return to step 2 and repeat 34 times. 
5. 72 °C for 10 minutes 
6. 4°C forever. 
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*For annealing temperatures and primer sequences, see tables Table 33 and Table 34 in 
Appendix B. 
2.5.5. Agarose Gel Electrophoresis 
PCR samples were run on an agarose gel prepared from 1% (w/v) Low EEO Agarose 
(NBS Biologicals Ltd, NBS-AG500), 1x TAE (40 mM Tris, 20 mM Acetic acid and 1 
mM EDTA) and 0.0001% (v/v) GelRed (Biotium, 41003). 5µL of DNA ladder (MBI 
Fermentas, SM0383, New England Biolabs, N3231s or N3232s) and 5µL of PCR 
product were loaded onto the agarose gel. This was run in 1x TAE, at 70 volts for 30 
minutes, using PowerPac Basics (Bio-Rad. 300V, 400mA, 75W). DNA bands were 
viewed using GelDoc-it 310 Imager (UVP). 
2.5.6. Sanger sequencing 
If PCR products were generated, samples were purified using QIAquick PCR 
purification Kit (QIAGEN, 28104), ready for sequencing. If PCR was performed in 48 
or 96 well plates then purification was performed by GATC Biotech. Typically samples 
were eluted with 30µL of H2O and sent to GATC Biotech for Sanger sequencing. 
Sequencing was performed using BigDye Terminator v3.1 (Life Technologies) and 
analysed on the Applied Biosystems 3730xl DNA Analyzer (Life Technologies). 
Sequences were then viewed using Sequencher (Gene Codes Corporation, Version 5.0). 
2.5.7. Sequence variant nomenclature 
Sequence variants were named using the recommendations given by the Human 
Genome Variation Society (den Dunnen and Antonarakis, 2000). 
2.5.8. Multiplex ligation-dependent probe amplification (MLPA) 
2.5.8.1. Background 
Multiplex ligation-dependent probe amplification (MLPA) is a PCR-based method 
(Schouten et al., 2002, Eldering et al., 2003), which can identify insertions or deletion 
in a region of interest. It has the benefit of detecting very small base changes and being 
a rapid, cost effective technique (Stuppia et al., 2012). However in some instances, 
MLPA will not pick up gene rearrangements. For example it is difficult to detect CNVs 
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in genes that have complete sequence homology. In these instances abnormalities would 
only be found by looking at the protein itself, via western blotting.  
MLPA probes are formed of two oligonucleotides that to bind to the region of interest 
via a complimentary sequence, known as the hybridisation sequence. The 
oligonucleotides are then ligated by a ligase enzyme, which allows for PCR to take 
place during the subsequent amplification steps. If ligation does not take place, then 
amplification does not occur, the aim of which is to minimise amplification of probes 
that bind non-specifically. Each MLPA probe contains a stuffer sequence that gives the 
probe a specific length, allowing them to be separated during electrophoresis. The 
amount of MLPA probes produced after amplification is proportional to the number of 
copies of the target sequence in the sample. This can then be compared to a control 
sample to determine if there are normal or abnormal numbers of gene copies. Where 
possible, at least one individual per family was tested for CNVs in CFH, CFHRs, CFI 
and MCP. 
 
Figure 2-1 Schematic diagram showing MLPA methodology. 
Each MLPA probe is composed of two oligonucleotides. They anneal to the target position on 
the DNA and then ligated using a ligase enzyme. PCR is then carried out to amplify the MLPA 
probes, which are then separated by electrophoresis. Grey indicates the standard probe 
sequence used specifically for either left or right probe part. Green shows the stuffer sequence. 
Blue shows the hybridisation sequence. Red indicates the DNA target sequence. Figure adapted 
from Schouten et al. (2002). 
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2.5.8.2. CFH and CFHRs MLPA probes 
Patients with a potential diagnosis of aHUS are screened routinely by the Northern 
Genetics Service for CNVs in the RCA cluster. They screen CFH, CFHR2, CFHR3 and 
CFHR5 using the SALSA MLPA probemix P236-A1 ARMD (MRC Holland), probe 
sequences can be found in Appendix D, Table 36. An additional high density MLPA for 
CFH and CFHR5, designed in house by Geisilaine Soares dos Reis Araujo. This was 
used to provide additional coverage, probe sequences can be found in Table 35 of 
Appendix C. Figure 2-2 shows the position of the MLPA probes in CFH and CFHRs. 
The probes used for CFH exons 21 and 22, designed in house, cross-react with CFHR1 
and therefore were not included in MLPA analysis.  
 
Figure 2-2 MLPA probe positions for CFH and CFHRs. 
Diagram shows the position of CFH and CFHRs in the RCA cluster. Each black line represents 
an exon and genes are highlighted by different colours. Black arrows indicate probes used by 
the Northern Genetics Service for routine testing. Grey arrows show the position of MLPA 
probes, designed in house for CFH and CFHR5. 
2.5.8.3. CFI and MCP MLPA probes  
The Northern Genetics Service also used a probe kit used to look for CNVs in CFI and 
MCP was SALSA MLPA probemix P296-A2 (MRC Holland). Table 37 in Appendix D 
shows the MLPA probe hybridization sequences. 
2.5.8.4. MLPA reaction 
Reactions were performed with a positive control, containing either a deletion or 
duplication and a negative control, containing the normal number of gene copies. 100-
200ng of genomic DNA was used per reaction. MLPA was carried out according to the 
manufacturer’s instructions (MRC-Holland, 2013), using SALSA MLPA P200 Human 
DNA reference-1 probemix (MRC-Holland, P200-100R), SALSA MLPA EK1 reagent 
kit (MRC-Holland, EK1-FAM) and MLPA probes for CFH or CFHR5, designed in 
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house. The amplification products were then run on an Applied Biosystems 3130 
Genetic Analyzer (Life Technologies). Data was analyzed using GeneMarker software, 
version 4.2 (SoftGenetics LLC). Values between 0.8 and 1.2 were considered to be 
within the normal range. These experiments were carried by the Northern Genetics 
Service, Geisilaine Soares dos Reis Araujo and myself. 
2.5.8.5. MLPA results 
The result of the in house CFH and CFHR5 and diagnostic CFI/CD46 MLPA were 
plotted in Excel. The x axis shows the gene and exon tested and the y axis shows the 
copy number, which is calculated by comparing the peak heights of a control and 
patient sample. Results are shown in the Supplementary data. Graphs could not be 
drawn for the SALSA MLPA probemix P236-A1, as the original data was not available. 
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Figure 2-3 Examples of MLPA data 
Examples of the MLPA data obtained using the MCP/ CFI probe kit and the in house CFH and 
CFHR5 probe kits. 
2.5.9. Whole Genome Amplification 
Patients with small quantities of DNA available had Whole genome amplification 
(WGA) carried out. This was done using either the GenomePlex Complete WGA kit 
(Sigma- Aldrich, WGA2- 50RXN), Repli-G mini kit (QIAGEN, 150023) or Repli-G 
FFPE mini kit (QIAGEN, 150243) for formalin fixed paraffin embedded (FFPE) tissue. 
See Appendix H, Table 42 to see the method used on specific samples. WGA samples 
were then purified using GenElute PCR Clean-up kit (Sigma- Aldrich, NA1020), to 
remove any remaining primers, nucleotides or other contaminants that may inhibit 
downstream experiments. 
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2.6. Whole exome sequencing 
2.6.1. Background 
Whole exome sequencing (WES) is a method used to sequence the coding region of the 
genome. To isolate the exonic regions of the DNA, specialist kits are used. In general it 
is based on the use of synthetic oligonucleotides, to pull out DNA fragments containing 
corresponding exon-specific sequences (Hodges et al., 2007). The captured DNA is 
then fixed to the surface of a flow cell, where it is amplified prior to sequencing 
(Metzker, 2010). This produces numerous clusters, containing identical copies of DNA, 
increasing the intensity of the fluorescence and thus allowing for more accurate 
detection. The sequencing chemistry used in this project was based on Sequencing by 
Synthesis (SBS) technology developed by Ju et al. (2006), where nucleotides are 
detected as they are incorporated into the newly synthesised strand. This can be done 
due to the presence of a fluorophore attached to the dNTP (deoxynucleotide 
triphosphates), causing sequence termination (Guo et al., 2008). Cleavage of the 
flurophore allows the addition of the next dNTP, which is repeated until the desired read 
length is achieved (Ju et al., 2006). Each dNTP has a specific fluorophore, which allows 
the detector to differentiate between them according to their emission spectra (Metzker, 
2010).   
There are some problems with each step. Exome capture has been shown to have some 
selection bias according to exon length (Hodges et al., 2007) and GC content (Clark et 
al., 2011). Amplification of DNA on the flow cell may introduce sequencing errors and 
if clusters get two big or are positioned too close together, then the fluorescent signals 
may interfere (Rizzo and Buck, 2012, Mamanova et al., 2010). Finally sequencing may 
be problematic due to interference from unbound dNTPs, overlapping emission 
wavelengths from fluorophores or the introduction of errors as the read length increases 
(Fuller et al., 2009).  
2.6.2. Sequencing 
DNA was sent to sequencing providers AROS AB and GATC Biotech. Three exome 
enrichment kits were used, TruSeq exome enrichment kit (Illumina), Nextera Rapid 
Capture Exome kit 37Mb (Illumina) and SureSelect
XT
 Human all exon V5 (Agilent). To 
see which enrichment kit was used on which sample, see Table 42 in Appendix H  
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DNA library formation required 1µg gDNA, when using Illumina kits and 3µg gDNA 
for the Agilent kit. Library preparation involved DNA fragmentation, fragment ligation 
to adaptors and amplification, using proprietary methods of AROS AB or GATC 
Biotech. DNA libraries were then amplified in order to add index tags and then enriched 
for exonic DNA. After enrichment libraries were then denatured and added to the flow 
cell. A final amplification step is required to produce clusters of identical DNA strands 
on the surface of the flow cell. Finally sequencing was carried out on a HiSeq 2000 
(Illumina). A schematic diagram showing these steps is shown in Figure 2-4. 
 
Figure 2-4 Diagram showing WES preparation steps 
Genomic DNA (exons are in black and introns are in grey) is fragmented, then during a 
hybridisation step the exome is captured by capture probes (shown in blue), which have 
sequences complimentary to the exome. These probes are biotinylated (orange circles), which 
allows them to be captured by streptavidin beads (shown in green). The unbound sequences are 
then removed during wash steps, leaving the final enriched exome library. This is then eluted 
and added to the flow cell ready for cluster amplification and sequencing steps. Adapted from 
Ku et al. (2012). 
2.6.3. Bioinformatic pipeline 
The sequencing reads were analyzed using the following workflow, designed and 
performed by Yaobo Xu and Mauro Santibanez-Koref, to generate a list of variants per 
family, demonstrated in Figure 2-5. The first step was to perform quality control (QC) 
on the sequencing reads, performed using FastQC (Andrews). Duplicate reads that arise 
during library amplification steps, were removed with FastUniq (Xu et al., 2012). The 
remaining reads were mapped to the human reference genome (GRCh37) with BWA (Li 
and Durbin, 2010). The alignments were refined with tools of the GATK suite 
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(McKenna et al., 2010). Variants were called according to GATK Best Practice 
recommendations (DePristo et al., 2011, Van der Auwera et al., 2002), including 
recalibration. Freebayes was also used to call variants from the same set of samples 
(Garrison and Marth, 2012). The variants called by Freebayes with total coverage ≥5, 
minor allele coverage ≥5 and variant call quality ≥20, were added to those identified by 
GATK. Annovar was used for annotations and prediction of functional consequences 
(Wang et al., 2010).  
 
Figure 2-5 Schematic diagram showing bioinformatic workflow. 
Variants that were not classed as exonic or in the 2bp region adjacent to exons, 
according to the Ensembl database (Cunningham et al., 2015), were removed. Then 
variants with MAF >5% in the 1000 Genomes (1000g) project (2012 Feb release) 
(Abecasis et al., 2012) and NHLBI GO Exome Sequencing Project (ESP6500) 
(Furukawa et al., 2011), were excluded. Table 5 gives additional information on the 
individual software used in the bioinformatic pipeline. 
Variant selection 
8. Exonic and splice site 9. MAF of <5% 
Variant  Annotation 
7. Annovar 
Variant calling 
5. GATK 6. Freebayes 
Processing read sequences 
2. Duplicates removed 
(FastUniq) 
3. Reference mapping 
(BWA) 
4. Alignment 
recalibrated  (GATK) 
Quality control 
1. FastQC 
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Name Function Reference 
FastQC 
Performs a series of quality checks on raw sequence 
data. It examines the quality score per base/ 
sequence, per base sequence content, GC content 
per base/ sequence and the sequence duplication 
level. 
(Andrews) 
FastUniq 
Identifies and removes duplicate reads, by comparing 
sequences within paired reads. 
(Xu et al., 
2012) 
BWA Maps reads to a reference genome. 
(Li and Durbin, 
2010) 
GATK 
Performs local de novo assembly and realigns 
INDELs. It also calls Insertions/deletions (INDELs) 
and Single Nucleotide Variant (SNVs), comparing 
them with known variants of good quality (from 
1000g), to see if called variants are true. 
(McKenna et 
al., 2010) 
FreeBayes 
This detects variants in alignment data by haplotype-
based methods, using a Bayesian statistical 
framework. 
(Garrison and 
Marth, 2012) 
Annovar 
A tool that utilises data from various databases to 
annotate SNVs. 
(Wang et al., 
2010) 
Table 5 Description of tools used in WES bioinformatic workflow. 
2.6.4. Coverage 
To see if genes of interest were covered by WES, .bam files were loaded onto 
Integrative Genomics Viewer (IGV) (Thorvaldsdóttir et al., 2013, Robinson et al., 
2011). This allowed us to see the number of sequencing reads there were at a given 
position. A position with coverage of more than 20 reads was deemed to be well 
covered. However all candidate variants were confirmed by Sanger sequencing. 
2.6.5. Ingenuity variant analysis (IVA) 
Another method used to look for disease-causing variants was Ingenuity Variant 
Analysis (IVA) (QIAGEN) . It is a web-based platform that utilises evidence-based 
information, annotation algorithms and other computational software, to allow users to 
manipulate WES data. It was used here as a ‘proof-of-principle’ tool, using their ‘Path-
to-phenotype’ data. This is a repository of curated publications that give evidence to 
support a mechanism of disease. 
2.6.6. In silico analysis 
2.6.6.1. Impact of mutations on proteins 
It can be difficult to differentiate sequence variants that would affect protein function 
and those that would be tolerated. Several prediction tools were used to help identify 
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variants that were likely to be pathogenic from those that were not. The prediction score 
thresholds used were based on what had been previously described in the literature (Li 
et al., 2014, Dong et al., 2015).  
PolyPhen-2 is a server that can predict the effects that a mutation would have on a 
protein (Adzhubei et al., 2010). It does this by searching for similar proteins and 
aligning the sequences, looking for any variations. A score is allocated to sequence 
variants depending on the pattern of substitutions, the amino acid changed that has 
occurred and possible structural features that may be affected. In doing so the software 
can predict whether a mutation would be damaging or benign . The model was trained 
on two datasets, giving two scores. The first data set HDIV contains known disease-
causing alleles classed as deleterious and variants that are different between human and 
other mammals, classed as benign. The second dataset HVAR contains known disease-
causing alleles classed as deleterious and common variants (MAF>1%) that are classed 
as benign. Scores of ≥0.453 or ≥0.447 in HDIV and HVAR respectively, were labelled 
damaging. Scores below these thresholds were considered to be benign. Scores cannot 
be calculated for nonsense mutations, splice site changes or INDELs. 
Mutation Taster is an online program that can be used to predict the outcome of 
sequence variants on protein structure and function (Schwarz et al., 2010, Schwarz et al., 
2014). It combines information from several databases (Swiss Prot, dbSNP, Ensembl, 
HapMap) and prediction programs to annotate variant data. It can predict if changes are 
within a conserved region and calculates allele frequencies . A score of ≥0.5 was classed 
as deleterious. Values below this threshold were classed as neutral and if it was also 
seen in HapMap database or in more than 4 cases, then reported as a polymorphism. 
Mutation Assessor is a server that predicts the impact of an amino acid substitution on a 
protein, basing this on whether the position is evolutionary conserved or not (Reva et al., 
2011). It cannot be used to calculate scores for nonsense mutations, splice site changes 
or INDELs. Scores >0.785 were classed as high impact and therefore deleterious. 
Remaining variants were classed as neutral (scores <0.55), low impact (0.55< χ <0.645) 
or medium impact (0.645< χ < 0.785). 
Functional Analysis through Hidden Markov Models (FATHMM) is an online platform 
that can determine if a missense variant will have an effect on a protein (Shihab et al., 
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2014, Shihab et al., 2013b). It does this by aligning protein sequences of homologous 
proteins and calculating conservation scores, combined with the tolerance of the protein 
to mutations (Shihab et al., 2013a). It cannot be used to calculate scores for nonsense 
mutations, splice site changes or INDELs. Scores of ≥0.453 were predicted to be 
deleterious. Variants with scores below this level were classed as ‘Tolerated’.  
RadialSVM is an ensemble-based approach that can combine multiple scoring methods, 
such as those that determine sequence conservation or effect on protein function (Dong 
et al., 2015). It cannot be used to calculate scores for nonsense mutations, splice site 
changes or INDELs. A score of ≥0.5 was classed as deleterious. Variants with scores 
below this level were classed as ‘Tolerated’. 
2.6.6.2. Sequence conservation 
If a sequence is considered to be evolutionary conserved, then it suggests that it 
performs a critical function. If mutations occur here, then they are predicted to be 
significant and potentially disease causing. 
PhyloP  is a program that examines the conservation of an area where a mutation has 
occurred. Conserved sequences are areas where evolutionary changes are very slow or 
slower than “Neutral drift” (Pollard et al., 2010). These areas are often very similar 
across several species and may indicate that an area is functionally important. The 
program analyses conservation by aligning 36 sequences of a variety of mammals and 
detecting differences between them (Pollard et al., 2010), calculating an estimated 
neutral evolution rate. It then compares the likelihood of observing substitutions at a 
neutral evolutionary rate. It cannot calculate scores for INDELs. A score >0.5 was 
considered conserved. 
GERP++ is a tool that identifies genomic regions that are evolutionary conserved 
(Davydov et al., 2010). It aligns sequences from multiple species and determines the 
neutral evolution rate. It then calculates the number of nucleotide substitutions that 
would be expected (at a neutral rate of evolution), then subtracts the number of 
substitutions that are actually observed. If there are fewer substitutions than expected 
(giving a higher score), then it indicates that the area is conserved (Davydov et al., 
2010). However it cannot calculate scores for INDELs. In this analysis a GERP++ 
score >2 was defined as conserved.  
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Amino acid sequence alignment was performed using UCSC Vertebrate Multiz 
Alignment & Conservation track (Blanchette et al., 2004). Species, UCSC version given 
in brackets, used in the alignment were human (hg19), chimp (panTro2), orangutan 
(ponAbe2), mouse (mm9), rat (rn4), rabbit (oryCun2), dolphin (turTru1), dog 
(canFam2), opossum (monDom5), platypus (ornAna1) and zebrafish (danRer6). The 
symbol ‘-’ is used when there is no amino acid in the aligned sequence. This could be 
due to an insertion or deletion in one of the species compared.  
2.6.6.3. Variant Database 
The Single Nucleotide Polymorphism Database (dbSNP) is a public collection of 
sequence variants (Sherry et al., 2001, Smigielski et al., 2000). The database 
accumulates variant data from large scale sequencing projects, such as 1000 genome 
project . The majority of the variants listed are missense mutations, compared to 
INDELs, occupying an estimated 99.77% of the database (Sherry et al., 2001). 
2.6.6.4. Population databases 
Population databases have several uses in WES data analysis. Firstly it provides a full 
compendium of sequence variants in the region of interest. This could provide 
information as to whether there are other previously described mutations with clinical 
significance. Secondly it can be used to calculate the minor allele frequency (MAF). 
This is the percentage at which a variant occurs within a population and thus whether it 
was a rare or common change.  
1000 genome (1000g) project is a database containing the sequence variants produced 
from a combination of exome and genome sequencing projects, from 14 populations 
(Abecasis et al., 2012). Exome Variant Server (EVS)  is another population database, 
containing whole exome data generated from the NHLBI GO Exome Sequencing 
Project (ESP6500). The dataset contains exomes from 2203 African American and 4300 
European American unrelated individuals.  
2.6.6.5. Splice site calculation 
A web-based program was used to predict the splice site score of a given sequence . It is 
based on how similar the sequence matches the mammalian consensus sequences 
(Shapiro and Senapathy, 1987, Carmel et al., 2004). The consensus sequence for the 3’ 
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splice site is ‘tttttttttttcag/G and for the 5’ it is ‘CAGgtaagt’, where uppercase indicates 
exonic nucleotides and lower case indicates intronic nucleotides. The maximum score 
available for both sites is 100, indicating ‘best fit’ with the consensus sequence. 
2.6.6.6. Phyre2 
The crystal structure of some proteins investigated here (MCP, INF2, C9 and DGKε) 
were unknown, therefore Phyre2 was used. This is a server that predicts the 
approximate protein structure of an inputted amino acid sequence (Kelley and Sternberg, 
2009), by comparing it to homologous proteins. This structure could then be used to 
model sequence variants and thus predict a potential effect on protein function. All 
proteins were run through the software in the ‘intensive’ modelling mode.  
Protein NCBI Reference sequence Amino acids entered 
MCP NP 722548 35-285 
INF2 NP 071934.3 1-250 
C9 NP 001728.1 1-559 
DGKε NP 003638.1 1-567 
Table 6 Protein sequences used in Phyre2. 
2.6.6.7. PyMOL 
Three-dimensional protein structures were manipulated using PyMOL (Schrödinger). 
Files were either generated using Phyre2 or downloaded from Protein Data Bank 
(Berman et al., 2000). Protein domain boundaries for INF2 and DGKε were taken from 
Pfam (Finn et al., 2014). 
2.7. SDS PAGE 
This was performed with the help of Geisilaine Soares dos Reis Araujo, Edwin Wong 
and Holly Anderson. Reducing sample buffer (Thermo Scientific, 39000) or non-
reducing sample buffer (Thermo Scientific, 39001) was mixed with protein, diluted to 
appropriate concentration. To remove albumin and IgG from patient serum, which make 
up >70% of serum proteins, the Pierce antibody-based albumin/ IgG removal kit 
(Thermo Scientific, 89876) was used. This was necessary to try and visualise proteins of 
interest that ran at the same size, such as FHR4/5. Samples were heated at 95°C for 5 
minutes and then centrifuged at a maximum speed of 13,200 rpm for 2 seconds. Tris-
glycine gels (Novex, Life Sciences. 1.0mm x 10 well (10%- EC6075BOX, 6%- 
EC6065Box and 16%- EC6045Box)) and the XCell SureLock mini-cell (Novex, Life 
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Technologies. EI0002) were set up according to manufacturer’s instructions (Life-
Technologies, 2012) using 1x running buffer (25mM Tris base, 192mM Glycine, 0.1% 
SDS pH 8.3) (Life Technologies, LC2675-5). 15µL of sample was loaded per well and 
7µL of molecular weight ladder (Thermo Scientific, 26619) or (Biolabs, P7708s). This 
was connected to a PowerPac (Bio-Rad. 300V, 400mA, 75W) and run for 90 minutes at 
125 volts. 
2.8. Western blotting 
2.8.1. Protein transfer 
XCell SureLock Mini-Cell was set up for gel transfer, as written in the manufacturer’s 
instructions (Life-Technologies, 2009) for Novex Tris-glycine gels onto a nitrocellulose 
membrane (Invitrogen, Life technologies. LC2001). Gels were transferred for 90 
minutes at 25 volts using 1x Tris-glycine transfer buffer (12mM Tris base, 96mM 
Glycine, pH 8.3, 20% Methanol), which was cooled to approximately 4°C before use. 
After transfer the nitrocellulose membrane and Tris-glycine gels were washed with H2O. 
To test if protein had transferred, the membrane was stained using Ponceau S solution 
(Sigma, P7170) and the gel with Coomassie G250 Stain (Bio-Rad, 161-0786). The 
membrane was then blocked with blocking solution, 5% non-fat milk powder in 1x 
TBST (50mM Tris.HCl, pH 7.4, 150mM NaCl, 0.05% Tween 20), for 1 hour at room 
temperature or 4°C overnight. A rotating table was used to ensure even coverage of 
solution over the membrane. Fresh blocking solution was then added, containing the 
primary antibody at the desired concentration. This was left for 1 hour at room 
temperature. The liquid was discarded and the membrane was washed for one 15 minute 
wash and two 5 minute washes, using fresh 1x TBST. Fresh blocking solution 
containing appropriate concentrations of secondary antibody was then added and left for 
1 hour at room temperature. The liquid was discarded and the wash steps repeated, as 
stated previously. Table 7 shows the conditions used for western blotting. 
  
 
4
1
   
Protein target FH FHRs 1,2 and 
FHL 
FHRs 4/5  FH FH FH 
Size range 150kDa 25-47kDa 50-70kDa 150kDa 150kDa 150kDa 
Reduced/ Non- 
reduced 
Reduced Reduced Reduced Non- reduced Non- reduced Non- reduced 
Serum 
preparation 
ND ND IgG and Albumin 
removed 
ND ND ND 
Serum dilution 1:1500 1:200 1:60 1:100 1:100 1:100 
Gel Percentage 6% 16% 10% 6% 6% 6% 
Primary 
antibody 
Polyclonal goat 
anti-FH 
(Calbiochem, 
341276) 
Polyclonal goat 
anti-FH 
(Calbiochem, 
341276) 
Polyclonal goat 
anti-FH 
(Calbiochem, 
341276) 
Mouse anti-CCP20 
of FH (L20/3) (Santa 
Cruz Biotechnology. 
SC-47686) 
Mouse anti- SCR5 
of FH (OX24) 
(Hybridoma cell line- 
Sigma-Aldrich, 
00010403) 
MBI6 and MBI7. 
Mouse anti-402 H or Y 
in CCP7 of FH. 
(Donated by Claire 
Harris, Cardiff 
University) 
Concentration 1:4000 1:4000 1:4000 1:2000 1:2000 1:2000 
Secondary 
antibody 
Rabbit anti-goat 
HRP 
(Calbiochem, 
401515) 
Rabbit anti-goat 
HRP 
(Calbiochem, 
401515) 
Rabbit anti-goat 
HRP 
(Calbiochem, 
401515) 
Sheep anti-mouse 
IgG HRP (Jackson 
Immuno Research, 
515-035-071) 
Sheep anti-mouse 
IgG HRP (Jackson 
Immuno Research, 
515-035-071) 
Sheep anti-mouse IgG 
HRP (Jackson 
Immuno Research, 
515-035-071) 
Concentration 1:8000 1:4000 1:4000 1:4000 1:4000 1:4000 
Table 7 Western blotting conditions. 
ND= Not done. HRP=Horseradish peroxidise. 
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2.8.2. Protein visualisation 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, 34077) was 
added to the membrane and left for 1 minute. The membrane was then dried, covered in 
cling film and place inside of the hypercassette (Amersham Biosciences, RPN 13642). 
Film (Sigma Aldrich, 1611342) was then placed over the membrane and the 
hypercassette was closed, leaving sufficient exposure time to yield bands. Finally the 
film was developed (Konica Minolta Medical + Graphic, Inc. SRX-101A).  
2.8.3. Membrane restoration 
If another antibody was to be tested on the same membrane, Restore Western Blot 
Stripping Buffer (Thermo Scientific, 21059) was used. Membrane was first washed in 
H2O and then incubated in stripping buffer for 10 minutes at room temperature, then 
washed in 1x TBST for 5 minutes. To ensure complete antibody removal, the membrane 
was developed as described previously.  
2.9. Immunoaffinity Chromatography 
Affinity chromatography is a technique that was used to separate molecules according 
to a specific factor, such as pH, size, charge or binding specificity. Immunoaffinity 
chromatography utilises antibody-specificity to separate proteins of interest. This 
method was used to separate the FH and FH/FHR3 hybrid protein species from patient 
serum. This technique was carried out on an Äktapurifier UPC 10  (GE Healthcare, 28-
4062-68). 
To separate FH and FH/FHR3 from serum a column was synthesised containing OX24, 
which is a monoclonal antibody specific to CCP 5 of FH protein and FHL, shown in 
Section 3.2.3.1, Figure 3-10. The conjugation of OX24 to the column would allow the 
proteins of interest to bind, separating them from other serum proteins. These proteins 
could then be eluted for further analysis.  
2.9.1. Tissue culture of OX24 hybridomas 
OX24 antibody was produced by a B cell hybridoma cell line (Sigma-Aldrich, 
00010403). Hybridomas were cultured at 37°C and 5% CO2 using Roswell Park 
Memorial Institute (RPMI) medium supplemented with 10% low immunoglobulin 
foetal calf serum, 2mM L-glutamine, 0.1units/mL penicillin, 0.1mg/mL streptomycin, 
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1mM non-essential amino acids, 1mM sodium pyruvate (all PAA) and 50uM β- 
mercaptethanol (Sigma-Aldrich). To obtain the OX24-containing cell media, the cell 
suspension was centrifuged at 300xg for 2 minutes. The supernatant was removed and 
stored at -20°C. 
2.9.2. Cryopreservation of cells 
To prepare cells for cryopreservation the cell suspension was centrifuged at 300xg for 2 
minutes. Once the supernatant was removed the cell pellet was resuspended in 
Recovery™ Cell Culture Freezing Medium (Life Technologies, 12648-010) and 
aliquoted into Cryogenic Tubes (Thermo Scientific, 377267). The tubes were then 
placed into a Mr. Frosty™ Freezing Container Freezing Container (Thermo Scientific, 
5100-0001) with 2-Propanol (VWR, 20842.323) and stored at -80°C. After 
approximately 24 hours the cryovials were transferred to liquid nitrogen storage. 
2.9.3. OX24 purification 
Supernatant from the OX24 hybridomas, containing the OX24 antibody, was mixed 
with PBS (0.01M phosphate buffer, 0.0027M potassium chloride and 0.137M sodium 
chloride, pH 7.4) and loaded onto a 5 mL HiTrap Protein G HP column (GE Healthcare, 
17-0405-01). The protein G within the column has a high affinity for the Fc region of 
the IgG (GE-Healthcare, 2015), allowing OX24 separation from the cell media. OX24 
was then eluted with 0.1M Glycine-HCl pH2.7 into 0.5mL fractions containing 80µL 
1M Tris base pH9.0 to neutralise the eluted antibody. Fractions containing the OX24 
antibody were buffer exchanged using Vivaspin 2 PSE, 5000MWCO (Fisher Scientific, 
VS0211) into 1mL coupling buffer (0.2M NaHCO3, 0.5M NaCl pH8.3).  
2.9.4. Construction of an OX24 column 
The OX24 column was made using a 1mL HiTrap NHS-activated HP (GE Healthcare, 
17-0716-01). The ester- activated N-hydroxysuccinimide (NHS) ligands on the column 
agarose matrix react with amino groups found on the antibody. This reaction produces 
amide bonds that stably bind the antibody to the column matrix, shown in Figure 2-6.   
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Figure 2-6 Diagram showing immobilisation of antibody to column. 
Column matrix is formed of agarose beads coated in ester-activated NHS ligands, attached via 
a 10 atom spacer arm. The ester groups then reacts with a free amino group on the antibody, 
forming an amide bond and releasing NHS (Thermo-Scientific). 
Formation of the antibody-conjugated column was performed manually, according to 
the manufacturer’s instructions for the HiTrap NHS-activated HP column (GE-
Healthcare, 2013b). During ligand coupling the antibody was flowed across the column, 
between two syringes at either end of the column. This was carried out at room 
temperature for 1 hour. After coupling the column was washed with 3 column volumes 
of coupling buffer and the eluate was collected, which was used to calculate the 
coupling efficiency. 
2.9.5. Calculating coupling efficiency 
To calculate the coupling efficiency, two methods were used to determine protein 
concentration of pre- and post- coupling solutions. First using a NanoDrop and second 
using a bicinchoninic acid (BCA) protein assay (Thermo Scientific, 23225). The PD-10 
desalting columns (GE Healthcare, 17-0851-01) were used to remove free amines 
release during the coupling reaction, which may affect the BCA assay and NanoDrop 
reading. The PD-10 columns were used according to the manufacturer’s gravity 
protocol (GE-Healthcare, 2013a). Absorbance of protein on the NanoDrop was 
measured at 280nm. Coupling efficiency was then calculated, as written in the 
manufacturer’s instructions (GE-Healthcare, 2013b), to be approximately 90%. The 
BCA protein assay was carried out according to manufacturer’s microplate protocol 
(Thermo-Scientific, 2013). The pre-coupling (diluted 1:10) and post coupling (after PD-
10 purification) antibody samples were tested. Absorbance was measured using a 
Thermo Labsystems Multiskan Ascent (Thermo Scientific), with a 570nm filter and 
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Ascent Software version 2.6 (Thermo Scientific, 5185430CD). Table 8 shows the 
standard curve for the blank-corrected absorbance for BSA standards. 
 
Table 8 Standard curve BSA standard dilutions. 
Graph showing the standard curve for blank corrected 570nm absorbance, for BSA standard 
dilutions. 
The average, blank-corrected absorbance for the pre-coupling sample was 0.56 and post 
coupling sample was 0.04. If these values are drawn on the curve, it gives an 
approximate sample concentration for the diluted pre-coupling sample of 450µg/mL 
(pure sample estimated to be 4500µg/mL) and post-coupling sample has a concentration 
of approximately 40µg/mL. This gives an approximate coupling efficiency of 99.1%.  
2.9.6. Serum purification using OX24 column 
Serum was diluted with an equal volume of binding buffer (PBS) and filtered using an 
Acrodisc Syringe filter (Pall Corporation, PN4612). The OX24 column was loaded onto 
the Äktapurifier and the diluted serum was loaded by hand or using a 10mL Superloop 
(GE Healthcare, 18-1113-81). Proteins of interest were eluted using 0.1M Glycine 
pH2.7 into 0.5mL fractions containing 50µL 1M Tris pH8.0, to neutralise the pH of 
eluted protein. Fractions containing protein of interest were then pooled and 
concentrated to an appropriate volume. This step was carried out with the assistance of 
Holly Anderson and Edwin Wong. 
2.10. Mass spectrometry 
Approximately 500µL of fresh serum was purified as described in section 2.9.6. The 
eluted material was pooled and concentrated to 30µL. This was then run on a 6% 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) and stained 
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with Coomassie G250. Mass spectrometry was performed by Achim Truemann, where 
protein bands were excised from the gel and reduced with 10mM DTT (Sigma-Aldrich) 
in 100mM NH4HCO3, alkylated with 50mM iodoacetamide (Sigma-Aldrich) in 100mM 
NH4HCO3. The proteins were then digested in gel, with 230ng modified trypsin 
(Promega) in 50mM NH4HCO3, 1mM CaCl2. Peptides were extracted from the gel 
pieces and the digests were analysed by LCMSMS using a Dionex U3000 nano-HPLC 
system (Thermo Scientific), coupled to an LTQ Orbitrap LTQ XL™ ETD (Thermo 
Scientific) mass spectrometer. Peptides were separated on a 25 cm x 75 µm PepMap 
column (Thermo Scientific) using a 37 min water acetonitrile gradient (0.05% Formic 
acid). Precursor ions were detected in positive mode at 350-1600 m/z with a resolution 
of 60,000 (at 400 m/z) and a fill target of 500,000 ions and a lockmass was set to 
445.120023 m/z. The five most intense ions of each MS scan (with a target value of 
10,000 ions) were isolated, fragmented and measured in the linear ion trap. Peaklists in 
the Mascot generic format (*.mgf) were generated using msconvert ((Kessner et al., 
2008, Chambers et al., 2012)) and the ensembl human genome (GrCh37.66) was 
searched using X!Tandem and the gom interface (version 2013.09.01.1(Craig and 
Beavis, 2004)), with carbamidomethyl set as a fixed modification and Met oxidation set 
as a variable modification. Two refinement steps were included in the search to include 
deamidation and methylation artefacts as well as protein phosphorylation, acetylation, 
dehydration of threonine and serine and carbamidomethylation of glutamine, histidine, 
aspartic acid, glutamic acid and lysine. The protein level false positive rate (as defined 
in: http://wiki.thegpm.org/wiki/False_po sitive_rate) in each band was below 1%.   
2.11. Cell Surface Decay Haemolytic assay 
Haemolytic assays are in vitro models that measure complement activity at the cell 
surface (Harris, 2000). The decay acceleration assay examines the ability of a FH to 
accelerate the decay of the AP convertase on a sheep erythrocyte. This requires FH to 
bind to GAGs on the surface of the erythrocyte, so that it is in close proximity to the 
convertase. The decay of the convertase on the erythrocyte surface will prevent the 
cleavage of C3, which is added back to the system. In doing so there will be less C3b 
formation and thus reduced terminal complement pathway activity. Fewer MACs will 
be produced and as a result there will be less lysis of the erythrocytes. If convertase 
decay fails to take place, due to an abnormality of FH, then the convertase will remain 
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intact. When serum is added to the system, C3 will be cleaved into C3b and activate 
terminal complement activity, which will lead to MAC formation and cell lysis. 
 
Figure 2-7 Schematic diagram of the cell surface decay haemolytic assay. 
Sheep erythrocytes were sensitized by mixing with anti-sheep stromal antibodies. This led to CP 
activation and CP C3 convertase (shown in blue) formation. This cleaved C3 into C3b (shown 
in grey) upon the addition of NHSΔBΔH. The absence of FB stopped AP activation, absence of 
FH prevented decay acceleration and the presence of a terminal pathway inhibitor prevented 
the cells from being lysed. FB and FD were then added, which led to the formation of the AP 
convertase. This is done in the presence of EGTA, which preferentially chelated Ca
2+
 ions, 
inhibiting CP activity. The FH species were then added (shown in yellow), wild type FH would 
accelerate the decay of the AP convertase and so will protect cells from lysis upon the addition 
of NHSΔBΔH. The FH/FHR3 would not accelerate the decay of the AP convertase and therefore 
the addition of NHSΔBΔH would activate the terminal pathway leading to MAC formation and 
thus cell lysis. This was carried out in EDTA, using NHSΔBΔH to prevent CP and AP activity, 
which may skew the results.  
2.11.1. Serum preparation 
Fresh patient and control FH species were purified using immunoaffinity 
chromatography with an OX24 column, as described in section 2.9.6. The eluted 
material was pooled and concentrated using Vivaspin 2 PSE, 5000 MWCO columns 
(Fisher Scientific, VS0211). Normal human serum depleted of FB and FH (NHSΔBΔH), 
was prepared by immunoaffinity chromatography, where serum was run across JC1 
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(FB-specific antibody) and OX24 antibody-conjugated columns in series, using the 
method described in section 2.9.6. NHSΔBΔH and purified FB and FH were collected 
and pooled, for use in the cell surface decay haemolytic assay. 
2.11.2. Protein quantification 
FH species were purified from approximately 500µL of fresh patient serum and 2mL 
fresh control serum, as written in section 2.9.6. The OD at 280nm for control FH was 
5.975mg/mL and patient FH mixture (FH and FH/FHR3) was 0.1535mg/mL. Molarities 
were calculated using Beer-Lambert Law: A= εLc, (where A= Absorbance, ε= Molar 
extinction coefficient, L= light path and c= Concentration). The extinction coefficients 
were determined using ProtParam, assuming all pairs of cysteines form cystines 
(Gasteiger et al., 2005). The protein sequences for FH (NP_000177) and FHR3 
(NP_066303) were obtained from NCBI Protein (NCBI Resource Coordinators, 2014). 
The leader sequences for FH (MRLLAKIICLMLWAICVA) and FHR3 
(MLLLINVILTLWVSCANG) were excluded from the analysis. The extinction 
coefficient for FH was 246800M.cm
-1
. To calculate the extinction coefficient for 
FH/FHR3, the first 1026 amino acids from FH and the 312 amino acids from FHR3 
were used. This produced an ε of 272170M.cm-1. This would ensure conservative 
estimates of the molar ratios and as such, differences demonstrated in the functional 
assays were an underestimate of the loss of function. 
2.11.3. Assay methodology 
The cell surface decay haemolytic assay was performed as previously described (Wong 
et al., 2014, Tortajada et al., 2009), using a method that had been optimized by Edwin 
Wong. I performed this experiment, with the assistance of Edwin Wong. Sheep 
erythrocytes were sensitised (EA) by coating cells with antibodies. To do this 2% 
washed sheep erythrocytes (TCS biosciences, SB068) were mixed with warmed 
Complement Fixation Diluent (CFD) (Oxoid, BR0016), containing 1:4000 anti-sheep 
erythrocyte stromal antibodies (Sigma, S1389). The mixture was then incubated at 37°C 
for 30 minutes and washed using CFD and resuspended to 2% (v/v). 
C3b was then deposited onto EA cells (EAC3b). To do this 8% NHSΔBΔH was mixed 
with 1:1666 Ornithodoros moubata complement inhibitor (OmCI) (gift from Varleigh 
Immuno Pharmaceuticals) in 2% (v/v) EA. This was incubated for several minutes at 
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room temperature, before being added to an equal volume of CFD. The mixture was 
then incubated at 37°C for 20 minutes. EAC3b was washed with AP Buffer (5mM 
sodium barbitone, pH7.4, 150mM NaCl, 7mM MgCl2, 10mM EGTA) and resuspended 
to give 2% (v/v) EAC3b cells. A convertase was formed on the sheep erythrocytes by 
adding 2% EAC3b cells to an equal volume of AP Buffer that contained 0.04µM FB 
(1:400) (prepared in house) and 0.2µg/mL FD (1:500) (Complement Technology, 
A136). This was incubated for 15 minutes at 37°C.  
The assay was performed in round bottom microtiter plates (USA Scientific, 5665-
0161). A 1:2 titration series (0.04μM – 80nM) of OX24-purified FH from control or 
patient was made in 50µL PBS/ 20mM EDTA. Three no FH controls (0.1% (v/v) Triton 
X-100 (Sigma-Aldrich, T8787), with serum or without serum) were done in parallel. 
100µL of convertase mixture was added to each well and the plate was incubated at 
room temperature for 15 minutes, to allow decay acceleration to take place. 50µL 8% 
(v/v) NHSΔBΔH in PBS/20mM EDTA was added to wells (except no FH and no serum, 
or no FH and Triton controls), to initiate lysis. The plate was covered with adhesive film 
(VWR, 391-1250) and incubated at 37°C for 30 minutes, then centrifuged at 1200rpm 
for 3 minutes. 100µL supernatant was then transferred into a flat bottom microtiter 
plates (Ratiolab, 6018211). The amount of haemoglobin released was measured on a 
Thermo Labsystems Multiskan Ascent (Thermo Scientific) using a 420nm filter and 
Ascent Software version 2.6 (Thermo Scientific, 5185430CD). All values were blank-
corrected, using the mean A420 of no serum/no FH controls. Maximal lysis was achieved 
by adding NHSΔBΔH to no FH wells (buffer only). Percentage of inhibition of lysis in 
the presence of increasing concentrations of FH was defined as: (A420[buffer only]-
A420[FH]) / A420[buffer only] *100%. 
2.11.4. Sigma Plot 
Results of the cell surface decay haemolytic assay were plotted using Sigma Plot (Systat 
Software Inc). 
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Chapter 3: Genetic abnormalities in CFH and CFHRs 
3.1. Introduction 
Previous studies have shown that the most common genetic abnormality in aHUS is in 
CFH, occurring in approximately 30% of the affected population (Caprioli et al., 2006, 
Loirat and Fremeaux-Bacchi, 2011, Maga et al., 2010). CFH is found in the RCA 
cluster, in close proximity to the genes encoding the 5 Complement Factor H related 
proteins (CFHRs) (Jozsi and Zipfel, 2008). This area contains several LCRs that can 
cause genomic instability and thus predispose this region to gene rearrangements and 
conversions (Skerka et al., 2013). 
3.1.1. Gene conversions 
Gene conversions are formed when genetic sequences are transferred between two sites, 
which share a high degree of sequence homology (Chen et al., 2007). Domains 18-20 of 
FH and domains 3-5 of FHR1 have been demonstrated to be highly homologous (Jozsi 
and Zipfel, 2008). Indeed CCPs 18 of FH and 3 of FHR1 differ by 3 amino acids, 
domains 19 and 4 share identical amino acid sequences, although there is a difference at 
1 nucleotide and finally CCPs 20 and 5 differ by 2 amino acids.  
Heinen et al. (2006) identified aHUS patients with sequence variants in CCP20 of FH; 
c.3572C>T, p.S1191L, c.3590T>C, p.V1197A or both. These variants correspond 
respectively to the amino acids L290 and A296, found in CCP 5 of FHR1. They 
demonstrated that these variants arose due to gene conversion between exon 6 of 
CFHR1 and exon 23 of CFH. Functional analysis demonstrated that recombinant 
proteins containing S1191L and V1197A (shown in Figure 3-14A), had a reduced 
affinity for C3b and C3d (Heinen et al., 2006) and Ferreira et al. (2009) demonstrated 
that this led to impaired cell surface complement regulation.  
3.1.2. Gene rearrangements 
Venables et al. (2006) identified aHUS patients possessing a CFH/CFHR1 hybrid gene, 
the result of NAHR. This produced a protein containing CCPs 1-18 from FH and CCPs 
4-5 from FHR1, shown in Figure 3-14D. This protein was indistinguishable in structure 
to the protein described by Heinen et al. (2006). This genomic rearrangement was not 
detected by Sanger sequencing, instead MLPA revealed a deletion of exons 21-23 of 
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CFH. The patient’s cDNA was analysed and demonstrated to contain an abnormal 
transcript. The patient had normal serum FH levels, indicating that the abnormal protein 
was secreted normally. 
Maga et al. (2011) then described an alternative CFH/CFHR1, also the result of NAHR. 
MLPA analysis of the CFH/CFHR gene cluster demonstrated a deletion ranging from 
exon 23 of CFH up to and including exon 5 of CFHR1. The resultant protein was 
identical in size to the FH/FHR1 reported by Venables et al. (2006), however it 
consisted of CCPs 1-19 of FH and CCP 5 of FHR1 (shown in Figure 3-14C). The 
protein was secreted, although functional analysis indicated that the protein lacked cell 
surface binding activity. 
Two reverse hybrids have been reported where the C-terminal domains of FHR1 are 
replaced by the C-terminus of FH. The first was reported by Eyler et al. (2013) where 
MLPA identified a duplication of exons 21 of CFH to exon 4 of CFHR1 and the break 
point was located in CFHR1 intron 4. NAHR produced a CFHR1/CFH hybrid gene 
encoding the first 3 CCPs of FHR1, followed by CCPs 19 and 20 of FH (shown in 
Figure 3-14F). The second reverse hybrid was reported by Valoti et al. (2015). This 
FHR1/FH hybrid was identical in size to the Eyler hybrid, although it contained CCPs1-
4 of FHR1 and CCP20 of FH, shown in Figure 3-14E. Functional analysis demonstrated 
decreased complement regulation at the surface of cells. The addition of C-terminal 
CCPs from FH was predicted to allow the hybrids to bind to the cell surface. However 
their lack of N-terminal regulatory domains (CCPs 1-4 in FH) meant that they were 
unable to regulate complement. Therefore they were hypothesised to competitively bind 
to the cell membrane and prevent FH-mediated complement regulation (Valoti et al., 
2015).  
Francis et al. (2012) discovered a CFH/CFHR3 hybrid that occurred as a result of a 
deletion of the end of CFH (exon 23), causing the gene to splice into the downstream 
gene, CFHR3. This was the first gene rearrangement to have occurred by an alternative 
repair mechanism, MMEJ. The resultant protein contained CCPs 1-19 from FH and all 5 
CCPs of FHR3, shown in Figure 3-14G. The protein was shown to be secreted normally; 
however it was unable to regulate complement at the cell surface due to the loss of 
CCP20 of FH, which prevented FH from binding to GAGs found on the cell surface. 
This was hypothesised to lead to onset of disease.  
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3.1.3. Chapter aims 
In this chapter the analysis of copy number variation in the RCA cluster is described, 
which was performed in all unsolved familial aHUS cases and selected others in the 
Newcastle cohort prior to further genetic analysis. All 28 families analysed in this 
project were analysed for CNVs using MLPA and western blotting, if there was DNA 
and sera available. The results can be found in the Supplementary data. 
A novel CFH/CFHR3 hybrid gene is described, with evidence of a secreted hybrid 
protein and functional analysis demonstrating the consequences of the altered protein 
structure. Gene rearrangements and conversion events in CFH and CFHRs are then 
examined and put into the context of all rare sequence variants reported in CFH in the 
Newcastle cohort. 
3.2. Hybrid CFH/CFHR3 gene 
3.2.1. Clinical history 
The patient presented at 8 months of age with no previous family history of disease, see 
Figure 3-1 for pedigree. The patient had a diarrhoeal illness and on further investigation, 
was found to have a creatinine level of 52μmol/L, MAHA was seen on a blood film and 
the LDH level was 5747U/L. His stool culture was positive for E. coli O157:H7, leading 
to a diagnosis of STEC HUS. Renal replacement therapy was not required and the 
patient did not receive plasma exchange. He was discharged 2 weeks later with a 
creatinine of 107μmol/L. 
 
Figure 3-1 Family pedigree. 
The affected proband is indicated by an arrow. 
Two weeks later the patient was readmitted with an upper respiratory tract viral 
infection. Blood tests revealed a creatinine of 141μmol/L, LDH 2398U/L and a blood 
film demonstrated MAHA. Serum levels of C3 (1.05g/L), C4 (0.30g/L), FH (0.51g/L) 
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and FI (71mg/L) were found to be within the normal range and ADAMTS13 activity 
was normal. A renal biopsy revealed thrombi in microcapillaries of the glomerulus 
confirming a diagnosis of aHUS, shown in Figure 3-2.  
 
Figure 3-2 Histological sections of patient renal biopsy. 
A- Haematoxylin and eosin staining (x400 magnification). B- Masson trichrome staining (x400 
magnification). Arrows indicate thrombi in glomerulus vasculature. Reprinted with permission 
from Challis et al. (2015). 
Plasma exchange was initiated and the patient required three haemofiltration sessions. 
The creatinine levels returned to a baseline of ~100μmol/L and a weekly regime of 
plasma exchange was started. This continued for three and a half years before switching 
to eculizumab. For three years the patient has not had any disease recurrence, with a 
current creatinine level of 200μmol/L. 
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3.2.2. Genetic analysis 
3.2.2.1. Sanger sequencing 
Diagnostic testing of aHUS-associated genes (CFH, CFI, CFB, MCP and C3) by the 
Northern Genetics Service, revealed no mutations. However it was noted that the patient 
was heterozygous for the polymorphism in CFH, c.1204C>T, p.Y402H (rs1061170).  
3.2.2.2. MLPA 
To detect potential CNVs in CFH and the CFHRs, which would not be detected by 
Sanger sequencing, MLPA screening was carried out. Initial diagnostic screening was 
performed by the Northern Genetic Service, of CFH, CFHR1, CFHR2, CFHR3 and 
CFHR5. The MLPA results, shown in Figure 3-3, detected a normal number of gene 
copies for all exons of all 5 genes, except for exon 23 of CFH, where the copy number 
was below the threshold (0.8), suggesting a deletion. The proband was also tested using 
the MLPA probes designed in house for CFH and CFHR5, by Geisilaine Soares dos 
Reis Araujo, which supported these findings (shown in the Supplementary data). 
        
Figure 3-3 MLPA screening results 
A- Gene positions of CFH and CFHRs on Chromosome 1. B- MLPA trace of CFH, CFHRs 
1,2,3 and 5 for proband (II:1). Reprinted with permission from Challis et al. (2015). 
3.2.2.3. Break point analysis 
To confirm the location of the deletion, Sanger sequencing was carried out by the 
Northern Genetic Service. Patient genomic DNA was amplified using a combination of 
primers positioned throughout the last exons of CFH and into the 3’untranslated region 
(UTR). Only when using a forward primer in exon 20 of CFH and a reverse primer in 
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CFH 3’ UTR, was a product made. Sequencing of this PCR product revealed that the 
break point, shown in Figure 3-4, was located 3’ of exon 20. This led to the deletion of 
exons 21 to 23 of CFH, comprising of a 6.3kb loss of sequence. The parents of the 
proband were then tested, but the deletion was not found. Maternal and paternal status 
was confirmed by the Northern Genetics Service, using microsatellite testing. This led 
to the conclusion that this was a de novo event.  
 
Figure 3-4 Sequencing chromatogram of break point. 
Top, sequencing chromatogram. The breakpoint in CFH is demonstrated with a line. Below, 
deletion is shown by a grey box. Primer positions are marked by arrows. Reprinted with 
permission from Challis et al. (2015). 
It was hypothesised that sequence homology between CFH and CFHR3, close to the 
position of the break point, may have predisposed this region to a genetic rearrangement. 
Therefore to test this, the genomic DNA (gDNA) sequence for the patient breakpoint 
was compared to the sequences for wild type CFH and CFHR3. A seven-nucleotide 
sequence ‘AATACAA’ was found to be identical in CFH and CFHR3 adjacent to the 
break point, highlighted by a box in Figure 3-5.  
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Figure 3-5 Breakpoint sequence homology. 
Sequence overlay for CFH and CFHR3 and CFH/CFHR3 breakpoint. Red- sequence for CFH 
seen in CFH/CFHR3, Blue- sequence for CFHR3 seen in CFH/CFHR3. Microhomology 
sequence is boxed and in bold text. Reprinted with permission from Challis et al. (2015). 
It was predicted that the rearrangement occurred by intrachromatidal recombination, 
due to MMEJ (Ma et al., 2003). MMEJ is a DNA repair mechanism that occurs at DSBs 
and uses LCRs in close proximity, to align the broken fragments (Chen et al., 2010). It 
was hypothesised that this mechanism, incorrectly aligned the 7bp sequence from the 
two genes, within a chromosome. As a result it caused exons 21- 23 of CFH to be 
excised and deleted, demonstrated in Figure 3-6. 
 
Figure 3-6 Diagram showing intrachromatidal MMEJ. 
A- Approximate position of aligned microhomologous sequences in CFH and CFHR3. B- The 
resulting hybrid CFH/CFHR3 gene containing exons 1-20 of CFH and exons 1-6 of CFHR3. 
This deletion was shown not to affect the reading frame, but the loss of the terminal 
exons and 3’ UTR of CFH was proposed to cause aberrant splicing of CFH. It was 
hypothesised that the intact splice donor site of CFH exon 20, would splice into the next 
available splice acceptor site. In silico software suggested that the splice acceptor site of 
exon 2 in CFHR3 would be used, shown in Figure 3-7. This was predicted to result in 
the formation of an inframe CFH/CFHR3 hybrid gene. 
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Figure 3-7 Schematic diagram of CFH/CFHR3 splicing. 
The sequences for exon 20 CFH are in white and exons 1 and 2 of CFHR3 are in grey. Top- 
positions of exons on DNA. Bottom- predicted splicing of exon 20 CFH and exon 2 of CFHR3. 
Sequence reading frame remains unaltered in hybrid gene. 
The mRNA product transcribed from the hybrid gene, was be predicted to contain all 
coding exons of CFH, except for 21-23, with the addition of exons 2-6 from CFHR3. 
To investigate if an mRNA transcript is produced from the hybrid gene and that it has 
the predicted structure, patient and control cDNA were analysed. The cDNA was 
amplified using primers, positioned across the junction between CFH and CFHR3. The 
forward primer was positioned in exon 20 of CFH and a reverse primer in exon 2 of 
CFHR3, shown in Figure 3-8. This design would only allow a product, with a predicted 
size of 108bp, to be made if there was a hybrid CFH/CFHR3 present. PCR would not 
take place using control cDNA or patient gDNA. This was because control cDNA does 
not contain the binding sites for both primers as they would be present on different 
mRNA transcripts. Then if patient gDNA was present as a contaminant, the intronic 
region between CFH and CFHR3 would be too large (approximately 27kb) to allow 
PCR to take place.  
When patient and control cDNA was amplified in this experiment, a product was only 
seen in the patient, shown in Figure 3-8. This supported the hypothesis that the patient 
had a hybrid mRNA transcript, produced from the hybrid CFH/CFHR3 gene. 
Insufficient quantities of cDNA meant that the PCR product was unable to be sequenced.  
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Figure 3-8 Confirmation of CFH/CFHR3 cDNA product. 
Left- schematic diagrams showing the C-terminus of the predicted CFH/CFHR3 hybrid and 
wild type CFH cDNA transcripts. Positions of forward and reverse primers are indicated by 
arrows. Right- Image of agarose gel. PCR product seen in proband is indicated by an arrow. 
Reprinted with permission from Challis et al. (2015). 
3.2.3. Proteomic analysis 
3.2.3.1. Western blotting 
From the genetic data obtained it was inferred that the hybrid CFH/CFHR3 gene 
contained exons 1-20 from CFH, followed by the 5 exons of CFHR3. Exon 1 of CFH 
encodes the 5’UTR and leader peptide. CCP2 is encoded by 2 exons, exons 2-3. The 
remaining 18 CCPs of FH are encoded by one exon each. Exon 1 of CFHR3 encodes 
the leader peptide and exons 2-6 encode the 5 CCPs. The resulting hybrid FH/FHR3 
protein was proposed to contain the 17 N-terminal CCP domains from FH and all 5 
CCPs of FHR3, shown in Figure 3-9. 
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Figure 3-9 Predicted CFH/CFHR3 mRNA transcript and protein. 
Top- mRNA transcripts of CFH and predicted CFH/CFHR3. Bottom- protein structure of FH 
and predicted FH/FHR3. Exons and CCPs derived from CFHR3 or FHR3 are grey. Exons and 
CCPs derived from CFH or FH are white. 
In order to determine if the hybrid mRNA transcript led to the formation of a protein, 
patient serum was analysed by western blotting. Several monoclonal antibodies were 
used that were specific to different epitopes on FH, shown in Figure 3-10. This would 
allow the differentiation of the wild type and hybrid FH species. OX24 binds to CCP 5, 
which was expected to be present in both FH species. Genetic testing showed that the 
patient was heterozygous for the Y402H polymorphism, so antibodies specific to 
histidine or tyrosine at amino acid position 402 (found in CCP 7) were used. The 
rationale was that the two FH protein species could be differentiated by the amino acid 
at this position. Finally L20/3 is an antibody specific for CCP 20 and therefore predicted 
to bind to the wild type FH protein only. The predicted hybrid protein structure, shown 
in Figure 3-9, did not contain the last 3 C-terminal CCPs and therefore L20/3 was not 
expected to bind.  
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Figure 3-10 Binding sites for anti-FH antibodies. 
Top- protein structure for FH. Bottom- predicted protein structure for FH/FHR3. CCPs derived 
from FHR3 are grey, CCPs derived from FH are white. Binding sites for anti-FH monoclonal 
antibodies OX24, 402H/Y and L20/3 are shown. Reprinted with permission from Challis et al. 
(2015). 
The results of western blotting with these antibodies are shown in Figure 3-11. Figure 
3-11A shows the proteins detected when the OX24 antibody was used and the wild type 
FH was observed in both serum samples, with a size of 150kDa. The patient serum also 
contained two additional bands, one running at approximately 160kDa and one at 
120kDa. The upper band was hypothesised to be the hybrid FH/FHR3 and the lower 
band, a hybrid degradation product. When the L20/3 antibody was used, Figure 3-11B, 
the upper and lower bands were no longer visible in the patient sample. This indicated 
that the proteins lacked CCP 20, supporting the predicted FH/FHR3 structure. Finally 
the sera was tested using the antibodies specific for either the tyrosine or histidine at 
amino acid 402, shown in Figure 3-11C. When the histidine-specific antibody was used, 
the wild type FH was seen in the control and the patient. When the serum was probed 
using the tyrosine-specific antibody, the FH/FHR3 protein and its degradation product 
were seen in the patient sample. This confirmed that the protein in the lower band 
originated from the FH/FHR3 protein. The presence of the intact hybrid protein as a 
doublet, was hypothesised to be the result of differential glycosylation of the FHR3 
portion of the protein (Skerka et al., 1993).   
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Figure 3-11 Western blotting results of sera from proband and control. 
A: OX24 antibody was used. B: L20/3 antibody was used. C: Antibodies specific to H402 or 
Y402. Arrows indicate protein bands containing FH, FH/FHR3 and a hybrid degradation 
product. Reprinted with permission from Challis et al. (2015). 
3.2.3.2. Mass Spectrometry 
Wild type FH and FH/FHR3 species were separated from the patient serum using 
immunoaffinity chromatography. This was done using OX24, which was demonstrated 
in Figure 3-11A to be specific to both proteins. Diluted serum was loaded onto the 
column and unwanted serum proteins were removed during wash steps. The proteins of 
interest, FH and FH/FHR3, were then eluted using a low pH buffer to disrupt the bonds 
between OX24 on the column and the proteins. The eluted proteins were then 
concentrated and run on an SDS PAGE, shown in Figure 3-12.  
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Figure 3-12 Mass spectrometry results. 
Left- SDS PAGE of the isolated FH mixture from proband. Right-protein structures for 
predicted FH/FHR3 and FH. CCPs in grey are derived from FHR3. CCPs in white are derived 
from FH. ‘*’ indicate where the detected peptide fragments are identical to reference sequence 
of FH or FH/FHR3. Reprinted with permission from Challis et al. (2015). 
The three bands seen on the SDS page were cut out and analysed by mass spectrometry, 
performed by Achim Truemann. The largest band contained peptides that were 
consistent with the predicted FH/FHR3 protein. The intermediate band contained 
peptide sequences that matched the FH reference sequence. Finally the smallest band, 
proposed earlier to be a degradation product of FH/FHR3, contained peptide fragments 
that matched to FH. These 7 peptides covered 8% of FH and did not include the 402 
amino acid position. As a result it did not offer further support to the earlier western blot 
findings (Figure 3-11C), which confirmed the 120kDa band was a degradation product 
of the hybrid FH/FHR3 protein. Detailed peptide sequence coverage from this 
experiment can be seen in Appendix F. 
3.2.3.3. Cell surface decay haemolytic assay 
The hybrid FH/FHR3 species was shown to lack the C-terminal region of FH, Figure 
3-11B, a region that is critical for cell surface binding (Ferreira et al., 2009). It was 
therefore predicted to have defective cell surface binding and thus, not able to regulate 
complement activity on the surface of cells. To test this hypothesis a cell surface decay 
haemolytic assay was performed. This assay measures the ability of FH species to 
accelerate the decay of the AP convertase on the cell surface. It was hypothesised that 
more OX24-purified FH and FH/FHR3 from the patient, would be required to offer the 
same degree of protection from lysis, as when using OX24-purified FH from a control. 
Figure 3-13 shows the results of the assay, performed with the help of Edwin Wong. 
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Figure 3-13 Results of the cell surface decay haemolytic assay. 
Control serum- filled circles and a solid line. Patient serum- filled triangles and a broken line. 
X-axis shows the Log concentration of purified FH or FH and FH/FHR3 mixture used, in nM. 
Y-axis shows the percentage protection from lysis. 
This graph demonstrated that when purified FH species from patient were used, the 
curve shifted to the right. This corresponded to the increased amount of protein needed 
to achieve comparable protection from lysis, as when using protein from the control. 
This supported the hypothesis that the purified FH mixture from the patient, was unable 
to perform as well as the control, due to the presence of half levels of wild type FH. The 
hybrid FH/FHR3 failed to function, due to the lack of the C-terminal domains of FH. 
This result was similar to what was seen by Francis et al. (2012) for another FH/FHR3 
hybrid protein, which contained CCPs 1-19 from FH and all 5 CCPs of FHR3. 
3.3. Overview of pathogenic changes in CFH 
CFH is the most commonly mutated gene, occurring in approximately 30% (Kavanagh 
et al., 2013, Maga et al., 2010, Fremeaux-Bacchi et al., 2013), of all aHUS patients. 
Gene defects include missense and nonsense sequence variants, genomic 
rearrangements and gene conversion events. This section examined all cases in the 
Newcastle aHUS cohort, both sporadic and familial, with CFH gene defects; firstly, to 
determine the types and frequency of genomic events in CFH and CFHRs; secondly, to 
review all rare point mutations and INDELs observed in CFH. 
To date there have been five different gene rearrangements reported (Maga et al., 2011, 
Venables et al., 2006, Valoti et al., 2015, Eyler et al., 2013, Francis et al., 2012) and 
three gene conversions (S1191L, V1197A or S1191L/V1197A) (Heinen et al., 2006), 
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shown in Figure 3-14. In this project one novel gene rearrangement was found between 
CFH and CFHR3 and one novel gene conversion in CFHR1 was reported. The novel 
CFH/CFHR3 was described in section 3.2 and labelled ‘H’ in Figure 3-14. The 
conversion of CCP20 of FH with CCP5 of FHR1, was not reported in the literature and 
led to the occurrence of two missense sequence variants p.L290S and p.A296V, see 
Figure 3-14B. 
 
Figure 3-14 Gene conversions and rearrangements between FH, FHR1 and FHR3. 
White CCPs= derived from FH, black CCPs= derived from FHR1 and grey CCPs= derived 
from FHR3. Structure of FH. Structure of 2 conversion proteins, A (Heinen et al., 2006) and B 
(not reported in literature). Structure of 6 rearrangement proteins, C (Maga et al., 2011), D 
(Venables et al., 2006), E (Valoti et al., 2015), F (Eyler et al., 2013), G (Francis et al., 2012) 
and H (described in section 3.2). 
Overall 36.8% of CFH defects seen in the Newcastle cohort were gene rearrangements 
or conversions. This highlights the importance of CNV screening in aHUS patients, 
because Sanger sequencing does not detect gene rearrangements. The frequency of gene 
conversions and rearrangements in sporadic compared to familial cases was 32.5% and 
60% respectively, shown in Table 9. It was interesting to observe that there were a 
higher proportion of gene rearrangements and conversions in familial compared to 
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sporadic cases. This might be because these genetic defects have increased disease 
penetrance.  
Gene conversions A and B were identified by Sanger sequencing, to reveal two possible 
missense variants, S1191L and V1197A or L290S and A296V respectively. These 
variants can occur together or alone, depending on the extent of the gene conversion 
tract. Gene conversions were identified in 15.8% of the cohort; mainly in subtype A 
(14.5% of cohort). S1191L alone was most commonly observed, followed by V1197A 
and S1191L/V1197A together. Only one gene conversion type B was observed, with the 
presence of both missense variants, L290S and A296V. No patients had the sequence 
variant Q1076E, which was reported as a potential gene rearrangement between FHR1 
CCP 3 and FH CCP18 (Heinen et al., 2006).  
Gene rearrangements were seen at higher frequency than gene conversions reported in 
21.1% of the cohort. CFHR1/CFH reverse hybrids, type E and F, were the most 
frequently observed (11.6% of cohort), followed by CFH/CFHR1 hybrids C and D 
(7.4%) and CFH/CFHR3 hybrids G and H (2.1%). CFH and CFHR3 are less similar, 
which might explain why rearrangements between them were less frequent compared to 
CFH and CFHR1. Rearrangements type D and F, which involved CCPs 19 and 20 of 
FH or CCPs 4 and 5 of FHR1, were more common than rearrangements C and E, which 
involved CCPs 20 of FH and CCP5 of FHR1. This was predicted to be because CCPs 
19 of FH and CCP 4 of FHR1 shared the greatest sequence identity (Jozsi and Zipfel, 
2008). 
It was interesting to observe that MMEJ only occurred in CFH/CFHR3 hybrids. This 
might be due to lower sequence homology between the two genes, meaning that HR 
occurs less frequently. The exact conditions that decide which DSB repair mechanism 
will take place, is still relatively unknown (Kass and Jasin, 2010). Ultimately the 
resulting proteins shared similar cell-surface binding defect as FH/FHR1 hybrids. 
 
  
 
6
6
 
CFH defect 
Number of cases 
Percentage (%) 
Sporadic Familial Total 
Mechanism Subtype 
Conversion 
A 
S1191L 3 4 7 7.4 
14.7 
15.8 
36.8 
 
V1197A 4 0 4 4.2 
S1191L/V1197A 3 0 3 3.2 
B 
L290S 0 0 0 0.0 
1.1 A296V 0 0 0 0.0 
L290S/A296V 1 0 1 1.1 
Rearrangement  
C 1 0 1 1.1 
7.4 
21.1 
D 4 2 6 6.3 
E 3 1 4 4.2 
11.6 
F 6 1 7 7.4 
G 0 1 1 1.1 
2.1 
H 1 0 1 1.1 
Rare missense, splice site, nonsense, 
INDEL  
54 6 60 63.2 
Total 80 15 95 100 
Table 9 CFH gene defects and the number of cases they are reported in. 
Sporadic cases are counted as one case. Affected family members are combined to give 1 familial case (15 families in total). 
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The remaining 63.2% of genetic abnormalities in CFH were rare missense, nonsense, 
small INDELs or affected splice sites. These variants were plotted on the FH protein, 
shown in Figure 3-15. In total 44 different sequence variants were observed in the 
aHUS cohort, of which 41% were located in CCPs 19-20, a region that was critical for 
cell surface regulation (Ferreira et al., 2009). Identification of the variants found within 
CCPs 1-18 revealed that less than half (42.3%) were missense variants, 26.9% were 
nonsense, 15.4% altered splice sites and 15.4% were INDELs. This suggested that 
variants in this area of the protein were likely to have a substantial effect on the protein. 
Indeed 4 out of the 11 missense variants reported, involved the loss of a cysteine residue, 
which was predicted to be highly detrimental to protein structure. Only 3 sequence 
variants were present in homozygosity, supporting previous reports that CFH 
haploinsufficiency caused aHUS (Warwicker et al., 1998). 
 
Figure 3-15 CFH mutations seen in Newcastle aHUS cohort. 
All missense, nonsense, INDELs and splice site variants are plotted on FH. This information 
includes 2 variants described in chapter 4 (E625* and C1152S). Sequence variants that were 
present in homozygosity are represented by ‘#’. 
3.4. Discussion 
The high degree of sequence homology between CFH and the CFHRs could lead to 
gene conversions or rearrangements leading to changes in copy number. Sanger 
sequencing does not detect gene rearrangements and as a result techniques such as 
MLPA and western blotting, were essential in detecting abnormalities.  
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The patient described in section 3.2 was shown to have a novel CFH/CFHR3 gene. 
MLPA screening indicated the deletion of exon 23 of FH and further genetic analysis 
revealed that this deletion extended to the last three exons of CFH (exons 21-23), the 
result of MMEJ.  This caused irregular gene splicing, leading to the incorporation of 
exons 2-6 of the adjacent gene, CFHR3. Analysis of cDNA from the patient revealed 
that an mRNA transcript was produced from the hybrid gene. Proteomic testing 
confirmed that a hybrid FH/FHR3 protein was produced in patient serum. Western 
blotting confirmed the loss of the C-terminal CCP20 of FH in the hybrid protein. Mass 
spectrometry of FH/FHR3 protein indicated the hybrid protein contained peptides 
identical to the FHR3 reference sequence.  
Functional analysis demonstrated that the loss of the C-terminal domains of FH 
prevented the regulation of complement at the cell surface, similar to what was seen in 
another FH/FHR3 protein (Francis et al., 2012). These results emphasised the 
importance of FH-mediated complement regulation at the cell surface, as had been 
previously reported (Ferreira et al., 2009). This patient had onset of disease after an E. 
coli and viral infections, indicating that an environmental trigger was necessary for 
onset of aHUS. This mutation caused haploinsufficiency where one functional copy 
CFH was unable to prevent disease onset. 
The Newcastle cohort was then analysed for all rare CFH sequence variants, genomic 
rearrangements and conversion events. Genomic rearrangements and conversion events 
occurred in 36.8% of cases with a CFH genetic aberration, of which 34.7% were 
between CFH and CFHR1. This was hypothesised to be the result of high sequence 
homology between these two genes. Gene rearrangements occurred mainly by NAHR, 
with the exception of two cases, which occurred by MMEJ. The exact mechanisms that 
determine which DNA repair mechanism is used, is not currently known. However it 
was hypothesised that CFH and CFHR3 do not possess sufficient sequence homology 
for HR to take place (Rubnitz and Subramani, 1984).  
Characterisation of rare sequence variants in CFH observed in the aHUS cohort 
revealed that 41% were located in CCPs 19-20, a region known to be critical for 
function. Variants occurring in CCPs 1-18 were shown to be highly deleterious, with 
57.7% comprising of nonsense variants, INDELs or variants affecting splice sites. Only 
3.2% of sequence variants (including gene rearrangements and conversions) were found 
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in homozygosity, indicating that CFH- associated aHUS has predominantly an 
autosomal dominant inheritance. The screening of the 28 familial aHUS cases did not 
identify CNVs in CFH or CFHRs, results shown in the Supplementary data. Therefore 
Sanger sequencing and WES were used to look for sequence variants occurring in genes 
known to cause TMA, described in chapter 4. 
 
  
  
70 
 
Chapter 4: Identification of mutations in known TMA-causing genes 
4.1. Introduction 
TMAs present with a combination of pathologies, including MAHA, thrombocytopenia 
and microvascular thrombosis due to endothelial injury (Scully and Goodship, 2014). 
Patients can experience an acute deterioration in kidney function, which requires urgent 
treatment (Barbour et al., 2012). 
One example of a TMA is aHUS, which as discussed in section 1.1.2, is the result of 
complement deregulation, caused by genetic variants in complement genes or 
autoantibodies against complement regulators (Kavanagh and Goodship, 2010). The 
second is Thrombotic thrombocytopenic purpura (TTP), where patients have a 
deficiency of A Disintegrin and Metalloproteinase with Thrombospondin type 1 motifs, 
member 13 (ADAMTS13) (Crawley and Scully, 2013). This is either the result of 
autoantibodies or inactivating mutations in ADAMTS13 (Shenkman and Einav, 2014). 
ADAMTS13 is a metalloprotease that can cleave von Willebrand factor (vWF) 
multimers (Furlan et al., 1996). vWF multimers are prothrombotic, as they promote 
platelet aggregation, therefore reduced ADAMTS13 activity leads to a prothrombotic 
environment (Sadler, 1991). Finally genetic abnormalities in MMACHC can lead to 
cobalamin c disease, where patients are at an increased risk of developing TMAs 
(Sharma et al., 2007). 
4.1.1. Aims 
This chapter investigated the genetic cause of disease in familial aHUS cases with an 
unknown genetic aetiology. The rationale for looking only at familial cases was that it 
was more probable that the disease was the result of a hereditary genetic factor. Patients 
were screened using Sanger sequencing and WES for known TMA-causing genes CFH, 
CFI, MCP, CFB, C3, THBD, MMACHC and ADAMTS13.  
4.2. Patient screening 
In total 28 familial aHUS cases with an unknown genetic aetiology were included in 
this project. All families had at least one family member screened for CNVs in CFH 
and CFHRs, MCP and FI, by MLPA and western blotting. However no CNVs were 
detected, all results are shown in the Supplementary data. All available clinical data is 
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shown in Appendix G (Table 41) and the screening results can be seen in Appendix H 
(Table 42). Routine Sanger sequencing was performed for CFH, MCP, CFI, C3, CFB 
and THBD if sufficient DNA was available for Sanger sequencing and WES. Out of the 
total of 28 families, 26 were also submitted for WES. WES data was screened for 
sequence variants occurring in CFH, MCP, CFI, C3, CFB, THBD, MMACHC and 
ADAMTS13.  
4.3. Factor H 
Factor H (FH) is an important regulator of the alternative complement pathway, with 
cofactor and decay acceleration activities. It is the most commonly mutated gene in 
aHUS patients, as discussed previously in section 1.3.1. CFH sequence variants were 
identified in two families, described below. 
4.3.1.  Family 23  
4.3.1.1. Clinical history 
This was a family from Brazil, with two affected offspring who have since been lost in 
clinical follow up. DNA was available for testing for II:1 only. Routine diagnostic 
screening of CFH exons 18-23, by the Northern Genetics Service, revealed no disease-
causing candidate variants.  
 
Figure 4-1 Pedigree for family 23. 
Proband was indicated by the arrow. ‘*’ indicated sample was sent for WES. 
There was a limited quantity of DNA available for the proband, so screening of the 
remaining disease-associated genes by Sanger sequencing was not feasible. To 
overcome this issue, WES was carried out. 
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4.3.1.2. Identified sequence variant 
WES revealed a heterozygous nonsense mutation in CFH; c.1873G>T, p.E625*. This 
nonsense variant was found in exon 12 of CFH, encoding CCP 11. This sequence 
variant was present on dbSNP (rs150694809) and had a MAF of 0% in 1000g and a 
MAF of 0.02% in ESP6500. This variant has been previously reported by Maga et al. 
(2010) in the American aHUS population. 
 
Figure 4-2 Sequencing chromatogram for CFH E625*. 
The chromatograms show the sequencing results for the patient (II:1) and a control. The amino 
acid sequence encoded by exon 12 is shown above, where the dotted line denotes the intronic 
region. 
4.3.1.3. In silico analysis 
The gain of stop codons are severely detrimental, as it would cause the cessation of 
mRNA translation, leading to protein truncation or nonsense-mediated mRNA decay 
(Miller and Pearce, 2014). This position was highly conserved with GERP++ and 
PhyloP scores of 5.12 and 2.876 respectively, suggesting that it had an important 
function. This was supported by the ‘deleterious’ prediction when using Mutation taster. 
If the protein was secreted, it would lack the C-terminal domains, which are critical for 
cell surface binding (Ferreira et al., 2009). This sequence variant had already been 
observed in conjunction with aHUS, although FH levels were not measured in this study 
so it cannot be established whether this nonsense variant abrogates protein secretion 
(Maga et al., 2010).  
4.3.2. Family 28 
4.3.2.1. Clinical history 
The proband was a 32-year old Caucasian female patient who was referred with a fever 
and headache, which had lasted for over a week. Laboratory evaluation showed MAHA, 
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thrombocytopenia, proteinuria, haematuria and elevated serum creatinine. Stool culture 
failed to demonstrate the presence of Shiga toxin-producing E. coli. ADAMTS13 
activity was within the normal range (73%) and anti-FH and anti-ADAMTS13 
autoantibody screening was negative. Serum levels of C4 was normal (0.28g/L), 
whereas the levels of C3, 80mg/dL (normal range 85-200mg/dL) and FH, 0.32g/l (0.35-
0.59g/L), were low.  This led to a diagnosis of aHUS and plasma exchange was initiated. 
The proband was then treated with eculizumab and after 20 months, had a normal 
creatinine and no evidence of MAHA. The proband’s mother (I:2) died in her early 
thirties with a clinical picture consistent with a TMA.  
 
Figure 4-3 Pedigree for family 28. 
Proband was indicated by the arrow. Genotype was shown in bold. 
4.3.2.2. Identified sequence variant 
Sanger sequencing performed by the Northern Genetics Service identified a 
heterozygous change in exon 21 of CFH, c.3454T>A, p.C1152S. This sequence variant 
has not been previously reported in dbSNP, ESP6500 or 1000g. It was hypothesised that 
it was inherited from the affected mother (I:2), although DNA was not available for 
testing. The father (I:1) and unaffected sister (II:6) did not carry the CFH variant, 
whereas the unaffected brothers (II:3, II:4 and II:5) did. Screening of the proband’s 
offspring (III:1-3) was not carried out. 
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Figure 4-4 Sequencing chromatogram for CFH C1152S. 
The chromatograms show the sequencing results for the patient (II:2) and a control. The amino 
acid sequence encoded by exon 21 is shown above. 
4.3.2.3. In silico analysis 
Loss of a cysteine residue is often highly detrimental to the secondary structure of a 
protein as it is involved in the formation of internal disulphide bridges. This was 
particularly important as FH is composed of 20 CCP domains, which contain 4 cysteine 
residues allowing the domains to be tightly compacted (Reid and Day, 1989). Figure 4-5 
demonstrated the disulphide bridge formed in CCP19 between C1152 and C1109. The 
substitution of cysteine for a serine would disrupt the disulphide bridge and as a result, 
predicted to cause the protein to misfold.  
 
Figure 4-5 Protein model of FH C1152 
Cartoon representation of factor H CCP19-20 (Protein Data Bank ID 3SWO) (Morgan et al., 
2012) displayed in PyMOL. CCPs were shown in grey, red and green indicated the intra-
modular disulphide bonds of C1152 and C1109, respectively. 
This prediction was supported by the use of in silico tools, which identified C1152S as 
being deleterious to the protein (PolyPhen-2 HDIV and HVAR, Mutation Assessor and 
FATHMM), although Mutation Taster classed this as a polymorphism. This sequence 
variant occurred in an evolutionary conserved area, with a PhyloP score of 2.737. When 
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amino acid sequences were aligned in multiple species, it was found to be conserved 
across all species, apart from Zebrafish. 
 
Figure 4-6 Amino acid sequence alignment for FH C1152. 
Human wild type and mutant sequences are compared to 10 species. Grey shaded column 
indicated position of C1152. Amino acids in bold indicate a difference to the human reference 
sequence. 
These deleterious predictions were supported by the low levels of FH observed in the 
proband, suggesting that misfolding of the protein prevented protein secretion. It was 
interesting to observe that the siblings (II:3, II:4 and II:5) who also carried this sequence 
variant, did not have disease. This coincided with previous findings that disease 
penetrance was not complete and that additional factors might be necessary to cause 
disease (Kavanagh et al., 2013). 
4.4. Factor I 
FI is a serine protease that can inactivate C3b and C4b by removing their alpha chains, 
in the presence of a cofactor, such as MCP and FH (Kavanagh et al., 2005). Mutations 
in CFI have been associated with aHUS, as discussed in section 1.3.3. A CFI sequence 
variant was identified in a familial case of aHUS, described below. 
4.4.1. Family 27  
4.4.1.1. Clinical history 
This was a family with two affected daughters, both of whom are now deceased. The 
proband was a 16 year old female, who presented with headache and vomiting. Further 
analysis indicated acute renal failure with hypertension, thrombocytopenia and MAHA. 
She then suffered a cardiac arrest and died. Diagnostic screening revealed normal serum 
levels of FH (0.45g/L) and C3 (1.33g/L). Her older sister (II:1) died at 19 years of age 
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after a similar episode, following recurrent aHUS-like episodes over the preceding 12 
months. The mother died at 39 years of age, although her cause of death was unclear. 
 
Figure 4-7 Pedigree of family 27. 
Proband was indicated by the arrow. ‘*’ indicated sample was sent for WES. Heterozygous 
genotype was indicated by RV. 
4.4.1.2. Identification of Genetic variants  
WES led to the discovery of a heterozygous CFI mutation in the proband, c.1246A>C, 
p.I416L. This was listed on dbSNP (rs61733901) and had a MAF of 0.14% in 1000g 
database and 0.4% in ESP6500. This change was found in exon 12 and encodes part of 
the serine protease domain of FI. 
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Figure 4-8 Sequencing chromatogram for CFI I416L. 
The chromatograms show the sequencing results for the patient (II:2) and a control. The amino 
acid sequence encoded by exon 12 is shown above. 
4.4.1.3. In silico analysis 
The pathogenicity of CFI I416L was predicted using in silico tools. GERP++ and 
PhyloP predicted this variant to be in an evolutionary conserved position, with scores of 
5.62 and 2.145 respectively. If the amino acid sequence of FI was aligned at the position 
of I416 and compared to other species, it was observed that the isoleucine was 
conserved in all species apart from rat.  
 
Figure 4-9 Amino acid sequence alignment of FI I416. 
Human wild type and mutant sequences are compared to 10 species. Grey shaded column 
indicated position of I416. Amino acids in bold indicate a difference to the human reference 
sequence. 
These results suggested that this amino acid may be important in FI function. Indeed 
I416L was predicted to be deleterious by all in silico tools apart from PolyPhen-2 and 
Mutation Assessor, which classed it as benign and medium impact, respectively. Protein 
modelling of I416L on FI was carried out to determine a possible mechanism for 
disease, shown in Figure 4-10. It was observed that I416L was located in close 
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proximity to the catalytic triad H362, D411 and S507 (Morley and Walport, 2000), 
suggesting that it may affect FI serine protease activity. 
 
Figure 4-10 Protein model of FI I416L. 
FI structure obtained from Protein Data Bank (2XRC) (Roversi et al., 2011) and viewed in 
PyMOL. FI is shown in a cartoon format, with the heavy chain in grey and the serine protease 
domain in green. Amino acids that make up the catalytic triad, H362, D411 and S507 (Morley 
and Walport, 2000), were shown as blue spheres. I416L was shown by red spheres. 
4.4.1.4. Evidence in literature 
This sequence variant had been previously reported by Sellier-Leclerc et al. (2007) in 
the French aHUS cohort, (annotated as p.I398L when numbered from beginning of 
mature protein). It was found in a patient with low C3 (348mg/L, compared to a normal 
range of 660-1260mg/L) and FI (70% of the expected amount) levels in the serum. 
Bienaime et al. (2009) then found 3 additional sporadic aHUS cases with I416L. Of 
these three individuals, 2 had low C3 levels and out of two with FI levels tested, 1 had 
low FI levels. Finally I416L had also been reported in one patient in the American 
aHUS cohort, although no clinical information was provided (Maga et al., 2010). Serum 
levels of FI for the proband were not available, however it was hypothesised that they 
were low, coinciding with observations of Bienaime et al. (2009) and Sellier-Leclerc et 
al. (2007).  
Bienaime et al. (2009) then performed in vitro functional analysis by recombinantly 
transfecting HEK293 cells with a wild type or mutant FI vector. They demonstrated that 
cells with the I416L mutant had lower FI levels in supernatant than cells containing the 
wild type FI vector. It was proposed that low FI secretion was due to the protein being 
retained within the cell. To test this hypothesis immunofluorescence was carried out on 
the mutant and control HEK293 cells. Control FI protein was found to colocalise with 
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wheat germ agglutinin, a marker of the trans-Golgi network, whereas the I416L mutants 
colocalised with protein disulfide isomerise, a biomarker of the endoplasmic reticulum 
(Bienaime et al., 2009).  
4.5. Membrane Cofactor Protein (MCP) 
MCP (Membrane cofactor protein) is a cell surface bound complement regulator, which 
acts as a cofactor to FI in the cleavage of 3b and C4b (Seya et al., 1986). MCP 
mutations have been reported in association with aHUS, as described in section 1.3.4. 
This section described MCP sequence variants identified in 4 familial aHUS cases. 
4.5.1. Family 4  
4.5.1.1.  Clinical history 
This family had two affected family members, across two generations (father and son). 
I:1 had normal complement levels (FH-0.67g/L, FI-47mg/L), 2 copies of CFHR1-3 and 
was negative for FH-autoantibodies. The proband had normal complement levels (FH- 
0.61g/L, FI- 46mg/L), 2 copies of CFHR1-3 and was negative for anti-FH 
autoantibodies. Routine Sanger sequencing of CFH revealed no mutations.  
 
Figure 4-11 Pedigree for family 4. 
Proband was indicated by the arrow. ‘*’ indicated sample was sent for WES. 
4.5.1.2. Identified sequence variant 
WES revealed a heterozygous mutation in exon 5 of MCP, c.565T>G, p.Y189D that 
segregated with disease. It was listed on dbSNP as rs202071781, had a MAF of 0.02% 
on 1000g and was not seen in ESP6500. This variant had been previously reported in 
aHUS patients (Fremeaux-Bacchi et al., 2006, Sullivan et al., 2010, Maga et al., 2010).  
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Figure 4-12 Sequencing chromatogram for MCP Y189D. 
Top was the result for the control, then I:1 and at the bottom was II:1. Y189D is indicated by an 
arrow. The amino acid sequence encoded by exon 5 is shown above. 
4.5.1.3. In silico analysis 
In silico analysis indicated that Y189 was a conserved amino acid, with a GERP++ 
score of 4.85 and a PhyloP score of 2.158. Figure 4-13 shows the amino acid sequence 
alignment of Y189 in 10 species. The tyrosine residue was highly conserved in all 
species except for platypus and zebrafish.  
 
Figure 4-13 Amino acid sequence alignment of MCP Y189. 
Human wild type and mutant sequences are compared to 10 species. Grey shaded column 
indicated position of Y189. Amino acids in bold indicate a difference to the human reference 
sequence. 
Y189D was predicted to have a deleterious effect on the protein by PolyPhen-2 (HDIV 
and HVAR), Mutation Assessor and RadialSVM. Mutation Taster and FATHMM 
reported it to be ‘neutral’ and ‘tolerated’ respectively. To determine a possible 
mechanism for disease, Y189D was plotted on a protein model of CCPs 1-4 of MCP. 
Y189D was found in CCP3 close to the hinge region between CCPs 3 and 4, an area 
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involved in C3b and C4b binding (Liszewski et al., 2000). This might indicate that 
Y189D could alter ligand binding, reducing its cofactor activity. 
 
Figure 4-14 Protein model of MCP Y189D. 
Predicted protein structure of MCP CCPs 1-4 (amino acids 35-285), created using Phyre2. 
CCPs are shown as cartoons in grey. Red spheres indicate the position of Y189D. Protein 
structure was positioned against the cell membrane, adapted from (Persson et al., 2010). 
4.5.1.4. Evidence in literature 
Experiments in vitro demonstrated that Y189D might cause a structural abnormality, 
leading to retention of protein in the endoplasmic reticulum. This was shown by the 
increase in the ratio of precursor and mature MCP observed, in cells transfected with a 
mutant vector (Fremeaux-Bacchi et al., 2006). This led to the hypothesis that Y189D 
altered protein folding, which caused a reduction in protein expression on the cell 
surfaces. Fremeaux-Bacchi et al. (2006) reported three aHUS patients with Y189D, who 
also carried either D185N on the same allele or IVS7-2A>G on an alternate allele. They 
found that patient peripheral blood mononuclear cells (PBMCs) containing the mutant 
MCP gene, had reduced cell surface expression, supporting in vitro experiments. 
Reduction of MCP expression would cause inadequate complement regulation on the 
surface of the cells, leading to onset of disease. Samples from the proband and the 
proband’s father were not available for testing, so reduced surface expression of MCP 
could not be demonstrated. 
  
82 
 
4.5.2. Families 18 and 22 
4.5.2.1. Clinical history  
Family 18 had an affected sibling pair. DNA was available for testing from both 
affected individuals. The proband’s FH serum level (0.70g/L) was normal and genetic 
screening of CFH exons 19-23 revealed no candidate mutations. II:2 had normal FH 
(0.68g/L) and FI (63mg/L) levels, was negative for anti-FH autoantibodies and genetic 
screening of CFH exons 19-23 revealed no mutations. MLPA screening revealed 2 
copies of CFHR1/3 in both II:1 and II:2.  
 
Figure 4-15 Pedigree for family 18. 
Proband was indicated by the arrow. ‘*’ indicated sample was sent for WES. Genotype was 
shown in bold. 
Family 22 contained two affected brothers. The proband had normal serum levels of 
complement proteins C3 (0.75g/L), C4 (0.20g/L), FH (0.50g/L) and FI (49mg/L). 
MLPA indicated the patient had 1 copy of CFHR1/3. Diagnostic screening of 
complement genes (C3, CFH and CFI) failed to identify any rare sequence variants. 
 
Figure 4-16 Pedigree for family 22. 
Proband was indicated by the arrow. ‘*’ indicated sample was sent for WES. Genotype was 
shown in bold. 
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4.5.2.2. Identified sequence variant 
The probands in families 18 and 22 were both found to have a sequence variant in MCP, 
c.286+2T>G. The affected sibling in family 18 (II:2) was also demonstrated to carry 
this variant in heterozygosity, shown in Figure 4-17. This variant occurred in the 5’ end 
of intron between exons 2 and 3, causing disruption to the splice donor site. This variant, 
also referred to as IVS2+2T>G, had been previously reported in the French (Fremeaux-
Bacchi et al., 2006), American (Maga et al., 2010) and Dutch (Westra et al., 2010) 
aHUS cohorts. It was listed on dbSNP (rs186757635), reported in 1000g with a MAF of 
0.02% and was not found on ESP6500. 
 
Figure 4-17 Sequencing chromatogram for MCP c.286+2T>G. 
The chromatograms show the sequencing results for the patients and a control. The amino acid 
sequence encoded by exon 2 is shown above, the dotted line denotes the intronic region. 
4.5.2.3. In silico analysis 
In silico analysis found that the nucleotide substitution would reduce the score of the 
donor splice site from 79.30 (maximum was 100) to 62.18, suggesting that it might have 
caused abnormal gene splicing. This variant was predicted to be deleterious by Mutation 
Taster and conserved by GERP++ (2.33) and PhyloP (0.661). 
4.5.2.4. Evidence in literature 
Fremeaux- Bacchi et al. (2006) sequenced mRNA from a patient who was homozygous 
for c.286+2T>G. They identified that this sequence variant caused the 45
th
 nucleotide of 
exon 2 to splice into exon 3, causing a 144bp deletion from the 3’ end of exon 2. The 
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resultant protein would have lost 48 amino acids. This patient was shown to have 
between 0-25% MCP expression on granulocytes compared to controls. It was predicted 
that the patients described here, who were heterozygous for c.286+2T>G would have 
approximately 50% reduction in the surface expression of MCP. However no patient 
material was available for testing to corroborate this hypothesis.  
4.5.3. Family 26  
4.5.3.1. Clinical history  
Family 26 was referred to the National aHUS Service from Saudi Arabia. The parents 
were not cousins but were from the same tribe and therefore classed as consanguineous. 
The parents (I:1 and I:2) and two unaffected offspring II:1 and II:5 had no reported 
renal phenotype. There had been 4 affected offspring, one of whom had died. 
II:2 first presented at 12 years old (now 24 years old) required transfusions to mediate 
frequent occurrences of thrombocytopenia. Individual II:3 was 15 years old when he 
had severe thrombocytopenia. He did not respond well to plasma therapy and died. II:4 
presented at 14 years old with frequent attacks of thrombocytopenia. He had one severe 
attack which was complicated with a central nervous system haemorrhage, however 
currently had normal renal function. The proband (II:6) presented at 10 years of age 
with flu-like symptoms, fever, thrombocytopenia and elevated serum creatinine. Serum 
C3 levels were borderline low (0.7g/L, normal range 0.68-1.38 g/L) and C4 levels were 
normal. 
 
Figure 4-18 Pedigree for family 26. 
Parents were consanguineous, indicated by double line. Proband was indicated by the arrow. 
MCP F246I genotype was indicated by ‘RV’ for heterozygous or ‘VV’ in homozygous. 
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4.5.3.2. Genetic variant 
Routine diagnostic testing of genes associated to aHUS, performed by the Northern 
Genetics Service, revealed the sequence variant c.736T>A, p.F246I in MCP. This was 
found in exon 4, encoding CCP 4 of MCP. The proband (II:6) and one of the other 
affected offspring (II:2), were identified as homozygous for the variant (no DNA was 
available for testing for II:3 and II:4). The parents and 2 unaffected offspring (II:1 and 
II:5) were shown to carry the variant in heterozygosity. This sequence variant was not 
previously described in any aHUS cohort, nor was it observed in 1000g or ESP6500 
databases. 
 
Figure 4-19 Sequencing chromatogram for MCP F246I. 
Each chromatogram refers to a family member from the pedigree shown in Figure 4-18. The 
amino acid sequence encoded by exon 4 is shown above. All affected individuals tested (II:2 and 
II:6) were homozygous for the change, whereas all remaining family members were 
heterozygous. 
4.5.3.3. In silico analysis 
In silico analysis was used to determine whether F246I occurred in an area that was 
conserved across evolution. Firstly PhyloP gave this sequence variant a score of 0.729, 
indicating it was evolutionary conserved. Secondly sequence alignment against 10 other 
species, shown in Figure 4-20, indicated that this amino acid was conserved in half of 
the species tested. 
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Figure 4-20 Amino acid sequence alignment of MCP F246. 
Human wild type and mutant sequences are compared to 10 species. Grey shaded column 
indicated position of F246. Amino acids in bold indicate a difference to the human reference 
sequence. 
F246I was then analysed to see if it was predicted to cause a detrimental effect to the 
MCP’s structure and function. PolyPhen-2 HDIV and HVAR classed this variant as 
deleterious, whereas Mutation Taster, Mutation Assessor and FATHMM classed it as 
‘polymorphism’, ‘medium impact’ and ‘tolerated’, respectively. This might indicate that 
this missense substitution had a lesser impact on the protein and only when present in 
homozygosity, would it cause disease. In order to investigate the potential effect of 
F246I on protein function, it was plotted on the protein model of CCPs 1-4 of MCP. 
F246I was positioned in CCP4, close to the hinge region between CCPs 3 and 4 and 
therefore predicted to alter protein conformation.  
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Figure 4-21 Protein model of MCP F246I. 
Predicted protein structure of MCP CCPs 1-4, created using Phyre2. CCPs are shown as 
cartoons in grey. Red spheres indicate the position of F246I and blue spheres indicate S240P. 
Protein structure was positioned against the cell membrane, adapted from Persson et al. (2010). 
Functional work had been performed on a nearby mutation S240P (Richards et al., 
2003). Patients with this mutation were shown to express MCP on their PBMCs, at 
levels comparable to controls. However in vitro experiments identified that the 
substitution abrogated C3b binding. No patient samples were available to test MCP 
expression on cell surfaces. It was hypothesised that the protein was either not present at 
the cell surface or if it was expressed, then it would not bind to C3b and would have no 
cofactor activity.  
The occurrence of MCP deficiency is very rare (10% of MCP-aHUS) (Liszewski et al., 
2007) and interestingly, nearly a half of these patients also develop common variable 
immunodeficiency (Fremeaux-Bacchi et al., 2006, Couzi et al., 2008). This may be 
because MCP-activated T cells induce B-cells more strongly, leading to increased Ig 
expression (Fuchs et al., 2009).  
4.6. ADAMTS13 
4.6.1. Gene background 
A Disintegrin and Metalloproteinase with Thrombospondin type 1 motifs, member 13 
(ADAMTS13) contains 29 exons and is located on chromosome 9q34 (Levy et al., 2001). 
It encodes a metalloprotease that can cleave large vWF multimers into smaller subunits 
(Crawley and Scully, 2013). Loss of ADAMTS13 activity leads to a build up of ultra 
large vWF multimers leading to a prothrombotic disease, known as TTP 
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(Stockschlaeder et al., 2014). TTP can be caused by sequence variants in ADAMTS13 or 
autoantibodies that inhibit ADAMTS13, both of which result in low ADAMTS13 
activity, approximately <5-10% (Scully and Goodship, 2014, Zheng et al., 2010). 
Sequence variants are inherited in an autosomal recessive or compound heterozygous 
pattern (Peyvandi et al., 2004). Figure 4-22 demonstrates all sequence variants reported 
in ADAMTS13 to date.  
 
Figure 4-22 Diagram showing sequence variants reported ADAMTS13. 
Variants were taken from TTP database (Peyvandi) and scientific literature, rare and common 
SNPs were included. The protein structure  was adapted from Plaimauer et al. (2006). Variants 
in bold, indicated that they were identified here.  
This section described two families that were found to have compound heterozygous 
sequence variants in ADAMTS13. 
4.6.2. Family 7 
4.6.2.1. Clinical history  
Family 7 had a history of TMA in the family. The father (II:2) and daughter (III:1) were 
referred with a diagnosis of aHUS and the paternal uncle (II:1) had a diagnosis of TTP. 
The father (II:2) was screened for mutations in CFH, MCP, CFI and CFB, which were 
found to be normal. The proband was found to have 1 copy of CFHR1/3 and was 
negative for anti-FH autoantibodies.  
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Figure 4-23 Pedigree for family 7. 
Grey- indicated family members with TTP, black- with aHUS.’*’ indicated samples sent for 
WES. Proband was shown by that arrow. Heterozygous genotype was indicated by RV. 
4.6.2.2. Identification of Genetic variants 
The initial analysis of known complement genes by Sanger sequencing failed to reveal a 
genetic cause for disease, therefore WES was undertaken. This led to the identification 
of several mutations in a TMA-associated gene ADAMTS13. These changes were then 
confirmed by Sanger sequencing in multiple family members, shown in Table 10. No 
DNA was available for the mother (II:3). R7W had the highest MAF, at 10% and 12% 
in ESP6500 and 1000g respectively and was reported in dbSNP database (rs34024143). 
A1033T was seen in ESP6500 and 1000g at 3% and reported in dbSNP (rs28503257). 
R1060W was reported in ESP6500 at 0.08%, 1000g at 0.05%, in dbSNP (rs142572218) 
and was previously reported in association with TTP (Tao et al., 2006, Camilleri et al., 
2008). Neither D217H nor I673F were reported in ESP6500, 1000g databases or dbSNP, 
however both have been previously reported in association with TTP (Camilleri et al., 
2012, Matsumoto et al., 2004).  
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Sequence variant 
Exon II:1 II:2 III:1 III:2 III:3 
MAF 
(%) Transcript Protein 
c.19C>T p.R7W 1 RR RR RV RR RR 12 
c.649G>C p.D217H 6 RR RR RV RR RR 0 
c.2017A>T p.I673F 17 RR RV RV RR RV 0 
c.3097G>A p.A1033T 24 RR RR RV RR RR 3 
c.3178C>T p.R1060W 24 RR RR RV RR RR 0.05 
Table 10 Sequence variants identified in ADAMTS13 in family 7. 
R= Reference allele, V= Variant allele. MAF was given as a percentage, based on 1000 genome 
database. 
The results indicated that that the proband was compound heterozygous for changes in 
ADAMTS13. I673F originated from the father and the other sequence variants were 
hypothesised to have been inherited from the mother or were de novo. The absence of 
maternal DNA, prevented this from being determined. It was apparent that the paternal 
uncle (II:1) and father (II:2) were not compound heterozygous for sequence variants in 
ADAMTS13, suggesting that neither was affected by TTP. Deeper clinical phenotyping 
was performed and demonstrated that both the father and uncle were not affected and 
the proband had evidence of haemolysis, normal renal function and a confirmed 
ADAMTS13 activity of 2.5%. Therefore this was in fact a sporadic case of TTP; 
however this case will continue to be referred to as family 7. The pedigree was redrawn 
to demonstrate this, shown in Figure 4-24. 
 
Figure 4-24 Updated pedigree for family 7. 
4.6.2.3. Functional significance 
In silico analysis was carried out to determine if the sequence variants occurred in 
conserved regions and if they were predicted to be deleterious. GERP++ and PhyloP 
were used to investigate whether variants occurred in an evolutionary conserved area. 
Sequence variants D217H, A1033T and R1060W had scores above the preset thresholds 
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of 2 and 0.5 for GERP++ and PhyloP, respectively. I673F had a score above zero but 
below the conservation threshold, indicating it was semi-conserved. R7W was identified 
as not conserved, with negative scores in both programs.  
Sequence variant GERP++ PhyloP 
R7W -6.55 -1.237 
D217H 4.69 2.161 
I673F 1.6 0.027 
A1033T 5.59 2.64 
R1060W 3.17 1.192 
Table 11 Conservation scores for ADAMTS13 variants in family 7. 
The amino acid sequence of ADAMTS13 was then aligned with 10 other species, at the 
position of the 5 missense substitutions, shown in Figure 4-25. The findings were 
comparable to the conservation scores produced using in silico tools. R7 was not well 
conserved, only occurring in the reference sequence for chimp and orangutan. D217, 
I673, A1033 and R1060 were highly conserved, each maintained across at least 9 other 
species. 
 
Figure 4-25 Amino acid sequence alignment for ADAMTS13 variants in family 7. 
Human wild type and mutant sequences are compared to 10 species. Grey shaded column 
indicated position of amino acid substitution. Amino acids in bold indicate a difference to the 
human reference sequence. 
The functional impact of these sequence variants was then investigated, shown in Table 
12. D217H was described as deleterious by all prediction programs, with the exception 
of Mutation Assessor, which classed it as a low impact substitution. I673F, A1033T and 
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R1060W were predicted to be deleterious by PolyPhen-2 HDIV and HVAR and 
Mutation Taster, yet considered to be tolerated by FATHMM and RadialSVM. 
Mutation assessor predicted I673F and R1060W to have a medium impact and A1033T 
to have a low impact on the protein. Finally R7W was predicted to be deleterious by 
FATHMM and either benign, tolerated or a polymorphism by the remaining programs. 
Variant 
In silico testing 
PolyPhen-2 Mutation 
Taster 
Mutation 
Assessor 
FATHMM RadialSVM 
HDIV HVAR 
R7W B B P N D T 
D217H D D D L D D 
I673F D D D M T T 
A1033T D D D L T T 
R1060W D D D M T T 
Table 12 In silico results of family 7 ADAMTS13 sequence variants. 
B= benign, D= deleterious, L= low impact, M= medium impact, N= neutral, P= polymorphism 
and T= tolerated. 
4.6.2.4. Evidence in literature 
In vitro analysis had been performed on several ADAMTS13 mutations, which identified 
defects in terms of protein secretion and activity, shown in Table 13. Feng et al. (2013) 
found that secretion of protein was comparable to the control in R7W-transfected cells, 
although there was a slight decrease in protein activity (86%). I673F caused proteins to 
be retained within transfected HeLa cells (Matsumoto et al., 2004).  D217H was shown 
to be secreted in transfected HEK293T cells but had greatly reduced protein activity 
(Camilleri et al., 2012). A1033T was shown to be secreted normally in transfected 
HEK293T cells, but had slightly decreased activity (80%) (Feng et al., 2013). Although 
in HeLa cells the activity of A1033T was shown to be comparable to wild type (Tao et 
al., 2006).  Camilleri et al. (2008) demonstrated using cell lysates that R1060W did not 
affect metalloprotease activity. However it led to reduced protein expression to 5% of 
normal in HEK293T cells (Camilleri et al., 2008) and 11% of normal in HeLa cells 
(Tao et al., 2006).  
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Sequence 
variant 
dbSNP ID Domain 
In vitro testing 
Secretion (%) Activity (%) 
R7W rs34024143 Sp 99* 86* 
D217H - MP 112+ 24+ 
I673F - SPR 0** ND 
A1033T rs28503257 T1-7 100*^ 80*, 100^ 
R1060W rs142572218 T1-7 5#, 11^ 100# 
Table 13 In vitro results of ADAMTS13 sequence variants seen family 7. 
Protein activity and secretion are given as a percentage compared to wild type ADAMTS13. 
Sp= Signal peptide, MP= Metalloprotease, SPR= Spacer, T1-7= Thrombospondin Type 1- 
repeat 7, ND= not done, *=(Feng et al., 2013), **=(Matsumoto et al., 2004), 
+
= (Camilleri et 
al., 2012), 
#
=(Camilleri et al., 2008) and  ^=(Tao et al., 2006). 
R1060W and I673F have been demonstrated using in vitro assays, to lead to reduced 
protein secretion and D217H reduced ADAMTS13 activity. Genotyping of the father 
and the unaffected siblings demonstrated that I673F was likely to have been inherited 
from the father. The absence of maternal DNA meant that it was unknown if D217H 
and R1060W were inherited together from the mother or if one had occurred de novo. 
The combination of these variants on alternate alleles would cause defective 
ADAMTS13 activity, which was demonstrated in the proband (2.5% activity).  
4.6.3. Family 24 
The pedigree for Family 24 was shown in Figure 4-26. They were referred to the 
National aHUS Service as having aHUS. The proband had normal levels of FH 
(0.61g/L), 1 copy of CFHR1/3 and was negative for anti-FH autoantibodies. Genetic 
testing of CFH exons 18-23 revealed no pathogenic sequence variants. The affected 
sister was also shown to have 1 copy of CFHR1/3 and no anti-FH autoantibodies. She 
underwent genetic testing of CFI, which revealed no candidate sequence variants. 
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Figure 4-26 Pedigree of family 24. 
Proband was indicated by the arrow. ‘*’ indicated sample was sent for WES. Genotype was 
shown in bold. 
4.6.3.1. Identification of Genetic variants 
WES identified multiple sequence variants in ADAMTS13, which segregated with 
disease. These variants were confirmed by Sanger sequencing in the affected siblings 
and the mother, shown in Table 14. DNA for the father was not available. R507Q was 
absent from ESP6500 and 1000g databases, although it had been previously reported by 
Veyradier et al. (2004) in a patient with TTP. E1382RfsX6 was reported in ESP6500, in 
1 out of 12,515 alleles and previously reported in association with TTP (Kentouche et 
al., 2002, Pimanda et al., 2004). Q448E and A900V were seen more frequently, with 
MAFs in 1000g of 27% and 7.7%, respectively and in ESP6500 at 30.1% and 11.3%, 
respectively. 
Sequence variant 
dbSNP ID Exon I:2 II:1 II:2 
MAF 
(%) Transcript Protein 
c.1342C>G p.Q448E rs2301612 12 VV RV RV 27 
c.1520G>A p.R507Q rs281875296 13 RR RV RV 0 
c.2699C>T p.A900V rs685523 21 RR RV RV 7.7 
c.4142_4143insA p.E1382RfsX6 rs387906343 29 RV RV RV 0 
Table 14 Sequence variants identified in ADAMTS13 in family 24. 
R= Reference allele, V= Variant allele. MAF was given as a percentage based on 1000g 
database. 
4.6.3.2. In silico analysis 
In order to predict if the sequence variants would be pathogenic, several in silico tools 
were used. The sequence conservation was examined using GERP++ and PhyloP, 
shown in Table 15. Q448E, R507Q and A900V were classed as evolutionary conserved 
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by GERP++ and PhyloP. The conservation score for E1382RfsX6 could not be 
calculated using either program. 
Sequence variant GERP++ PhyloP 
Q448E 4.25 0.678 
R507Q 5.42 2.535 
A900V 4.55 0.971 
Table 15 Conservation scores for ADAMTS13 variants in family 24. 
Scores could not be calculated for E1382RfsX6, because INDELs are not compatible with either 
program. 
The amino acid sequence was then aligned with 10 other species. Q448 and A900 were 
poorly conserved, which differed from the predictions of GERP++ and PhyloP. R507 
was shown to be highly conserved, apart from in Zebrafish. Finally E1382 was 
maintained across 6 species, indicating that it was also evolutionary conserved. 
 
Figure 4-27 Amino acid sequence alignment for ADAMTS13 variants in family 24. 
Human wild type and mutant sequences are compared to 10 species. Grey shaded column 
indicated position of amino acid that is changed by a mutation. Amino acids in bold indicate a 
difference to the human reference sequence. 
In silico tools were used to predict the effects of the variants on the protein, shown in 
Table 16. Predictions could not be calculated for E1382RfsX6. However due to the 
occurrence of a premature stop codon, it was predicted to be functionally significant. 
R507Q was predicted to be deleterious by PolyPhen-2 (HDIV and HVAR) and 
Mutation Taster. It was then classed as having a ‘medium’ impact on ADAMTS13 by 
Mutation Assessor and predicted to be tolerated by FATHMM and RadialSVM. Q448E 
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and A900V were both predicted to be benign by PolyPhen-2 HDIV and HVAR, 
polymorphisms by Mutation Taster, neutral by Mutation Assessor and tolerated by 
FATHMM and RadialSVM. 
Variant 
In silico testing 
PolyPhen-2 Mutation 
Taster 
Mutation 
Assessor 
FATHM
M 
Radial
SVM HDIV HVAR 
Q448E B B P N T T 
R507Q D D D M T T 
A900V B B P N T T 
Table 16 In silico results of ADAMTS13 sequence variants seen family 24. 
B= benign, D= deleterious, N= neutral, P= polymorphism and T= tolerated. Predictions could 
not be calculated for E1382RfsX6. 
These predictions suggested that Q448E and A900V would have little effect on the 
protein, whereas R507Q would be highly detrimental. E1382RfsX6 was predicted to be 
damaging to the protein, as it led to the formation of a premature stop codon. 
4.6.3.3. Evidence in literature 
Feng et al. (2013) carried out in vitro analysis of ADAMTS13 sequence variants A900V 
and Q448E. They found that A900V had 0% activity and that Q448E had a slight 
reduction in activity (75%) and secretion (95%) that of the wild type ADAMTS13. 
Pimanda et al. (2004) demonstrated that E1382RfsX6 nearly entirely abolished protein 
secretion in transfected cells. 
Sequence 
variant 
Domain 
In vitro testing 
Secretion (%) Activity (%) 
Q448E Cysteine rich 95** 75** 
R507Q Cysteine rich ND ND 
A900V T1-5 ND 0** 
E1382RfsX6 CUB-2 14+ 85+ 
Table 17 In vitro results of ADAMTS13 sequence variants seen family 24. 
Secretion and activity are represented as a percentage of normal activity. **(Feng et al., 2013) 
or 
+
(Pimanda et al., 2004) 
Schneppenheim et al. (2003) identified carriers of E1382RfsX6 had ADAMTS13 levels, 
less than half that seen in healthy controls. Unaffected carriers of R507Q were also 
shown to have half the normal level of ADAMTS13 (Veyradier et al., 2004). The 
mother was confirmed to carry E1382RfsX6 and not R507Q, which confirmed that 
R507Q was on the alternate allele. This suggested that the proband and affected sibling 
were compound heterozygous and thus had absent ADAMTS13 activity, causing TTP. 
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Due to the presence of R507Q in both affected offspring, it is predicted to have been 
inherited from the father. It appeared unlikely that the same sequence variant arose de 
novo in two separate events in one family. However the absence of paternal DNA 
prevented this from being tested. 
4.7. Discussion 
In this project 28 familial aHUS cases with an unknown genetic cause, were examined 
for sequence variants occurring in genes known to be associated with TMAs. This 
included CFH, CFI, MCP, CFB, C3, THBD, MMACHC and ADAMTS13. 
Routine Sanger sequencing identified two novel sequence variants, one in CFH and one 
in MCP. The proband of family 28 carried the sequence variant C1152S in CFH, in 
heterozygosity. In silico analysis predicted that this amino acid was highly conserved 
and deleterious to the protein. The loss of a cysteine was hypothesised to disrupt protein 
folding and as a result alter protein secretion, which was supported by the low serum 
levels of FH. Unaffected family members also carried this variant, indicating 
incomplete disease penetrance. The MCP F246I was observed in a consanguineous 
family, inherited in an autosomal recessive pattern. In silico predictions indicated that it 
was in an evolutionary conserved area and deleterious in 2 out of 5 programs. Protein 
modelling demonstrated that it was positioned near the hinge region between CCPs 3 
and 4, suggesting it might impact protein conformation and possibly lead to retention of 
protein within the cell. Functional work on a nearby variant S240P, demonstrated that 
this region might be involved in C3b binding, so F246I could alternatively cause disease 
by reducing MCP cofactor activity. 
The remaining 26 families were submitted for WES and of these, 7 were found to have 
sequence variants in genes known to be associated with TMAs (CFH, MCP, CFI and 
ADAMTS13). The CFH change E625* was very rare and in silico analysis determined 
that this was a conserved amino acid and that the gain of a stop codon would be 
deleterious, suggesting it was likely to be the genetic cause of disease. This sequence 
variant had been previously described in an aHUS patient, further supporting this 
hypothesis. The mutation I416L in CFI was rare, in an evolutionary conserved region 
and predicted to have a serious impact on protein structure and function. It was 
previously reported in patients with low FI levels in serum, indicating that this sequence 
variant abolished protein expression.  
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Two sequence variants were observed in MCP, Y189D and c.286+2T>G, both of which 
were autosomal dominant in inheritance. These variants were rare and had been 
previously reported in the literature in association with aHUS. They were both predicted 
to be conserved and deleterious. Y189D and c.286+2T>G were demonstrated in the 
literature to cause reduced cell surface expression of MCP. Samples from the patients 
described here, were not available to confirm a reduction in MCP expression on cells. 
Two families were referred as having a clinical diagnosis of aHUS. Genetic screening of 
the affected individuals found compound heterozygous changes in ADAMTS13. Review 
of clinical data for one family (family 7) led to the observation that there was no renal 
involvement in the proband. Therefore these patients were reclassified as having TTP. 
This suggested that the similar phenotypes in aHUS and TTP could lead to 
misdiagnoses, which would have a serious implication in the treatment received by 
patients.  
WES was used as a screening tool to analyse genes, which due to a lack of DNA, would 
not have been possible. However WES only covers approximately 1% of the genome 
and as a result, it is possible that some disease-causing sequence variants were missed. 
The sequence variants identified in these genes were very rare and predicted to be 
deleterious by in silico tools. In addition the majority of sequence variants were 
previously described in the literature in association with disease, with the exception of 
CFH C1152S and MCP F246I, which were both novel.  
The screening of familial aHUS cases yielded no rare sequence variants that segregated 
with disease in CFB, although rare, functionally significant changes have been 
identified in the sporadic cohort. Screening of THBD in familial cases did not identify 
rare variants that segregated with disease. Further screening of 75 sporadic cases only 
identified two SNPs (data shown in the Supplementary data). Therefore no evidence 
was found in this cohort that supported THBD as being associated with disease, 
comparable to what was observed in the French aHUS cohort (Fremeaux-Bacchi et al., 
2013). Finally no sequence variants were identified in MMACHC in either the familial 
or sporadic cohort. This may be due to the distinctive phenotype, which means that 
clinicians are not referring these patients. The remaining 19 families were analysed with 
a multistep, candidate pipeline to try and identify novel gene candidates, described in 
chapter 5.   
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Chapter 5: Novel TMA-causing genes 
5.1. Introduction 
There are many approaches that can be used to identify sequence variants that cause a 
disease. Firstly Sanger sequencing can be carried out, although this is very time 
consuming and requires prior knowledge (Ku et al., 2012). Linkage analysis identifies 
genes that segregate in individuals with disease, however genetic heterogeneity can be 
confounding (Bishop, 1994). Homozygosity mapping can be performed on 
consanguineous families, identifying autosomal recessive genes that have been inherited 
from parents (Lander and Botstein, 1987). Yet linkage analysis and homozygosity 
mapping have poor resolution, identifying large areas that contain many candidate genes. 
Therefore additional analysis by Sanger sequencing is required to identify the candidate 
sequence variant. Finally GWAS can detect common sequence variants that may have 
an association with disease. However these variants are more likely to have a small 
effect on disease, accounting for a small proportion of disease heritability (McCarthy et 
al., 2008).   
Next generation sequencing technologies such as WES and WGS have the ability to 
screen vast amounts of DNA. This is beneficial as it enables screening of genes without 
prior knowledge, allowing the diagnosis of other pathologies, which is advantageous if 
the phenotype is unclear or an atypical presentation. The rational for utilising WES, was 
that despite examining approximately 1% of the genome, the exome is thought to 
contain around 85% of Mendelian disease causing sequence variants (Choi et al., 2009). 
Therefore compared to WGS, it is comparatively faster and more cost effective 
(Bamshad et al., 2011). 
WES was first successfully used to identify disease-causing sequence variants in 
Freeman-Sheldon syndrome (Ng et al., 2009). They demonstrated that the use of 
filtering steps could reduce the number of candidate variants for disease. It has since 
been successful in the detection of novel candidate genes in many diseases, such as 
Miller syndrome (Ng et al., 2010b) and Kabuki syndrome (Ng et al., 2010a). The use of 
multistep filtering pipelines can help to prioritise candidate variants (Bamshad et al., 
2011). This can include using an appropriate mode of inheritance, frequency of the 
variant in the general population and predicted functional impact (Gilissen et al., 2012). 
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However this has limitations and can lead to removal of potential candidate variants 
(Erlich et al., 2011). 
5.1.1. Chapter aims 
The proportion of patients in aHUS cohorts, who have no genetic aetiology, had been 
previously reported to be approximately 30-50% (Sellier-Leclerc et al., 2007, Maga et 
al., 2010, Fremeaux-Bacchi et al., 2013). In the Newcastle aHUS cohort 55% of 
families did not have a genetic cause of disease. The aim of utilising WES was to try 
and identify novel genetic causes of aHUS. 
5.2. Patient screening 
In this project 28 families with no known genetic cause for disease were analysed. 
Chapter 3 described the rearrangements and gene conversions that occurred in CFH and 
the CFHRs. In the Newcastle aHUS cohort, the frequency at which these changes arise 
in the patients with CFH abnormalities was 36.8%. Since these rearrangements are not 
always detected by Sanger sequencing methods, where possible, patients were also 
screened using MLPA (CFH, CFHRs, CFI and MCP) and western blotting (FH and 
FHRs). No abnormalities were detected suggesting that the genetic cause of disease was 
not due to CNVs occurring in these genes. However there is still the possibility that 
CNVs have occurred elsewhere in the genome. 
The first stage of the analysis involved screening patients for sequence variants in genes 
associated with TMAs, shown in Table 44 of Appendix J. The results of this screening 
were described Chapter 4, where 9 families were found to have sequence variants in 
genes associated with TMAs.  
The second stage of the analysis investigated the genetic cause of disease in the 
remaining 19 families. The probands in these families and where available, additional 
family members, were analysed using WES. Overall there were 6 families with 1 family 
member screened by WES, 11 families with 2 tested, 1 family with 4 tested and 1 
family with 7 tested. In total 5 families in this study were consanguineous. 4 samples 
were whole genome amplified (WGA) due to insufficient quantities of DNA for WES. 
The use of WGA samples in WES has been previously described, some found the 
sequencing results were comparable to non-amplified samples (Hollegaard et al., 2013, 
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Hasmats et al., 2014). However Pinard et al. (2006) demonstrated that WGA samples 
had lower target coverage and increased bias, reducing data quality. 
5.3. WES raw data 
The raw data received was separated into whether or not they had been WGA prior to 
WES; the complete list was shown in Appendix E. The mean and standard deviation 
(SD) was calculated for each group, shown in Table 18, for the total number of reads 
received, the number of reads that mapped to reference genome (after removal of 
duplicate reads) and the percentage of exome covered at various read depths. 
The total number of reads and the total number of reads mapped to the reference 
genome (after removal of duplicate reads), the mean coverage and percentage coverage 
(at all read depths) was higher in non-amplified samples compared to WGA samples 
This is similar to what has been previously reported (Rykalina et al., 2014). This may 
be because WGA samples were not evenly amplified, and therefore during exome 
enrichment, the target region will not be evenly represented (Pinard et al., 2006). This 
results in a library with low complexity, where fewer reads will map uniquely to the 
reference genome.  
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Non WGA (n=46) WGA (n=4) 
Mean SD Mean SD 
Total number of reads 
received 
99723087.3 35933194.4 63117915.5 16355994.0 
Total number of reads 
mapped to the 
reference genome 
(after removal of 
duplicates) 
91009750.0 29863736.6 60214572.0 13824960.1 
Mean coverage (x) 73.0 16.7 42.2 16.0 
Percentage 
of exome 
Covered 
1x 97.8 1.2 82.5 23.5 
5x 95.6 3.7 68.0 31.9 
10x 92.1 7.3 56.7 30.5 
20x 82.1 12.5 38.9 24.7 
40x 56.4 16.8 19.6 14.2 
Table 18 Read and coverage data for WES samples. 
The total number of reads received from the sequencing provider and the total number of reads 
that map to the reference genome, once duplicates have been removed (arise from amplification 
bias). SD=Standard deviation.  
WES allows for the interrogation of functionally important regions of the genome, as 
previously described in section 1.6. This is an unbiased approach and will lead to the 
generation of large quantities of data. It can be difficult to determine the sequence 
variants that are responsible for aHUS and those that are not. Table 19 shows the 
number of variants before any filtering has taken place, after exonic and splice site (2 
intronic nucleotides either side of exon) are positively selected for and after an initial 
removal of common sequence variants (with a MAF of greater than 5% in ESP6500 and 
1000g). These steps were carried out in the bioinformatic pipeline shown in Figure 2-5. 
The average starting number of variants for WGA samples was 412,499 compared to 
210,825 in non-WGA samples. This was not as expected as the quality of the 
sequencing for WGA samples was worse than non-amplified samples, shown by the 
reduced exome coverage at all read depths (Table 18). Therefore it was predicted that 
more the variants in the WGA samples would be removed during the quality control 
(QC) steps of the bioinformatic pipeline. The reasons for this could not be determined. 
There were also far higher numbers of variants in WGA samples than non-amplified 
samples, after removing variants outside regions of interest and with frequencies >5%. 
For example Families 13 and 14 have an average of 19,621 variants, compared to an 
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average of 2,032 variants for all other families. This was also unexpected and the 
reasons for this observation were not known. The variant list for family 5 also contains 
a large number of variants, which is the result of the inclusion of the WGA sample (II:5) 
and the large sample number (7 family members tested in total).  
Family 
Total number of variants 
Total 
Exonic and 
splice site 
MAF <5% 
1 220101 15807 1755 
2 160304 12866 1320 
3 215791 15517 1718 
5*ǂ 418076 20252 3775 
6 207680 13493 1321 
8 238937 15948 1856 
9 234571 15710 1824 
10 321184 21243 3325 
11*ǂ 331942 19031 2609 
12 229649 16661 2101 
13*ǂ 428821 31327 24746 
14* 471155 24479 14495 
15ǂ 161227 17186 1938 
16 230854 17365 1924 
17 142845 13849 1254 
19 203247 17577 2075 
20 239632 17220 2081 
21 190075 17092 1893 
25 166279 10891 1772 
Table 19 Total number of variants observed in a family. 
The total number of variants are shown for the 19 families with no known genetic aetiology. 
This is a culmination of all variants seen in all family members, where variants occurring in 
multiple family members are reported once. Firstly the total number of variants in the 
annotation file before any filtering has taken place. Secondly the number of variants that are 
located in an exon or splice site. Thirdly the number of variants with a MAF of <5% in 1000g 
and ESP6500. These filtering steps were carried out as part of the bioinformatic pipeline.* 
indicates families containing WGA samples, ǂ indicates consanguineous families.  
5.4. Variant filtering strategy 
Filtering strategies are a series of steps that aim to reduce the number of candidate 
variants to a smaller, more manageable number. This includes using tools that either 
look at the frequency, functional impact or conservation of a sequence variant, shown in 
Figure 5-1. This analysis aimed to identify the good candidates for disease, i.e. rare, 
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conserved and with a detrimental impact on the protein. Although it was possible that 
this method would lead to rejection of a causative sequence variant.  
 
Figure 5-1 Variant filtering strategy. 
This was performed for remaining 19 families with no genetic cause of disease. Each analysis 
was performed three times, using the three different inheritance patterns listed in step 1.  
5.4.1. Variant segregation  
There are several possible mechanisms for pathogenic variants to be inherited, such as 
recessive (homozygous and compound heterozygous variants), X-linked or autosomal 
dominant. Variants can also arise as de novo events, however due to the presence of 
multiple affected individuals within a family; it was assumed that variants were 
inherited by descent. The formatting of the data in Excel sheets meant that it was 
necessary to separate the analyses for homozygous and compound heterozygous 
variants. However they were later combined to try and identify candidate genes, where a 
complete functional deficiency was necessary to cause disease. 
4. Conserved 
Keep variants with a GERP++ score of >2 and PhyloP score of >0.5 
3. Rare 
Keep variants with a MAF of <1% in 1000g and ESP6500 
2. Deleterious 
Keep variants classed as deleterious by at least one prediction program 
1. Segregates 
Autosomal recessive or X-
linked recessive  
Autosomal dominant or  
X-linked dominant  
Compound heterozygous 
Screened for known TMA-causing genes 
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To perform these analyses, several assumptions were made. Variants inherited in a 
dominant fashion were considered to have complete penetrance. This meant that only 
affected individuals carried the sequence variant. For a recessive mode of inheritance, 
all affected offspring must contain the same pathogenic variants in homozygosity, with 
the assumption of complete penetrance. If parental samples were available for testing, 
both must have the same variant in heterozygosity. Any unaffected siblings with DNA 
available for screening must not be homozygous for the variant.  
For compound heterozygous analysis it was assumed that the affected offspring 
inherited one defective allele from each parent. If there were affected family members 
in two generations, such as mother and daughter, then this analysis was contraindicated 
and thus not performed. Complete penetrance was assumed, where all affected offspring 
must have the two sequence variants and unaffected siblings must not. Variants cannot 
be present in homozygosity in any family member.  
Finally X-linked inheritance was considered if male offspring were affected. The 
software used annotates these variants as VV (homozygous for variant allele), despite 
there being only one allele present. Therefore these variants were included in the list of 
variants that were autosomal recessive. Any variants with poor coverage and given a 
genotype ‘NA’ (not available) by annotation software were removed from the analysis. 
These assumptions allow for stringent filtering, leading to the formation of a smaller 
candidate list. However there are caveats with the methods used. Firstly there is the 
possibility that variants have arisen de novo and therefore would not follow the 
requirements set out previously. This was considered improbable, due to the occurrence 
of multiple affected family members. Secondly any variants with poor coverage have 
been removed from the analysis, which could remove a sequence variant of interest. 
However inclusion of these results would increase the number of variants in the final 
candidate list, making it difficult to find potential disease-causing variants. Thirdly the 
disease penetrance has been assumed to be complete. Yet this may not be true, as other 
genes associated with aHUS do not have complete penetrance (Kavanagh et al., 2013). 
However data for unaffected family members, which allows negative selection to take 
place, was only available in two families (families 5 and 15). 
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5.4.2. In silico functional predictions 
The next step selected for variants that were predicted to be deleterious by at least one 
of 6 prediction programs (PolyPhen-2 HDIV and HVAR, Mutation Taster, Mutation 
Assessor, FATHMM and RadialSVM), described in section 2.6.6.1. This meant that any 
differences between programs, would not lead to variants from being falsely discarded 
(Gray et al., 2012). For example Tennessen et al. (2012) used four functional prediction 
programs and three conservation prediction methods, to see the overlap in the variant 
predictions. They found that using at least one tool, called approximately 74% of 
nonsynonymous variants deleterious and when using all 7, 1% of nonsynonymous 
variants were classed as functionally significant. It is possible that the method used here 
will keep numerous false positive variants, because they have been classed as 
pathogenic by only one program. In the future a more stringent method could be used, 
where a variant must be classed as deleterious by more than one prediction program. 
The exception to this step was that all INDELs were removed from the analysis. This 
was done because the accuracy of INDEL calling is very poor, where approximately 
56.5% of INDEL calls are true (Fang et al., 2014). 
5.4.3. Variant frequency 
This step aimed to further reduce the number of variants that were common in the 
general population. Since aHUS is a rare disease and it is hypothesised that the 
sequence variant causing disease, would also be rare. This step was performed using the 
MAF from the 1000g and ESP6500 databases. Variants with a MAF >1% in both 
population databases were removed from the analysis.  
5.4.4. In silico conservation predictions 
The final filtering step used was to positively select for variants that were found in 
highly evolutionary conserved sequence regions. This was determined using GERP++ 
and PhyloP. Variants with a GERP++ score of >2 and a PhyloP score >0.5 were 
positively selected. These thresholds were more conservative than those used in other 
studies (Dong et al., 2015), yet sufficient to remove non-conserved variants defined as 
<0 for GERP++ (Davydov et al., 2010) and <0 for PhyloP (Pollard et al., 2010). 
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5.5. Candidate variant lists 
The remaining 19 families with no known genetic cause of disease were run through the 
candidate selection pipeline. The analysis for family 8 was performed twice, first 
assuming just the mother was affected and secondly assuming both mother and daughter 
were affected. This was because the renal phenotype of the daughter had not been 
confirmed by biopsy and although she had proteinuria, she was noted to have diabetes 
mellitus, which is a known cause of proteinuria.  
The results for dominant analysis are shown in Table 20. It can be seen that the number 
of variants in the final candidate list was far greater in some of the samples that have 
been WGA. For example families 13 and 14, have 7143 and 4147 variants respectively. 
This made analysis of these families, very difficult due to the large number of candidate 
variants. The average number of variants per family (excluding families 13 and 14) was 
93, with a range of 1 to 335 variants. In some families there was only DNA available for 
testing in one individual. This made the analysis more difficult, because the final 
number of variants after filtering was higher, on average 164.4 variants compared to 
66.1 variants (excluding WGA samples). In total 1589 variants were in the candidate 
variant list, consisting of a total of 1348 genes (excluding the data from families 13 and 
14). 
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Family 
Number of variants 
Segregates Deleterious MAF <1% Conserved 
1 533 123 80 65 
2 1178 291 203 170# 
3 453 126 74 61 
5*ǂ 5 1 1 1 
6  1178 259 150 114# 
8 
II:2 affected  524 135 91 77# 
II:2 and III:1 affected 526 116 71 61 
9 694 161 113 92 
10 154 28 19 16 
11*ǂ 319 76 51 39 
12 625 141 76 58 
13*ǂ 24622 7980 7940 7143# 
14* 14377 4720 4634 4147# 
15ǂ 513 148 110 95 
16 571 114 78 58 
17 1153 256 160 126# 
19 455 112 68 60 
20 686 145 102 87 
21 597 137 91 74 
25 1717 456 382 335# 
Table 20 Variant table for a dominant mode of inheritance. 
Analysis for sequence variants that segregate following a dominant mode of inheritance. #= one 
family member tested using WES *= families containing WGA samples, ǂ=consanguineous 
families. 
Table 21 shows the combined list of variants from the autosomal recessive and X-linked 
modes of inheritance. There were fewer variants in the final candidate variant list 
compared to autosomal dominant inheritance analysis. 4 families were not run in this 
analysis, as they had multiple affected females across two generations, suggesting that it 
was not the result of an autosomal recessive or X-linked disorder. In total 43 genes had 
variants inherited in either an autosomal recessive or X-linked fashion, none of which 
segregated with more than one family. 
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Family 
Number of variants 
Segregates Deleterious MAF <1% Conserved 
1 8 0 0 0 
2 52 13 11 4 
3 8 5 4 2 
5*ǂ 12 3 3 2 
6 50 3 0 0 
8 
II:2 affected 16 1 1 1 
II:2 and III:1 affected NA NA NA NA 
9 16 2 1 0 
10 NA NA NA NA 
11*ǂ 11 3 2 2 
12 20 0 0 0 
13*ǂ 209 18 18 12 
14* 50 11 7 6 
15ǂ 40 18 15 10 
16 NA NA NA NA 
17 25 7 4 2 
19 32 2 0 0 
20 15 3 3 2 
21 15 1 1 0 
25 NA NA NA NA 
Table 21 Variant table for a recessive mode of inheritance. 
Analysis for sequence variants that segregate following an autosomal recessive or X-linked 
mode of inheritance.* = families containing WGA samples, ǂ= consanguineous families, NA= 
Not available, indicates the families containing only affected females across several generations, 
which contraindicated this mode of inheritance.  
Compound heterozygous analysis was then performed, the results of which are shown in 
Table 22. For sequence variants to segregate with disease there must be more than one 
occurring within a gene, which was shared by all affected individuals. However it may 
be that only one of these variants would meet all the remaining criteria (deleterious, 
with a MAF of <1% and evolutionary conserved). 4 families were not analysed as they 
contained affected family members in multiple generations, which meant that according 
to our criteria, a compound heterozygous inheritance pattern was contraindicated. 
Families 13 and 14 contain WGA samples and found to have a far greater number of 
candidate variants compared to other families, on average 409.5 compared to 15.7 
variants. Family 5 was also contained a WGA sample, however due to the large number 
of family members tested, no variants segregated with disease. In total there were 204 
candidate variants found in 132 genes (excluding the data from families 13 and 14). 
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Family 
Number of variants 
Segregates Deleterious MAF <1% Conserved 
1 105 27 19 10 
2 270 76 50 34 
3 120 39 27 22 
5*ǂ 0 0 0 0 
6 297 91 61 35 
8 
II:2 affected 158 40 27 22 
II:2 and III:1 affected NA NA NA NA 
9 155 35 20 12 
10 19 1 0 0 
11*ǂ NA NA NA NA 
12 178 35 19 7 
13*ǂ 612 406 393 328 
14* 1075 608 582 491 
15ǂ 28 16 11 8 
16 NA NA NA NA 
17 248 60 38 24 
19 62 18 10 7 
20 165 38 25 12 
21 99 27 19 11 
25 NA NA NA NA 
Table 22 Variant table for a compound heterozygous mode of inheritance. 
Analysis for sequence variants that segregate following a compound heterozygous mode of 
inheritance.* indicates families containing WGA samples, ǂ indicates consanguineous families. 
NA= Not available, indicates the families containing affected family members in different 
generations, which contraindicated this mode of inheritance. 
The genes that contained candidate variants were then pooled for each mode of 
inheritance. The aim of which was to observe the number genes that are mutated in the 
different modes of inheritance. It would also enable the identification of genes that are 
mutated in more than one family, which may indicate a possible candidate for disease. 
The autosomal dominant and compound heterozygous analyses for families 13 and 14 
generated a very large number of variants. This was predicted to be the result of WGA, 
which may have produced more sequencing errors. Therefore they were excluded from 
the analysis, to prevent dilution of meaningful candidates.  
Figure 5-2 shows the results of the pooled gene lists for each inheritance analysis. 
Recessive inheritance (X-linked and autosomal recessive combined) saw the smallest 
number of genes in the remaining candidate list with 43 genes in total, all of which 
segregated in only one family. Compound heterozygous analysis identified 132 genes as 
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potential candidates in the 17 families investigated; 86% occurred in only 1 family, 9.8% 
in 2 families, 2.3% in 3 families and 1.5% in 4 families. Finally the dominant analysis 
identified 1202 genes; 89% occurred in only 1 family, 8.6% in 2 families, 1.6% in 3 
families, 0.4% in 4 families and 0.15% in 5 families. In total 1359 genes segregated 
with 1 family, 129 genes with 2 families, 25 genes in 3 families and 8 genes in 4 
families. Since aHUS is a very rare disease and the number of families available for 
testing was small, the large number of genes segregating in one family may not be 
surprising. If the exome data obtained in this project was combined with that of other 
international and European aHUS cohorts, it may identify genes that segregate with 
multiple families, which would not be seen in this study. 
 
Figure 5-2 Frequency of candidate genes found in families. 
Genes that were found by the candidate selection pipeline were pooled from all 19 families, to 
see if genes segregated in more than one family. The gene candidates for families 13 and 14 
using the compound heterozygous and dominant analyses were excluded. The Y axis was broken, 
so the total number of genes identified in the dominant analysis in 1 family, was 1202. 
Two genes were found in 5 families, which were GPR98 and RGPD3. The variant 
p.T4090N, in GPR98, was seen in 4 out of 5 families. It seemed very unlikely that a 
single variant would be seen so frequently in a rare disease, leading to the hypothesis 
that this may be a sequencing artefact. Moreover, review of the literature indicated that 
mutations in GPR98 were associated with Usher syndrome, an autosomal recessive 
disorder, characterised by deafness and blindness (Ebermann et al., 2009). Due to the 
absence of those phenotypes in the families described here, GPR98 was not considered 
for further analysis. RGPD3 had minimal information available that could suggest a 
possible mechanism of disease; therefore this gene was not prioritised for further 
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analysis in this project. However due to their fulfilment of the search criteria, they could 
be considered for further analysis in the future. 
The gene lists for recessive (autosomal recessive and X-linked) and compound 
heterozygous analyses were then pooled, in order to determine if these analyses had any 
common genes, suggesting that a functional deficiency would cause disease. In total 
132 genes had variants that occurred in compound heterozygous analysis and 43 genes 
had variants that were observed in an autosomal recessive or X-linked analysis. Only 1 
gene was found that was found in both analyses, shown in Figure 5-3. This gene was 
Diacylglycerol kinase ε (DGKE), described in section 5.6. 
 
Figure 5-3 Venn diagram of genes identified in recessive and compound heterozygous 
analyses. 
Genes containing variants that were inherited in the recessive analysis (autosomal recessive 
and X-linked combined) were shown in white. Genes with compound heterozygous variants 
were shown in black. Genes containing variants found in both analyses are in the overlapping 
grey section. 
5.6.  Diacylglycerol kinase epsilon (DGKE) 
5.6.1. Gene  
Diacylglycerol kinases (DGKs) are important in regulating the formation of 
Diacylglycerol (DAG), a component of an intracellular lipid signalling pathway known 
as the Phosphatidylinositol (PI) cycle (Shulga et al., 2011a). The PI cycle is based on 
the hydrolysis of phosphatidylinositol (4,5)-bisphosphate (PIP2), by Phospholipase C 
(PLC) into DAG (Dolley et al., 2009). DAG is then able to activate PKC (Protein 
Kinase C), leading to many downstream effects including changes in vascular tone 
(Dolley et al., 2009, Khalil, 2013), the release of prothrombotic factors (Kikkawa et al., 
1989, Lemaire et al., 2013) and changes to the actin cytoskeleton (Brandt et al., 2002). 
The role of DGKs is to regulate the formation of DAG. They can do this by 
phosphorylating DAG, converting it into phosphatidic acid (PA). 
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Figure 5-4 Schematic diagram of PI pathway. 
PLC converts PIP2 into DAG, which can then activate PKC, leading to downstream effects such 
as actin remodelling, vasoconstriction and increased expression of prothrombotic factors. 
DGKε prevents this by converting DAG into PA. Adapted from Lemaire et al. (2013). 
There are currently ten described DGKs, divided into 5 subtypes that share a common 
protein structure (Shulga et al., 2011a). Diacylglycerol kinase epsilon (DGKε) is a type 
III kinase, encoded by DGKE located on chromosome 17q22 (Hart et al., 1999). It is a 
64kDa protein composed of 5 domains, including an N-terminal hydrophobic domain 
(HD), two cysteine-rich (Cys1-1 or 2) domains, a kinase catalytic domain (KCD) and a 
C-terminal kinase accessory domain (KAD) shown in Figure 5-5. It is the only DGK 
that lacks a regulatory motif, suggesting that DGKε is constitutively active (Topham 
and Epand, 2009). DGKε is localised to the endoplasmic reticulum (ER) and the plasma 
membrane (Decaffmeyer et al., 2008). It has been shown to be expressed in podocytes 
(Ozaltin et al., 2012), platelets (Yada et al., 1990) and glomerular endothelial cells 
(Lemaire et al., 2013).  
 
Figure 5-5 Protein structure of DGKε. 
Adapted from Lemaire et al. (2013) 
The HD domain contains approximately 20 hydrophobic residues that allow DGKε to 
interact with the intracellular aspect of the cell membrane (Decaffmeyer et al., 2008) 
and the ER (Matsui et al., 2014). The precise function of Cys1 domains is not currently 
known. However they contain zinc finger-like motifs and are thought to be involved in 
DAG-binding (Shulga et al., 2011a). KCD has a region that mediates ATP binding, 
which is critical for DGK function (Sakane et al., 1996). Studies have suggested that the 
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KCD and KAD domains are not able to function alone, also requiring the other domains 
to provide functional kinase activity (Rodriguez de Turco et al., 2001).  
Unlike other DGKs, DGKε has specificity to certain DAGs containing arachidonoyl 
chains at the sn-2 position (Shulga et al., 2011b), also known as 1-stearoyl-2-
arachidonoyl glycerol (Tang et al., 1996). 
 
Figure 5-6 Phosphorylation of DAG into PA by DGKε. 
DGKε specifically targets DAG containing an arachidonoyl chain at the sn-2 position. When it 
converts DAG into PA the OH group highlighted in the red box is phosphorylated. Adapted 
from Shulga et al. (2011a). 
This specificity was hypothesised to be due to the presence of an amino acid motif at 
position 431-443, LX(3-4)RX(2)LX(4)G found within the KAD (Shulga et al., 2011b). It 
was thought that amino acids L431 and L438 form the bottom of the DAG-binding 
pocket and their mutation reduced binding affinity (Shulga et al., 2011b). This section 
described the sequence variants found in DGKE in this project. 
5.6.2. Family 20 and 8 
Family 20 has two affected siblings with recurrent aHUS. The affected proband had a 
biopsy at 4 years of age confirming TMA. There were also features of 
membranoproliferative glomerulonephritis (MPGN) with C3 deposition (+++), IgM (++) 
with little IgG on immunofluorescence. His brother (II:2) was biopsied at 13 years of 
age that demonstrated a MPGN with no C3 deposition, IgM (++) with little IgG on 
immunofluorescence. There was also evidence of secondary focal segmental 
glomerulosclerosis. Complement levels were measured at 27 years of age and C3 
(1.25g/L), C4 (0.33g/L), FH (0.57g/L) and FI (51mg/L) and found to be within the 
normal range and MCP expression was normal. 
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Figure 5-7 Pedigree of family 20. 
The proband is indicated by an arrow. ‘*’ indicated samples tested by WES. Genotype was 
indicated by RV (heterozygous) or VV (homozygous). 
Family 8 has two affected individuals in the second generation, one of whom is now 
deceased (II:3). The affected proband (II:2) had aHUS at the age of two, which was 
confirmed by a renal biopsy. Dialysis was not required. Complement levels in serum 
were normal (C3 1.01g/L, FH 0.55g/L, FI 57mg/L), except for C4, which was low 
0.14g/L (normal 0.18-0.6g/L). Routine Sanger sequencing of MCP, CFH and CFI did 
not reveal any disease causing variants. The proband’s sister (II:3) died of aHUS at the 
age of three, no DNA was available for testing. The proband’s offspring (III:1) did not 
have a renal biopsy, but had proteinuria which was thought to be due to poorly 
controlled diabetes mellitus. Her kidney function was said to be normal. Due to the lack 
of definitive evidence, analysis was undertaken assuming both affected and unaffected 
status 
 
Figure 5-8 Pedigree of family 8. 
Proband is indicated by the arrow and ‘*’ indicates all family members tested by WES. The 
proband and deceased sibling (II:3) had confirmed aHUS, shown by black circles. The daughter 
III:1 has diabetes and proteinuria, shown in grey. Genotype was shown in bold. 
WES analysis was carried out using several modes of inheritance (autosomal recessive 
and X-linked, autosomal dominant and compound heterozygous) and candidate variants 
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were pooled to see if any gene had variants in multiple families. Using this method, 
DGKE was found in the autosomal recessive/X-linked and compound heterozygous 
analyses, suggesting that complete functional deficiency led to disease. Family 20 had a 
homozygous change c.1597A>C, p.T533P, located in exon 12, which was present in 
both affected offspring, II:1 and II:2. Both parents were confirmed to be heterozygous. 
Family 8 had a compound heterozygous change, found only in the proband (II:2). The 
changes found were c.1427T>C, p.L476P, occurring in exon 11 and c.463A>G, 
p.R155G in exon 2. Only R155G was seen in the daughter III:1, suggesting that the two 
mutations were found on separate alleles. Due to her lack of compound heterozygosity, 
III:1 was now treated as unaffected. Table 23 shows that all three variants reported in 
DGKE were not seen in the 1000g or ESP6500 databases. 
Family 
Sequence variant 
Exon Genotype MAF % 
Transcript Protein 
20 c.1597A>C p.T533P 12 VV 0 
8 
c.463A>G p.R155G 2 RV 0 
c.1427T>C p.L476P 11 RV 0 
Table 23 DGKE variant data in families 20 and 8. 
DGKE variant data in Families 20 and the affected proband in family 8 (II:2). RV= indicates 
that patients had one copy of the reference and mutant alleles. VV= indicates that patients were 
homozygous for the mutant allele.  MAF frequency listed is from 1000g project and ESP6500. 
These variants were then confirmed by Sanger sequencing. Figure 5-9 shows that the 
parents of family 20, were heterozygous for T533P and the affected proband (II:1) was 
homozygous, the trace for II:2 was not shown.  
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Figure 5-9 Sanger sequencing trace for family 20. 
Top trace is the control, showing a homozygous c.1597A, p.T533. The next two traces are for 
the mother and father, showing a heterozygous c.1597A>C, causing an amino acid substitution 
T533P. Finally the trace for the affected proband, II:2, shows homozygosity for T533P. The 
amino acid sequence encoded by exon 12 is shown above. 
Figure 5-10 shows the Sanger trace for the proband in family 8. The results of the 
unaffected offspring (III:1) were not shown. 
 
Figure 5-10 Sanger sequencing trace for family 8. 
Left chromatogram shows sequencing trace of DGKE R155G and the right for DGKE L476P. 
Top trace is the control and the bottom trace is for the proband of family 8 (I:2). The amino 
acid sequence encoded by the exon is shown above, where the dotted line denotes the intronic 
region. 
The finding of two families with DGKE variants, led to the review of all exome data for 
any other DGKE sequence variants. This led to the finding that there was a 
heterozygous change in DGKE, in Family 13. This was c.826delG, p.V276FfsX8, which 
was not seen in 1000g, ESP6500 or dbSNP databases. This variant was removed during 
variant filtering, because it was an INDEL.  
This was a consanguineous family, where the parents are first cousins (Kaplan et al., 
1992), shown in Figure 5-11. There have been 4 affected offspring, 3 of whom are now 
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deceased. There was no history of aHUS in previous generations. The proband was 
treated with plasma exchange and Sanger sequencing of CFH, MCP and CFI revealed 
no sequence variants. 
 
Figure 5-11 Pedigree of family 13. 
Proband is indicated by the arrow and ’*’ indicates all members tested by WES. The double 
band between parents I:1 and I:2, indicates that there is consanguinity. Genotype was shown in 
bold. 
With the knowledge that this family is consanguineous and that the DNA sample for the 
proband was WGA and therefore poor quality, it was hypothesized that this variant may 
have been poorly covered by the exome sequencing and that the proband may in fact be 
homozygous. Therefore Sanger sequencing was carried out on non-amplified DNA, 
which led to the confirmation that the patient is homozygous for V276FfsX8, shown in 
Figure 5-12. 
 
Figure 5-12 Sanger sequencing trace for family 13. 
The top trace shows the result of the control, the bottom trace shows the result for the affected 
proband, II:7, shows homozygosity for V276FfsX8. The amino acid sequence encoded by the 
exon is shown above. 
At this point there were two publications that supported the findings described here, 
which was that complete functional deficiency of DGKε was associated with aHUS 
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(Lemaire et al., 2013, Ozaltin et al., 2012). There was then report of an intronic variant 
in DGKE, c.888+40A>G, which was associated with disease and reported to cause 
aberrant splicing of exon 5 (Mele et al., 2015). The WES coverage for this position was 
poor therefore Sanger sequencing primers were designed to analyse this region. All 
families with an unknown genetic cause of disease were analysed. However this variant 
was not identified in any patients. 
5.6.3. Newcastle aHUS cohort rescreening 
It was observed in other cohorts and also in the data presented here, that all affected 
individuals with DGKε deficiency, presented with disease early in life and had disease 
recurrence during eculizumab treatment (Ozaltin et al., 2012, Lemaire et al., 2013, 
Sanchez Chinchilla et al., 2014). Therefore it was hypothesised that there may be 
additional patients within the Newcastle cohort with DGKε deficiency. These patients 
would not respond to eculizumab treatment (Lemaire et al., 2013) and therefore it may 
be prudent to withdraw treatment, due to its high cost and its associated risk to 
meningococcal infections. All sporadic paediatric and adults cases, who were being 
treated with eculizumab were screened for all exons of DGKE, including the intronic 
variant c.888+40A>G. In total 52 paediatric and 61 adults cases were screened, which 
identified three sporadic paediatric cases with DGKE sequence variants, all of which 
were present in homozygosity. Sporadic patients 1-3 were referred to as Sp1-3.  
Sp1 was born of consanguineous parents. Renal biopsy of the proband confirmed TMA 
and also demonstrated features of MPGN. Complement levels were normal (C3 1.01g/L 
and C4 0.22g/L). 
Sp2 presented with HUS at 7 months, which occurred after a diarrhoea illness. There 
was no evidence of E. coli O157 in her stools or serology. She was treated with 
peritoneal dialysis for two weeks, during which time she had oligoanuria and 
thrombocytopenia. This was followed by two further disease relapses within one year, 
during which time she was treated with fresh frozen plasma. At 8 years old she had 
chronic kidney disease, with a marginally elevated creatinine of 69µmol/L, proteinuria 
and hypertension. ADAMTS13 activity was 33%, excluding the diagnosis of TTP. 
Complement levels (C3 1.64g/L, C4 0.81g/L, FH 0.72g/L and FI 69mg/L) and MCP 
expression were normal.  
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Sp3 is a child of Middle East origin, who presented with aHUS at 8 months of age and 
was treated with plasma therapy, whilst on this treatment the patient had multiple 
disease relapses. Eculizumab treatment was initiated at 6 years of age and administered 
for 5 years. During this time the patient relapsed on two occasions. At age 11 she had 
chronic kidney disease and continued to have nephrotic syndrome whilst on eculizumab 
treatment. 
 
Figure 5-13 Pedigrees for Sporadic aHUS patients with DGKE mutations. 
A-Pedigree for Sp1, B-Pedigree for Sp2 and C-Pedigree for Sp3. The proband is indicated by 
an arrow. ‘#’ indicates predicted genotype. 
Sequence variants were confirmed by Sanger sequencing in Sp2 and Sp3, shown in 
Figure 5-14B and C respectively. There was no DNA available for Sp1, so Sanger 
sequencing was performed on the parents, shown in Figure 5-14A. The parents both 
carried the mutant allele in heterozygosity, which led to the hypothesis that the affected 
offspring had inherited the allele from each parent and therefore was homozygous for 
M1L. 
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Figure 5-14 Sanger traces for Sporadic patients. 
A- The parents of the proband, Sp1. B- Sp2.  C- Sp3. The amino acid sequence encoded by the 
exon is shown above the sequence chromatogram, where the dotted line denotes the intronic 
region. 
M1L and K109E were not present in either 1000g or ESP6500 databases. W322* is 
listed on dbSNP (rs138924661) and had a MAF in ESP6500 of 0.015%; however it was 
not found in 1000g database. W322* was reported by Lemaire et al. (2013) and 
Sanchez Chinchilla et al. (2014), both in homozygosity and compound heterozygosity, 
in aHUS patients. 
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Patient ID 
Sequence variant 
Exon Genotype MAF % 
Transcript Protein 
Sp1 c.1A>T p.M1L 1 VVǂ 0 
Sp2 c.966G>A p.W322* 6 VV 0.015 
Sp3 c.325A>G p.K109E 2 VV 0 
Table 24 DGKE variants observed in sporadic paediatric cases. 
VV= indicates that patients were homozygous for the mutant allele. ‘ 
ǂ
’ Indicates the predicted 
genotype as no DNA was available for testing. MAF frequency listed is from ESP6500 as no 
variants were reported in 1000g. 
All DGKE variants reported in this project were nearly entirely absent from the normal 
population. The only exception is W322*, which was seen in ESP6500. However this 
was still very rare (MAF of 0.015%) and the occurrence of a premature stop codon is 
highly likely to be pathogenic. This suggested that these sequence variants were likely 
to be functionally significant. Consequently functional analysis was performed to see if 
they were predicted to be pathogenic. 
5.6.4. In silico analysis 
To examine the effects of these sequence variants on the protein, several in silico tools 
were used. V276FfsX8 was not analysed because none of the programs used were able 
to formulate predictions for INDELs. However the formation of a premature stop codon 
was considered to be severely detrimental.  
The amino acid substitution M1L resulted in the loss of the initiating methionine and as 
a result, it was predicted to disrupt protein translation. Even so M1L was only predicted 
to be deleterious in 1 out of 4 tools, showing the limitations of these tools. The 
remaining DGKE variants were predicted to be deleterious by at least one in silico tool, 
shown in Table 25.  
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Patient ID Variant 
In silico testing 
PolyPhen-2 Mutation 
Taster 
Mutation 
Assessor 
FATHM
M 
Radial 
SVM HDIV HVAR 
Family 20 T533P D P D L T T 
Family 8 
R155G B P D M D D 
L476P D D D M T T 
Sp1 M1L B B D NA T NA 
Sp2 W322* NA NA D NA NA NA 
Sp3 K109E D D D M D NA 
Table 25 In silico data for DGKE variants 
Table shows the in silico predictions for the DGKE variants identified. Software not able to 
calculate predictions were labelled as NA, not available. B= Benign, D= deleterious, L= Low, 
M= medium, P= polymorphism, T= Tolerated. Scores could not be calculated for V276FfsX8. 
One other mechanism to determine if a variant might be functionally significant, was to 
see if it occurred in a region of DNA that was evolutionary conserved. If it was 
maintained across several species then it indicated an importance in function. To 
examine if these variants occur in conserved areas, the human protein sequence of 
DGKε, was compared to 10 other species. It can be seen in Figure 5-15 that all 5 
variants found in the Newcastle cohort were found to occur in highly conserved regions. 
With the exception of M1, all amino acids were maintained through to zebrafish. 
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Figure 5-15 Amino acid sequence alignment for DGKE variants. 
Amino acid sequence alignment for sequence variants in DGKE. Human with and without the 
variant are compared to 10 other species. Highlight grey is the position of the variant described 
here. Amino acids in bold, indicate differences to the reference sequence.  
These results were expected as the conservation scores from GERP++ and PhyloP were 
above our preset threshold of 2 and 0.5 respectively. Table 26 shows the values 
obtained using GERP++ and PhyloP. Scores for M1L, W322* and K109E could not be 
calculated using GERP++, as this was not a web-based platform. The score for 
V276FfsX8 was unavailable as neither GERP++ nor PhyloP could calculate scores for 
INDELs. 
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Patient ID Variant GERP++ PhyloP 
Family 20 T533P 5.80 2.216 
Family 8 
R155G 4.56 0.936 
L476P 5.36 2.15 
Sp1 M1L NA 3.313 
Sp2 W322* NA 5.709 
Sp3 K109E NA 4.553 
Table 26 Conservation scores for DGKE variants. 
NA= Not available. Scores could not be calculated for V276FfsX8. 
Analysis of variants using a combination of in silico tools demonstrated that all variants 
found in DGKE, in Newcastle patients, were predicted to be deleterious by at least 1 
prediction tool and disrupted highly conserved amino acids. V276FfsX8 could not be 
analysed with prediction software used. However due to the occurrence of a premature 
stop codon, it was predicted to be pathogenic. In addition amino acid sequence 
alignment demonstrated that this was an evolutionary conserved area, indicating it may 
have a critical function.  
5.6.5. Protein modelling 
To investigate the effect of the point mutations K109E, R155G, L476P and T533P on 
DGKε, protein modelling was carried out. A predicted protein structure of DGKε was 
obtained using Phyre2 and manipulated in PyMOL. K109E was positioned close to the 
HD, Cys1-1 and KCD domains, suggesting that it might have a subtle effect on the 
function of all three domains, which might include disrupting DGKε localisation to the 
cell membrane and the ER, altering affinity to DAG or altering ATP binding. R155G 
was positioned on the surface of the Cys1-2 domain, the function of which is not 
currently known. L476P and T533P were in close proximity to the two amino acids, 
which have been previously demonstrated to be required for DAG arachidonoyl 
specificity (Shulga et al., 2011b). However it is possible that these variants cause 
disease by preventing the expression of DGKε. 
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Figure 5-16 Predicted DGKε protein model. 
Phyre2 was used to create a predicted protein model of DGKε. Protein shown in surface mode, 
at a transparency setting of 0.4. Amino acids L431 and L438, thought to important for DAG 
specificity are shown blue spheres. Amino acid substitutions identified in this project are shown 
by red spheres. HD (amino acids 22-42) shown in blue, Cys1-1 (amino acids 60-109) shown in 
dark green, Cys1-2 (amino acids 125-178) shown in light green, KCD (amino acids 219-350) 
shown in pink and KAD (amino acids 369-524) shown in orange. 
5.6.6. Pathophysiology 
At the time this project was started there were no reported genes associated with aHUS 
that were outside the complement system, with the exception of THBD and MMACHC. 
However there is now increasing evidence from other European cohorts that DGKε 
deficiency is associated with early onset aHUS. Figure 5-17 demonstrates the sequence 
variants in DGKε, reported by other cohorts and those described here. It can be seen 
that sequence variants occurred across the entire length of the protein and all variants 
reported here were novel, apart from W322*, which was also reported by Lemaire et al. 
(2013) and Sanchez Chinchilla et al. (2014).  
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Figure 5-17 Diagram showing mutations reported in DGKE. 
Green lines are from Ozaltin et al. (2012). Red lines are from Lemaire et al. (2013). Blue lines 
are from Sanchez Chinchilla et al. (2014). Black lines are reported here. W322* is in bold, 
indicating it was found in the Newcastle cohort, but it had been perviously reported. All 
variants described here were homozygous, with the exception of R155G and L476P, which were 
found in compound heterozygosity. Added in proof: another paediatric case has been 
demonstrated to be compound heterozygous for DGKE mutations (c.465-2A>G and c.393C>G, 
p.N131K). 
The current mechanism of disease is unknown, but evidence had suggested that the loss 
of DGKε was distinct from the complement system (Bruneau et al., 2014). This was not 
surprising as patients with an absence of functional DGKε, did not respond to 
eculizumab, a complement-directed therapy (Rother et al., 2007). It was proposed that 
the accumulation of DAG would lead to increased PKC signalling, the downstream 
effects of which would lead to aHUS (Noris et al., 2015), shown in Figure 5-18. 
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Figure 5-18 DAG signalling pathway. 
PLC converts PIP2 into DAG, which has many downstream signalling targets, such as TRPC6 
and PKC. DGKε regulates this pathway by converting DAG into PA. Adapted from Noris et al. 
(2015). 
One downstream effect of PKC signalling was the activation of p38- Mitogen-activated 
protein kinase (MAPK) (Vijayan, 2015, Bruneau et al., 2014). Bruneau et al. (2014) 
demonstrated using HUVECs and human dermal microvascular endothelial cells 
(HMECs) that p38-MAPK signalling created a prothrombotic environment. This was 
due to the up regulation of Intercellular Adhesion Molecule 1 (ICAM-1), E-selectin, 
tissue factor and the reduced migration and angiogenic responses of endothelial cells. 
PKC-mediated activation of MAPK and MAPK kinase (MEK) was also demonstrated 
to play a role in vasoconstriction (Khalil, 2013).  
PKC signalling also increased the production of prothrombotic mediators such as vWF 
(Carew et al., 1992) and plasminogen activator inhibitor-1 (PAI-1) (Ren et al., 2000). 
PKC can also activate cytosolic phospholipase A2 (cPLA2), leading to arachidonic acid 
production, which can be converted into prostaglandins by cyclooxygenases (COX) 1 or 
2 (Noris et al., 2015). PKC has been shown to down regulate VEGF receptor (VEGFR) 
2 in porcine aortic endothelial cells, by targeting it for degradation (Singh et al., 2005). 
VEGF inhibitors are known to cause TMA due to damage to glomerular endothelial 
cells, altering their fenestrated structure (Eremina et al., 2008). Therefore DGKε 
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deficiency may lead to decreased VEGF signalling, causing vascular endothelial cell 
damage, similar to what is seen in VEGF inhibitor-mediated aHUS. 
Studies have shown that elevated DAG can lead to increased activity of a cation channel 
Transient receptor potential cation channel, subfamily C, member 6 (TRPC6) (Ozaltin 
et al., 2012, Hofmann et al., 1999) TRPC6 is found in the podocyte slit diaphragm and 
activating mutations have been associated with FSGS (focal segmental 
glomerulosclerosis) (Winn et al., 2005). This is the result of increased intracellular Ca
2+
 
that causes podocyte dysfunction and thus disruption of the glomerular filtration barrier 
(GFB) (Heeringa et al., 2009). Patients with DGKE mutations also get proteinuria 
between thrombotic events, which has been suggested to be caused by a similar 
mechanism (Noris et al., 2015). 
Down regulation of DGKE was shown by Matsui et al. (2014), to make cells more 
vulnerable to apoptosis as a result of ER stress. The use of DGK inhibitor R59022, led 
to increased platelet secretion and aggregation in response to thrombin (Nunn and 
Watson, 1987). This suggested that loss of functional DGKε could cause podocyte 
damage and create a prothrombotic environment in the glomerulus. Mouse models have 
shown that knocking out DGKE, slows the PI pathway. These mice are more tolerant to 
seizures caused by electroconvulsive shocks but do not develop a renal phenotype, 
although this may be the result of differential localisation of DGKε between mice and 
humans (Rodriguez de Turco et al., 2001).  
One study identified DGKε localisation to actin stress fibres in rat aortic smooth muscle, 
suggesting it plays a role in cytoskeletal regulation (Nakano et al., 2009). Indeed PKC 
has been shown to be involved in cytoskeletal rearrangements, specifically the 
disassembly of the stress fibres in vascular smooth muscle cells (Brandt et al., 2002). 
Thus one hypothesis could be that the loss of DGKε resulted in increased PKC-
mediated stress fibre disassembly, potentially affecting the integrity of the GFB.  
The study by Sanchez Chinchilla et al. (2014) identified the coinheritance of THBD and 
C3 mutations in patients with DGKE sequence variants. The THBD mutation observed 
had been previously reported in association with aHUS (Delvaeye et al., 2009) and the 
C3 mutation described was novel and predicted to be deleterious. The patients with the 
THBD and C3 mutations had a more severe phenotype with increased disease 
recurrence. It was also noted that the patient with a C3 mutation had a positive response 
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to eculizumab therapy. These results suggested mutations in genes known to cause 
aHUS may increase disease severity. No mutations in complement genes or THBD were 
seen in concomitance with DGKE sequence variants. 
M1L leads to loss of the initiating methionine that was hypothesised to lead to failure of 
protein translation. K109E was located between the two Cys1 domains and R155G 
occurred in the second Cys1 domain. The functions of the Cys1 domains are still 
unclear; however it is thought they are involved in DAG binding, therefore these 
variants may disrupt this interaction. L476P and T533P were both located in the KAD 
and therefore could disrupt DGKε’s arachidonoyl chain-specificity, due to their close 
proximity to the DAG recognition motif (Shulga et al., 2011b). The occurrence of 
premature stop codons in V276FfsX8 and W322* were predicted to lead to either 
truncated proteins or nonsense-mediated mRNA decay and thus DGKε deficiency. 
Consequently all these variants were hypothesized to lead to absence of functional 
DGKε activity. This would cause uncontrolled DAG signalling that was predicted to be 
prothrombotic, leading to disease onset. It would be important to try and test DGKε 
expression in biopsy tissue from affected individuals to test if whether or not these 
sequence variants abolish protein expression. If there was protein expression then it 
would be necessary to undertake functional analysis to determine their potential effects. 
Finally further work is needed to elucidate the precise mechanism in which DGKE 
mutations cause disease. 
5.7. Inverted formin 2 (INF2) 
Inverted formin 2 (INF2) is a regulator of actin polymerisation and depolymerisation 
(Chhabra and Higgs, 2006). It is encoded by INF2 which is found on chromosome 14 
and encoded by 22 exons (ENST00000330634). This section described sequence 
variants identified in INF2 in familial aHUS cases. 
5.7.1. Gene function 
Actin filaments are linear, double helix structures that are composed of many actin 
monomers (Alberts et al., 2002). The actin cytoskeleton is involved in many cellular 
processes such as cell migration, phagocytosis, immunological synapses and adherens 
junctions (Chhabra and Higgs, 2007). Filaments are constantly being formed, with new 
actin monomers being added and removed from the ends of filaments. Monomer 
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addition occurs at a greater rate at the barbed end and monomer removal occurs more at 
the pointed end, creating a ‘treadmilling’ effect (Alberts et al., 2002). Once actin 
monomers have joined Adenosine triphosphate (ATP) is hydrolysed into Adenosine 
diphosphate (ADP), to form a stable filament (Lodish et al., 2000), demonstrated in 
Figure 5-19. This process is regulated by associated proteins, such as the Arp2/3 
complex, spire proteins and formins (Chhabra and Higgs, 2007). 
 
Figure 5-19 Schematic diagram of actin filament assembly. 
ATP- actin monomers are incorporated or lost at the pointed or barbed ends of actin filaments. 
Once they are bound ATP is hydrolysed to form ADP. Grey shapes indicate ATP-actin 
monomers. White shapes indicate ADP-actin monomers. The larger arrows indicate the 
preferential addition or loss of actin subunits. Adapted from Lodish et al. (2000). 
Formins are a group of proteins that are involved in the maintenance and regulation of 
actin and tubulin cytoskeletal networks (Goode and Eck, 2007). Formins produce actin 
filaments that are not branched, unlike the action of Arp2/3 complexes and they are also 
able to elongate actin filaments, unlike Spire proteins (Chhabra and Higgs, 2007). In 
mammals there are 15 formin genes, subdivided into 7 subgroups (Goode and Eck, 
2007). They share a characteristic structure with an N-terminal GTPase-binding domain 
(GBD), followed by the Diaphanous Inhibitory Domain (DID) domain, Formin 
homology 1 and 2 (FH1 and FH2) domains and then a Diaphanous Autoregulatory 
Domain (DAD) domain at the C-terminus (Breitsprecher and Goode, 2013). They are 
able to regulate themselves by autoinhibition, due to the interaction of the DID and 
DAD domains (Breitsprecher and Faix, 2010). They have several functions such as 
actin nucleation (Gould et al., 2011) and filament elongation (Chesarone et al., 2010).  
Inverted formins (INFs) form one subgroup of formins and includes INF2. 
INF2 has a similar structure to other formins although it lacks a GBD and has a WH2 
(Wiskott-Aldrich syndrome protein-homology 2) motif within the DAD (Chhabra and 
Higgs, 2006). The FH1 domain binds to profilin, a protein which sequesters actin 
monomers, accelerating the polymerisation activity of the FH2 domain (Kovar et al., 
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2006). The FH2 domains dimerise and encircle the filaments, accelerating nucleation 
and elongation of the barbed ends of filaments (Gurel et al., 2014). The C-terminal 
WH2 domain has several functions. Firstly in conjunction with the FH2 domain it can 
sever filaments and thus accelerate filament depolymerisation, a feature not seen in 
other formins (Chhabra and Higgs, 2006). Secondly this motif allows INF2 to bind to 
actin monomers that compete with DID, which results in activation of actin 
polymerisation, by preventing DID-DAD interactions (Ramabhadran et al., 2013). The 
autoihibition via DID-DAD interactions inhibits the depolymerisation activity of INF2, 
but not the actin nucleation activity (Chhabra et al., 2009).  
 
Figure 5-20 Functional INF2 dimer and autoinhibited structure. 
A- Schematic diagram of an INF2 dimer interacting with an actin filament, where the FH2 
domains form a ring-like structure around the actin filament (Gurel et al., 2014). Arrows 
indicate the interactions for the DID, FH1 and DAD domains. B- The autoinhibited INF2 
conformation, due to DID/DAD interactions. Adapted from Campellone and Welch (2010). 
There are two INF2 C-terminal splice variants (CAAX and non-CAAX) that have 
different intracellular localisation, which suggests that each isoform might have a 
different function (Ramabhadran et al., 2011). INF2 CAAX is farnesylated, enabling it 
to localise to the ER Golgi (Chhabra et al., 2009). INF2 non-CAAX is found in the 
cytosol and thought to be involved in maintenance of the Golgi (Ramabhadran et al., 
2011). It has also been demonstrated that INF2 colocalised with proteins called myelin 
and lymphocyte protein (MAL), which are involved in apical transport of proteins 
(Puertollano and Alonso, 1999).  This transcytosis transportation mechanism was shown 
to include the regulation of CD59 cell surface expression (Madrid et al., 2010). This 
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was dependent on a Rho-GTPase (Cdc42) that bound to the N-terminus of INF2 and 
MAL2, which bound to the C-terminus of INF2 (Madrid et al., 2010). 
5.7.2. Disease association 
INF2 has been shown to be expressed in Schwann cells and podocytes by Boyer et al. 
(2011b). This might explain why mutations in INF2 have been previously associated 
with a glomerulopathy, Focal Segmental Glomerulosclerosis (FSGS) and a neuropathy, 
Charcot Marie Tooth (CMT) disease (Boyer et al., 2011b). FSGS is characterised by 
proteinuria and podocytes foot process effacement (demonstrated by electron 
microscopy) (Bose and Cattran, 2014). Patients with CMT can experience muscle 
weakness and wasting, walking difficulties, a decrease in the number of myelinated 
fibres and reduced median-nerve velocities (Boyer et al., 2011b). 
Currently, published disease-causing mutations have occurred in patients who have 
either CMT and FSGS (Boyer et al., 2011b, Mademan et al., 2013, Rodriguez et al., 
2013, Toyota et al., 2013, Park et al., 2014) or FSGS alone (Barua et al., 2013, Boyer et 
al., 2011a, Brown et al., 2010, Gbadegesin et al., 2012, Laurin et al., 2014, Lee et al., 
2011, Lipska et al., 2013). Sequence variants found to date have been dominantly 
inherited and mainly occur in exons 2-4, encoding the DID domain, demonstrated in 
Figure 5-21. However there has been a report of a change that has occurred in exon 6 
(Sanchez-Ares et al., 2013), although this also codes for part of the DID domain. This 
highlighted the importance of the autoinhibitory function of DID domain.  
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Figure 5-21 Reported mutations in INF2. 
Top- mutations that were associated with CMT and FSGS. Bottom- mutations associated with 
FSGS only. Adapted from Mademan et al. (2013). 
This section described the sequence variants found in INF2 in this project. 
5.7.3. Family 16 
Family 16 had two members with aHUS and CMT disease. The proband presented with 
pex cavus and difficulty walking at age 7, leading to a diagnosis of CMT disease. She 
then presented with severe proteinuria at age 15, 5 days after a mild undiagnosed sore 
throat and after several months of malaise and fatigue. At presentation she was 
hypertensive (185/110mmHg), anaemic (Haemoglobin (Hb) 9.4g/dl), had a low platelet 
count (119×10
9
/L) and had schistocytes present in a blood film. A daily regime of 
plasma exchange and haemodialysis was commenced. Treatment with eculizumab was 
started with continuation of haemodialysis. Platelet count increased temporarily 
(173×10
9
/L), before falling to 100×10
9
/L. Eculizumab concentration was sufficient and 
complement activity was completely suppressed (CH50). Three months later a kidney 
biopsy demonstrated TMA, with features of glomerulosclerosis, shown in Figure 5-22. 
After 9 months with no renal recovery eculizumab was withdrawn. 
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Figure 5-22 Renal biopsy of proband, family 16. 
A- Glomerulus (left) showing global sclerosis and occluded arteriole (right), 20x periodic acid–
Schiff (PAS) staining. B- two arterioles (right) showing features of active thrombosis and small 
artery (left) with some intimal oedema with fibrosis, 20x Haematoxylin and eosin (HE) staining.  
The mother (I:2) presented aged 10yrs with walking difficulties and pex cavus. A motor 
axonal neuropathy was found with no sensory issues leading to a diagnosis of CMT. 
Age 17 she presented with proteinuria (12g/L) and an elevated serum creatinine. A renal 
biopsy demonstrated end-stage changes with diffuse global sclerosis. She had 
haemodialysis for 2 years when she had a renal transplant, which lasted for 6 years. 
After a further 5 years on dialysis she had another renal transplant. After 5 years she 
presented with worsening renal function, low platelets and low haptoglobins. A biopsy 
of the renal transplant demonstrated TMA, shown in Figure 5-23. 
 
Figure 5-23 Biopsy of renal transplant from 1:2 of family 16. 
Graft biopsy from the mother demonstrated an occluded arteriole (PAS staining). 
The proband was found to have low C3 (0.56g/L, normal is 0.68-1.38g/L) and normal 
levels of C4 (0.19g/L), FH (0.39g/L) and FI (47mg/L). Testing for anti-FH  
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autoantibodies was negative. Routine MLPA screening found that they had 1 copy of 
CFHR1 and two copies of CFHR3. They were screened for all known disease- 
associated genes (CFH, CFI, CFB, MCP, C3, THBD and ADAMTS13) and no 
pathogenic sequence variants were found. Genetic analysis did not detect the C5 single 
nucleotide polymorphism (p.R885H) known to prevent eculizumab binding (Nishimura 
et al., 2014). Testing for cobalamin C disorder was normal. 
 
Figure 5-24 Pedigree of family 16.  
Family members with CMT, are shown in grey and aHUS in black. Proband is indicated by the 
arrow and ’*’ indicates all members tested by WES. Genotype was shown in bold. 
Due to the complex phenotype seen in this family, a gene list was created to see if there 
were sequence variants that may explain the observation of a renal and/or neurological 
phenotype. These gene lists can be seen in Table 45 and Table 46 of Appendix J. 
Screening of WES data for variants occurring in these genes, revealed a heterozygous 
change in exon 2 of INF2, c.305T>A, p.V102D. V102D was not reported in 1000g, 
ESP6500 or dbSNP. Autosomal dominant changes in INF2 have been previously 
reported in association with both CMT and a renal disease, FSGS. Combined with the 
absence of this variant from control populations, INF2 was considered a good candidate 
for disease. Sanger sequencing confirmed both affected individuals carried V102D in 
heterozygosity, the sequencing trace for the proband is shown in Figure 5-25. 
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Figure 5-25 Sequencing chromatogram of V102D in family 16. 
Sequencing chromatogram for control and proband (II:1), data for I:2 not shown. The amino 
acid sequence encoded by exon 2 is shown above. 
In light of this finding, the candidate gene lists for the three inheritance patterns from 
section 5.5, were reviewed and revealed that in the dominant analysis, a second family 
had an INF2 sequence variant, family 9.  
5.7.4. Family 9 
This family had two affected male offspring, both of whom presented with disease 
within the first year of life. The proband had recurrent disease, without developing 
ESRF. The proband (II:2) had low C4 (0.10g/L, normal range 0.18-0.6g/L) and normal 
C3 (1.18g/L), FH (0.72g/L) and FI (58mg/L) levels. MLPA indicated 0 copies of 
CFHR1/3 and screening for anti-FH autoantibodies was negative. Panel screening of 
complement genes (CFH, CFI and MCP) revealed no sequence variants. The serum 
levels in the deceased brother (II:1) were normal for C3 (0.63g/L) and FI (53mg/L). 
 
Figure 5-26 Pedigree for family 9. 
Proband is indicated by the arrow and ’*’ indicates all members tested by WES. Genotype was 
shown in bold. 
WES identified a sequence variant in exon 19 of INF2, c.2848C>T, p.R950W. It 
segregated in an autosomal dominant fashion and was reported in ESP6500 and 1000g 
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databases with MAFs of 0.04% and 0.05% respectively and was listed on dbSNP 
(rs199873407). Sanger sequencing confirmed that it segregated with disease, shown in 
Figure 5-27. 
 
Figure 5-27 Sanger sequencing trace for family 9. 
Sequencing chromatogram for control and affected patients (II:1 and II:2). The amino acid 
sequence encoded by exon 19 is shown above. 
5.7.5. Sporadic patient screening 
The finding of rare sequence variants in INF2 in two familial cases, led to the 
hypothesis that there may also be INF2 sequence variants within the sporadic aHUS 
population. In order to examine this, all coding exons of INF2 were screened by Sanger 
sequencing in sporadic aHUS patients. Exons 2-4 contain the majority of disease-
associated variants (Rodriguez et al., 2013, Mademan et al., 2013, Lee et al., 2011, 
Brown et al., 2010, Boyer et al., 2011b, Boyer et al., 2011a, Barua et al., 2013) so were 
screened in 161 patients and the remaining exons 5- 22 were screened in 96 patients. 
However this did not yield any rare sequence variants. Subsequent analysis of exome 
data for 18 sporadic patients identified a rare heterozygous sequence variant in sporadic 
patient 4. 
5.7.6. Sporadic patient 4 
Sporadic patient 4, now referred to as Sp4, presented with aHUS at age 28 and 
developed ESRF. She had a living related transplant from her mother and there was 
delayed graft function due to intra- and post-operative hypotension. A biopsy at day 6 
demonstrated features of acute tubular necrosis. By day 16 her creatinine had fallen to 
220µmol/L. At day 23 she represented with hypertension, anaemia (Hb 6.0g/dl), 
thrombocytopenia (platelet count 96x10
9
/L) and a blood film demonstrating MAHA.  
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Her tacrolimus levels were always within the normal range. A renal transplant biopsy 
demonstrated TMA and plasma exchange was commenced. Over the next months she 
received daily plasma exchange with fresh frozen plasma and a further 2 transplant 
biopsies demonstrated on-going TMA. Her renal function continued to deteriorate and 
haemodialysis was initiated. Serum levels of complement proteins C3 (0.97g/L), C4 
(0.26g/L), FH (0.50g/L) and FI (60mg/L) were normal. Anti-FH autoantibody screening 
and genetic screening (CFH, CFI, MCP, C3, CFB and DGKE) were negative. 
 
Figure 5-28 Pedigree for Sp4 
Proband is indicated by an arrow and ’*’ indicates all members tested by WES. Genotype was 
shown in bold. 
WES identified a heterozygous change in exon 4 of INF2, c.530G>A, p.R177H in Sp4, 
shown in Figure 5-29. This variant was not seen in 1000g, ESP6500 or dbSNP 
databases, however it was previously reported in patients with FSGS (Boyer et al., 
2011a, Gbadegesin et al., 2012).  
 
Figure 5-29 Sanger sequencing trace for Sp4. 
Sequencing chromatogram for control and affected proband (Sp4). The amino acid sequence 
encoded by exon 4 is shown above. 
Review of clinical data for this patient identified a family history of aHUS, however the 
proband will continue to be referred to as Sp4. The father (II:2), paternal uncle (II:3) 
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and cousin (III:2) all had a clinical diagnosis of aHUS. The father died at 25 years of 
age whilst on dialysis. III:2 presented age 36 with accelerated hypertension. A renal 
biopsy demonstrated very severe medial thickening and fibromuscular intimal 
proliferation with evidence of subacute arterial TMA. 8 glomeruli were sclerosed with a 
further two demonstrating segmental sclerosis. Serum levels of complement proteins C3, 
C4, FH and FI were described as normal. Anti-FH autoantibody screening and genetic 
screening (CFH, CFI, MCP, C3, CFB and DGKE) were negative. An updated family 
pedigree is shown in Figure 5-30. 
 
Figure 5-30 Updated pedigree for Sp4. 
DNA was available for a cousin (III:2) and Sanger sequencing confirmed that he was 
also a carrier of INF2, c.530G>A, p.R177H. 
 
Figure 5-31 Sanger sequencing trace for the affected cousin (III:2) of Sp4. 
Sequencing chromatogram for control and affected cousin (III:2) of Sp4. The amino acid 
sequence encoded by exon 4 is shown above. 
The finding of 3 rare sequence variants, suggested that INF2 was a good candidate for 
disease. They were found in two families and one sporadic case, which was later 
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demonstrated to be familial. Further analysis was performed to determine the predicted 
pathogenicity of the variants. 
5.7.7. In silico analysis 
To predict whether these three INF2 variants would cause a detrimental effect to the 
protein, several in silico tools were used. All variants were described as deleterious by 
PolyPhen-2 (HDIV and HVAR) and Mutation Taster, shown in Table 27. V102D and 
R177H were also classed as deleterious by FATHM and Radial SVM, whereas R950W 
was predicted to be tolerated. Finally Mutation Assessor classed V102D and R177H as 
having a medium impact on protein structure and function, whilst R950W was 
described as neutral. These predictions suggest that V102D and R177H may perturb the 
protein to a greater degree than R950W. 
Patient ID Variant 
In silico testing 
PolyPhen-2 Mutation 
Taster 
Mutation 
Assessor 
FATHM
M 
Radial 
SVM HDIV HVAR 
Family 16 V102D D D D M D D 
Family 9 R950W D D D N T T 
Sp4 R177H D D D M D D 
Table 27 In silico predictions for the INF2 variants found. 
D= deleterious, T= Tolerated, M= medium N= neutral. 
The sequence conservation was then examined for each sequence variant by aligning the 
amino acid sequence for human, human with mutation and 10 other species. V102 was 
the least conserved, maintained only in chimp and orangutan. The presence of a valine 
in zebrafish was unlikely to be due to conservation, because surrounding amino acids 
are dissimilar to the human sequence. If the evolutionary tree is examined , the branch 
for the primates is after vertebrates such as Platypus and opossum, placental mammals 
such as mouse, rat, dolphin and dog. This suggested that the conversion to valine might 
have occurred within primates only. R177 is conserved across all available sequences 
and R950 is conserved in all available species apart from opossum and platypus. 
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Figure 5-32 Protein sequence alignment of INF2. 
Amino acid sequence alignment, showing the amino acid substitutions in INF2. Human with and 
without the variant are compared to 10 other species. All nucleotides in bold, represent 
differences to the human reference sequence.  
The conservation scores calculated using GERP++ and PhyloP are shown below, in 
Table 28. Interestingly the GERP++ software described V102D as being most 
conserved, with a score of 4.76, compared to 4.48 and 2.53 for R177H and R950W 
respectively. This contrasts the results of the amino acid sequence comparison. 
Although it could be that V102 may be conserved across species that were not used in 
the alignment. R950W had the lowest conservation score using both programs, which 
suggested that it is in a region of INF2 that might be less critical to function. Indeed all 
mutations previously associated with CMT and FSGS are found in the DID domain, 
whilst little is known about the C-terminal portion of INF2.  
Patient ID Variant GERP++ PhyloP 
Family 16 V102D 4.76 1.777 
Family 9 R950W 2.53 0.91 
Sp4 R177H 4.48 2.027 
Table 28 Conservation scores for INF2 variants. 
5.7.8. Protein modelling 
Two amino acid substitutions were found in the DID domain of INF2, an area with 
known functional importance. To examine the position of these variants within this 
domain, protein modelling was carried out. Phyre2 created a predicted protein structure 
that was manipulated in PyMOL. This would allow the visualisation of V102D and 
R177H in relation to  the putatitive DAD binding site (amino acids R106, N110, A149, 
and I152). Figure 5-33 shows the predicted DID domain of INF2, annotated with the 
positions of V102D and R177H in relation to the amino acids involved in binding to the 
DAD. V102D was located close to the DAD binding site, particularly amino acid R106. 
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Although it was not present at the protein surface, it was predicted to disrupt the 
architecture of the 8
th
 α-helix of the DID domain. R177H resided before the 13th α-helix 
of the DID domain and was surface exposed. However it was found on the opposite face 
of the DID domain, in relation to the DAD binding site.  
 
Figure 5-33 Protein model of INF2 DID domain. 
Phyre2 was used to create a predicted protein model of INF2 DID domain, shown in grey. On 
the left is the DAD-binding site and on the right is the protein after a 180° rotation on y axis. 
Amino acids critical for DAD-binding (R106, N110, A149 and I152) are shown as blue spheres, 
V102D is shown as red spheres and R177H is shown in orange. 
Figure 5-34A shows all reported mutations in the DID domain of INF2 associated with 
FSGS only (blue) or FSGS and CMT (yellow). This figure demonstrated that the 
mutations associated with FSGS and CMT or FSGS alone, cluster in distinct regions of 
the protein. Rose et al. (2005) had previously reported that mutations occurring in 
patients with FSGS and CMT, were found in the central portion of the domain, closer to 
the DAD binding site. Our results show similar results, with V102D and R177H 
segregating with the two respective phenotypes. Figure 5-34B shows the same 
information however showing the protein in surface format. This figure demonstrated 
that sequence variants associated with these two phenotypes, were found equally on the 
protein surface. It was observed that there may be more sequence variants, associated 
with a neurological phenotype, seen on the opposite face of the DID domain, in relation 
to the DAD- binding site. This might indicate a possible interaction site with a protein 
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found in the nervous system only, however there was no evidence in the literature to 
corroborate this observation. 
 
Figure 5-34 Reported mutations in INF2 DID domain. 
Phyre2 model of INF2 DID domain showing mutations previously reported in the literature. A- 
Protein in a cartoon format. On the left is the DAD- binding surface and on the right is the 
protein rotated 180° on y axis. B- Protein in a cartoon format. On the left is the DAD- binding 
surface and on the right is the protein rotated 180° on y axis. Yellow- Mutations associated with 
CMT and FSGS. Blue- mutations associated with FSGS. Red- V102D. Orange- R177H. 
These models suggested that V102D may have a greater effect on INF2 autoinhibition, 
as it was located in close proximity to the DAD binding site. Whereas R177H is located 
on the alternate face of the DID domain, clustering with other FSGS-associated 
sequence variants.  
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5.7.9. Pathophysiology 
Podocytes are epithelial cells found in the glomerulus that are involved in formation of 
the GFB, along with the glomerular basement membrane (GBM) and fenestrated 
capillary endothelium (Swiatecka-Urban, 2013). Podocytes have complex structures 
that are dependent on the regulation of the cytoskeleton (Mathieson, 2012). Sequence 
variants in ACTN4 (Kaplan et al., 2000) CD2AP (Shih et al., 1999) and INF2 (Brown et 
al., 2010) lead to alterations to the  podocyte cytoskeleton, disrupting the GFB and have 
been found in association with nephrotic syndromes (Faul et al., 2007). 
The evidence demonstrated here indicated that INF2 sequence variants V102D, R950W 
and R177H were rare and predicted to be pathogenic. V102D and R177H were found in 
the DID domain, an area containing sequence variants associated with CMT and FSGS 
or FSGS alone. R950W occurred closer to the C-terminus, between the FH2 and DAD 
domains, which had not undergone the same degree of functional analysis. This made it 
difficult to postulate how it is involved in disease pathogenesis, unless it prevented the 
protein from being secreted or disrupted the depolymerisation activity, known to be 
reliant on the C-terminal domains of INF2. In addition the clinical history of family 9 
was very limited so it was unknown if there was a phenotype that would correspond to 
an INF2 defect.  
Functional analysis of R177H had been previously undertaken and was identified to 
disrupt INF2 cell localisation (Boyer et al., 2011b). In control conditions INF2 had a 
perinuclear localisation, however when HeLa cells were transfected with an R177H 
mutant construct, INF2 was found in the cytoplasm (Boyer et al., 2011b). These cells 
were found to have a disrupted actin cytoskeleton, which was thought to lead to disease 
formation by causing podocyte dysfunction (Boyer et al., 2011a).  
However INF2 does not explain how these patients acquire aHUS. The occurrence of 
three rare INF2 mutations, occurring in three separate aHUS cases, strongly suggested it 
was involved. INF2 disruption has been demonstrated to alter the intracellular transport 
of CD59 (Madrid et al., 2010), therefore one possible mechanism for disease could be 
that these sequence variants altered the expression levels of the cell surface regulator 
CD59. Podocytes are important in maintaining the integrity of the GFB, in part due to 
the secretion of VEGF (Eremina et al., 2008). It is well documented that VEGF 
inhibitors damage podocytes, predisposing patients to TMA (Eremina et al., 2008). 
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Therefore the podocyte damage occurring as a result of FSGS could alter VEGF 
secretion and thus lead to a prothrombotic phenotype. As a result INF2 may be a 
pleiotropic gene, causing both renal phenotypes (FSGS and aHUS). 
Yet there have been no reports in the literature of patients with INF2 mutations having 
TMAs. This included the 3 families with R177H mutations (Gbadegesin et al., 2012, 
Boyer et al., 2011a). There have been cases of patients with nephrotic disease who have 
later developed aHUS (Manenti et al., 2013).  This led to the hypothesis whether aHUS 
was actually a secondary phenomenon occurring after the FSGS-related damage, caused 
as a consequence of INF2 sequence variants. Manenti et al. (2013) found that of 248 
patients with the glomerulopathy, 6 developed aHUS. The underlying renal diseases 
were FSGS (1 case), MPGN (2 cases), C3 glomerulopathy (1 case) and small vessel 
vasculitis (2 cases). Then reviewing the literature they found a further 17 cases of 
nephrotic syndrome (FSGS- 8 cases, membranous glomerulonephritis (MGN)- 7 cases 
and minimal change disease- 2 cases), 17 cases of MPGN and 32 cases of vasculitis 
associated with aHUS. 
There is a known risk haplotype in CFH and MCP that has been shown to increase an 
individual’s risk of developing aHUS. The presence of additional risk SNPs may lead to 
increased complement activation and thus predisposing these patients to aHUS. Manenti 
et al. (2013) found that 4/6 patients with secondary TMA had CFH-H3 in homozygosity 
and 1/6 had MCPggaac in homozygosity with CFH-H3 in heterozygosity. It was 
hypothesised that the patients reported here might have these risk haplotypes. Therefore 
these patients were screened and the results are shown in Table 29 . 
Risk SNPs 
Genotype 
Family 16 Family 9 Sp4 family 
I:2 II:1 II:1 II:2 III:1 (Sp4) III:2 
CFH- H3 VV VV ND RR ND ND 
MCPGGAAC RV VV ND RV ND ND 
Table 29 Genotypes for Complement SNPs. 
V- variant allele, R- reference allele and ND- not done. 
The affected family members of family 16 were both homozygous for the CFH-H3 
haplotype and the proband (II:1) was also homozygous for the MCP risk haplotype. 
Only one affected member of family 9 was tested (II:2) and they were found to be 
homozygous for the reference CFH haplotype and heterozygous for the MCP risk SNPs. 
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It would be interesting to see if either the second affected individual from family 9 (II:1) 
or Sp4 also carried these risk SNPs. If they do then it might suggest that additional 
genetic variants are necessary to cause aHUS in patients with INF2 changes.  
It is unusual that these patients also had disease recurrence in renal allografts as it 
suggests a circulating factor is responsible. Since INF2 is an intracellular molecule it is 
difficult to propose a mechanism in which it would lead to disease recurrence post 
transplantation. Sp4 had a living related transplant from her mother, however it was 
thought that the INF2 variant was inherited from her father, who died at 25 years of age 
whilst on dialysis and who also had an affected brother and nephew. Therefore the 
possibility that the renal transplant also contained a genetic abnormality was low, 
although DNA testing of the mother was not carried out. Other studies have 
demonstrated FSGS recurrence post transplantation, including a patient with an INF2 
mutation (Gbadegesin et al., 2012). However there are several other potential causes of 
TMA in a renal transplant including post operative infections (Murer et al., 2000), anti-
rejection drugs (Zarifian et al., 1999, Ruggenenti, 2002) or acute rejection (Ponticelli 
and Banfi, 2006). Further work needs to be undertaken to determine the functional 
significance of these sequence variants and to try and elucidate a mechanism of disease 
in these individuals.  
5.8. Complement component 9 (C9) 
5.8.1. Gene 
Complement component 9 (C9) is located on chromosome 5p13 (Abbott et al., 1989) 
and encodes a 71kDa protein (Tegla et al., 2011). C9 is amphipathic, meaning that it 
contains a hydrophobic C-terminus and a hydrophilic N-terminus that allows it to be 
positioned within lipid bilayers (DiScipio et al., 1984). The complement system 
terminates in a common pathway that leads to the formation of MACs, of which C9 is a 
key component. 
The first step in MAC formation requires the formation of C5b from the cleavage of C5 
by a C5 convertase, produced from either the classical, lectin or alternative pathways 
(Walport, 2001a, Walport, 2001b). C5b can then bind to C6, followed by the addition of 
C7 and C8, shown in Figure 5-35A. At this point the complex is inserted into the cell 
membrane, due to the hydrophobic tail of C8 (Senior and Wallace, 2014). C9 then joins 
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the complex and self-polymerises to form a pore in the cell membrane, shown in Figure 
5-35B. Approximately 6-16 C9 molecules have been shown to be involved in pore 
formation (Podack et al., 1982). The formation of MAC is regulated by CD59, a 
membrane bound molecule that prevents C9 from interacting with the C5b-8 complex, 
or self-polymerising (Huang et al., 2006). 
 
Figure 5-35 Schematic diagram showing MAC assembly.  
A- Steps involved in MAC formation. C5b forms a complex with C6-8 and inserts into the cell 
membrane. C9 then binds and polymerises to form a pore structure.CD59, which inhibits MAC 
formation, is shown in yellow. B- The final structure of MAC. Figure is adapted from Bubeck 
(2014). 
The use of the candidate variant pipeline to look for rare, high impact, conserved 
sequence variants that segregated with disease, identified a sequence variant in C9 in 
one familial case. C9 was on the candidate gene list due to its involvement in the 
complement system, which was known to be involved in the pathogenesis of aHUS. 
Therefore this sequence variant was selected for further analysis. This section described 
the sequence variants found in C9 and how they were thought to cause disease.  
5.8.2. Family 1 
Family 1 has two affected siblings, both of whom have had disease recurrence after 
transplantation. The proband (II:1) has low C3 (0.63g/L) and normal C4 (0.29g/L), FI 
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(0.44g/L), and FI (68mg/L) levels. He had 2 copies of CFHR1/3 and no anti-FH 
autoantibodies. Sanger sequencing of C3, MCP, CFH, CFB, CFI and THBD revealed no 
sequence variants. 
 
Figure 5-36 Pedigree of family 1. 
Proband is indicated by the arrow and ’*’ indicates all members tested by WES. Genotype was 
shown in bold.  
WES found a rare sequence variant in exon 5 of C9, c.499C>T, p.P167S. This variant 
had a MAF of 0.32% in 1000g, 0.6% in ESP6500 and was listed on dbSNP, rs34882957. 
Sanger sequencing confirmed that this variant segregated with both affected siblings, 
shown in Figure 5-37. 
 
Figure 5-37 Sanger sequencing trace showing C9 P167S. 
This variant was a good candidate as it was rare, segregated with disease and was found 
within the complement system, the major pathway involved in disease pathogenesis. It 
had also been previously associated with another complement-mediated disease, Age-
related Macular Degeneration (AMD) (Seddon et al., 2013). Finally it was found in a 
family with disease recurrence post transplantation, suggesting a serum factor, which is 
in keeping with a C9 abnormality. Therefore to investigate the possibility that there may 
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be additional patients with C9 mutations, screening of sporadic aHUS cases was 
performed. 
5.8.3. Sporadic patient screening 
Firstly a panel of 96 sporadic aHUS patients were screened for exon 5 of C9 by Sanger 
sequencing. This screening led to the discovery of another P167S sequence variant in a 
sporadic patient, referred to now as Sp5. Two other patients were found to have 
c.607A>G, p.I203V. This was listed on dbSNP (rs13361416) and had a MAF of 3% in 
1000g and 2.7% in ESP6500. Due to the high MAF in both population databases, I203V 
was not further analysed. Secondly WES data for sporadic patients were reanalysed. 
This led to the discovery of C9, c.376G>A, p.G126R in a sporadic patient, referred to 
now as Sp6. This variant was listed on dbSNP (rs199939436) and reported in ESP6500 
database with a MAF of 0.01%. Both variants were confirmed by Sanger sequencing, 
shown in Figure 5-38. 
 
Figure 5-38 Sanger sequencing traces for C9 variants in sporadic cases. 
A- Sequencing chromatogram for Sp5, confirming the P167S change. B- Sequencing 
chromatogram for Sp6, confirming the G126R change. The amino acid sequence encoded by the 
exon is shown above. 
Sp5 presented at 15 years old with a rash and flu-like symptoms. She was positive for 
Measles virus and Parvovirus (serology was IgM positive). She had anaemia (Hb 
6.1g/dL), low platelet count (30x10
9
/L), MAHA (LDH 1489 IU/L) and no urine output. 
Complement serum levels were normal (C3 1.24g/L, C4 0.18g/L, FH 0.71g/L and FI 
81mg/L). Disease rapidly resolved. Figure 5-39A shows the pedigree for Sp5. 
Sp6 was a 38 year old female who presented with breathing difficulty from fluid 
overload, due to renal failure, requiring haemodialysis. She had no diarrhoea. Dialysis 
was discontinued after a year, due to some recovery of kidney function. 12 months later 
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a kidney biopsy showed chronic damage and her serum creatinine was elevated, which 
led to continuation of haemodialysis treatment. A year later she received a living related 
transplant from her unaffected brother. She had recurrent allograft HUS and despite 
plasma exchange, progressed to ESRF. It should be noted that the brother was not 
sequenced; therefore it was possible that he carried a sequence variant, which may be 
the cause of the disease recurrence. C3 and C4 levels were borderline low at 0.67g/L 
(normal 0.68-1.38 g/L) and 0.19g/L (normal 0.18-0.6g/L), respectively. FH and FI 
levels were normal at 0.46g/L and 62mg/L, respectively. MCP expression was normal 
and ADAMTS13 activity >10%. Routine genetic screening revealed that she had 2 
copies CFHR1/3 and no sequence variants in CFH, CFI, MCP, CFB, C3 or DGKE. 
Figure 5-39B shows the pedigree for Sp6. 
 
Figure 5-39 Pedigrees for Sp5 and Sp6. 
A-Pedigree for Sp5 and B-Pedigree for Sp6. Proband was indicated by the arrow. ‘*’ indicated 
sample was sent for WES. Genotype was shown in bold.  
The variants were then analysed using in silico tools, to determine whether they may 
affect protein structure and function.  
5.8.4. In silico analysis 
The sequence variants found in C9 were further analysed using in silico tools to predict 
whether or not a variant would be deleterious to the protein. The results are shown in 
Table 30. The two variants were predicted to be deleterious by PolyPhen-2 (HDIV and 
HVAR) and Mutation Taster. Neither variant was considered deleterious using Mutation 
Assessor, with a predicted impact of ‘Medium’. FATHMM and RadialSVM classed 
P167S as tolerated and G126R as deleterious.  
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Patient ID Variant 
In silico testing 
PolyPhen-2 Mutation 
Taster 
Mutation 
Assessor 
FATHM
M 
Radial
SVM HDIV HVAR 
Family 1, 
Sp5 
P167S D D D M T T 
Sp6 G126R D D D M D D 
Table 30 In silico predictions for C9 variants. 
D= deleterious, M= medium and T= tolerated. 
The protein sequences were then compared to multiple species, in order to determine if 
they were evolutionary conserved areas. The results of the sequence alignment can be 
seen in Figure 5-40. The sequence for Zebrafish was not available for comparison. Both 
amino acid positions were well conserved, P167S was maintained through to the 
opossum and G126R to platypus.  
 
Figure 5-40 Protein sequence alignment of C9. 
Amino acid sequence alignment showing the amino acid substitutions in C9. Human with and 
without the variant were compared to 10 other species. Grey indicates the position of either 
P167S or G126R. All nucleotides in bold, represent differences to the human reference 
sequence. Sequence not available in a species is represented with a ‘-’. 
In silico predictions for sequence conservation were made using GERP++ and PhyloP. 
The scores obtained also demonstrated higher sequence conservation for G126R 
compared to P167S, however both were considered to be evolutionary conserved. 
Patient ID Variant GERP++ PhyloP 
Family 1, Sp5 P167S 3.81 1.401 
Sp6 G126R 5.32 2.484 
Table 31 Conservation scores for C9 variants. 
To try and understand how these variants might affect C9 function, protein modelling 
was carried out. 
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5.8.5. Protein modelling 
The predicted protein structure of C9 was calculated using Phyre2 and viewed using 
PyMOL software. Figure 5-41 shows the polymerisation surface of C9 either as a 
cartoon (A) or as a surface (B) model. On this protein model neither P167S nor G126R 
reside close to the CD59 binding site, amino acids 366-371 (Huang et al., 2006). This 
suggested that these variants did not disrupt MAC regulation by CD59. One other 
hypothesis for their role in disease was that they improved the ability of C9 to 
polymerise, however the specific amino acids involved in polymerisation are not 
currently known. G126R was found on the protein surface so was thought to have a 
direct impact on C9 polymerisation, shown in Figure 5-41C. P167S was not present 
directly at the protein surface; however due to its close proximity, it was thought that it 
may also influence C9 polymerisation.  
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Figure 5-41 Protein model of C9. 
Phyre2 predicted protein model of C9. A- The polymerisation surface protein in a cartoon 
format and B- polymerisation surface in a surface format, shown at transparency 0.4. C- Figure 
B was rotated at 90° on  Y axis and shown at transparency 0.4. CD59 binding site was shown by 
yellow spheres, P167S is shown by red spheres and G126R is shown by blue spheres. 
The evidence described here demonstrated that C9 variants G126R and P167S were rare 
variants that were predicted to be deleterious. Modelling of mutations in the protein, 
suggested that they did not disrupt CD59 binding. Therefore an alternative hypothesis 
was that these variants enhanced MAC formation, by enhancing C9 polymerisation. The 
proposed mechanism through which these variants can cause aHUS, was described in 
the next section. 
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5.8.6. Mechanism of disease 
There are several diseases that have involvement of the terminal complement pathway 
in disease pathogenesis. These include Paroxysmal Nocturnal Haemoglobinuria (PNH) 
(Takeda et al., 1993) and AMD (Seddon et al., 2013). Insertion of adequate quantities 
of MAC into a cell membrane, leads to cell lysis. When complement activation is 
reduced, sublytic amounts of MAC can initiate intracellular signalling mechanisms 
(Cole and Morgan, 2003, Bohana-Kashtan et al., 2004). There has been a report of a 
patient with a CFH deficiency and low C9 levels (Falcão et al., 2008). Low C9 levels 
may be the result of deregulated complement regulation and thus increased terminal 
complement activity, leading to enhanced consumption of C9. Currently it is unclear 
whether C5a, C5aR or MAC is predominantly important in aHUS. Identification of a 
functionally significant variant in the last component of the terminal pathway would 
support the importance of MAC formation in disease. 
Witzel-Schlomp et al. (1997) first reported C9 deficiency as a result of compound 
heterozygous mutations in C9. These patients had recurrent bacterial meningitis (Zoppi 
et al., 1990). It has since been shown that C9 deficiency is common in the Japanese 
population, with one homozygote occurring in every thousand individuals (Horiuchi et 
al., 1998). There have been no reports of individuals developing TMA and it had been 
demonstrated that C9 deficiency conferred a reduced risk of developing AMD 
(Nishiguchi et al., 2012). This is fitting as both diseases are thought to occur as a result 
of complement over activation. Therefore the mutations in C9 reported here were 
predicted to be activating. This would result in a mutant MAC that had either increased 
formation or increased resistance to breakdown, to form what was termed here a ‘Super 
MAC’. This was predicted to have two possible effects; firstly increased cell lysis and 
secondly augmented sublytic signalling. The downstream effect of sublytic MAC 
signalling is shown in Figure 5-42 and reviewed below. 
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Figure 5-42 Schematic diagram of sublytic MAC signalling  
Intracellular signalling pathways affected by MAC insertion into the cell membrane. Direct 
interaction of MAC with TRAF6 or G-proteins can lead to downstream pathways culminating in 
Cell proliferation or apoptosis. The influx of Ca
2+
 into the cytosol has several effects that can 
result in cell proliferation or the increased expression of prothrombotic or proinflammatory 
molecules. Adapted from Cole and Morgan (2003). 
The PI signalling pathway has been demonstrated to be affected by MAC insertion. The 
loss of DGKε as previously described, led to increased PKC signalling, which was 
thought to mediate tissue injury (Lemaire et al., 2013). Several studies have shown that 
the addition of MAC to rat glomerular epithelial cells also caused increased PKC 
signalling (Carney et al., 1990, Cybulsky and Cyr, 1993). Therefore increased MAC 
sublytic signalling could cause tissue injury in a similar mechanism to DGKε functional 
deficiency. Some of these effects may be due to the rapid influx of Ca
2+
 into the cytosol 
(Carney et al., 1990), causing increased PLC activation and thus more DAG formation 
(Cybulsky and Cyr, 1993). However some studies have shown that increased expression 
of DAG was also due to the direct effect of MAC, where the addition of EGTA (a 
chelating agent), still resulted in PLC activation and DAG formation (Cybulsky et al., 
1989). In addition the treatment of HUVECs, coated in MAC, with sphingosine (PKC 
inhibitor) was shown to inhibit the release of vWF multimers from α granules in 
platelets (Hattori et al., 1989). This suggests that PI signalling might be up regulated in 
patients with C9 mutations, similar to what is seen in DGKε deficient patients. 
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Qiu et al. (2012) showed that MAC induced mesangial expansion in rats with anti-Thy1 
nephritis (a model for glomerulonephritis). The mechanism for this was based on MAC 
binding to TNF receptor-associated factor 6 (TRAF6) leading to the ubiquitination and 
phosphorylation of AKT1. This resulted in increased extracellular matrix (ECM) 
synthesis and proliferation of the mesangium. Additionally Halperin et al. (1993) 
demonstrated that MACs sensitize Swiss 3T3 cells to the mitogenic effects of platelet-
derived growth factor (PDGF) and that MACs can also induce cell proliferation in the 
absence of exogenous growth factors. A study by Benzaquen et al. (1994) also showed 
an increase in expression of PDGF and basic fibroblast growth factor, potent mitogens, 
when rat mesangial cells were treated with MAC. Finally activation of PKC (Kraus and 
Fishelson, 2000) and phospholipase A2 gamma (PLA2γ) (Elimam et al., 2013) by MAC 
has been shown to desensitize cells to complement-mediated lysis. As a result cells may 
continue to secrete prothrombotic or proinflammatory molecules. Increased cell 
proliferation may cause narrowing of the glomerular vasculature, potentially facilitating 
thrombus formation. However other studies have shown that MACs can lead to 
mesangial cell apoptosis (Nauta et al., 2002).  This was caused by MAPK signalling 
pathways, which up regulated caspase 3 expression (Nauta et al., 2002, Cole and 
Morgan, 2003). It is possible MAC activates different intracellular signalling pathways, 
resulting in alternative downstream cellular responses. 
Hansch et al. (1984) demonstrated that macrophages and monocytes treated with 
purified MAC components, led to the expression of proinflammatory molecules 
arachidonic acid, Prostaglandin E and thromboxane B2 and that these effects were 
independent of C3 and C5 cleavage products, C3a and C5a, which are known 
anaphylatoxins. They then replicated this study using platelets (Hansch et al., 1985). 
This may be mediated by induction of COX2 in a MAPK, PKC or calcium ion-
dependent mechanism (Takano et al., 2001, Noris et al., 2015). Other proinflammatory 
effects have been seen as a downstream effect of MAC formation. Lovett et al.(1987) 
found that treating mesangial cells with MAC increased interleukin (IL) 1β levels and 
Kilgore et al. (1997) reported the nuclear translocation of p65 in response to MAC, 
activating nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
signalling. Similarly the use of anti-CD59 antibodies on retinal pigmented epithelial 
cells saw the increase in secretion of IL- 6 and 8, monocyte chemoattractant protein-1, 
VEGF and matrix metalloproteinases (MMP) 2 and 9 (Lueck et al., 2011). MMPs 2 and 
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9 may alter angiogenesis and ECM regulation (Stamenkovic, 2003, Bandyopadhyay and 
Rohrer, 2012), which could predispose the vasculature of the glomerulus to thromboses.   
Prothrombotic effects of MAC include conversion of prothrombin into thrombin and 
increased platelet factor 4 release from platelets, which was not dependent on the lysis 
of cells (Wiedmer et al., 1986). Hattori et al. (1989) incubated HUVECs with sublytic 
quantities of MAC components and found that it led to the release of platelet α granules. 
Importantly they found that the presence of C9 was critical for this to take place. The 
content of these granules include coagulation and growth factors, chemokines and 
adhesive proteins, which would promote thrombus formation (Nurden, 2011). 
As stated previously there are two diseases associated with increased terminal 
complement activity, AMD and PNH. AMD is one of the most common causes of 
blindness in the elderly population, in the developed world (Hageman et al., 2005). Risk 
of AMD has been associated with mutations in complement genes, including CFH, CFI, 
C3 and C9 (Seddon et al., 2013, Hageman et al., 2005). These mutations were 
hypothesised to lead to increased complement activity in the eye, leading to local 
inflammation (Klein et al., 2005). Seddon et al. (2013) previously reported C9 P167S in 
association with an increased risk to AMD, with an odds ratio of 2.2. Schramm et al. 
(2014) proposed that deficiency of C9 would be protective against AMD, whereas 
P167S would increase risk. This association was good evidence for the potential role of 
C9 sequence variants in aHUS. Both aHUS and AMD are based upon complement 
deregulation, although the former is an acute disease and the latter is chronic. The 
tissues affected by both diseases, the glomerular basement membrane and Bruch’s 
membrane, are similar in that they are exposed and fenestrated basement membranes, 
suggesting a common susceptibility to complement dysfunction (Kelly et al., 2010). 
PNH is a clonal disorder of erythrocytes that contain sequence variants in PIGA, which 
encodes the glycosylphosphatidylinositol (GPI) anchor, necessary for anchoring 
complement regulators to the cell membrane (Takeda et al., 1993). It results in the  loss 
of complement regulators CD59 and CD55 and leads to excess complement activation 
and thus augmented lysis of erythrocyte (Wong and Kavanagh, 2015). These patients 
have an increased susceptibility to thromboses. When CD59 is blocked in rats they 
develop glomerular thromboses, similar to PNH patients (Nangaku et al., 1998). 
Eculizumab has been successfully used to treated patients with PNH, as it targets C5 
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preventing MAC formation and haemolysis (Hochsmann et al., 2014, Hillmen et al., 
2006). There has been a case in the literature of a patient with PNH combined with C9 
deficiency (Yonemura et al., 1990). The patient had a milder phenotype, indicating the 
importance of C9 in haemolysis. It was proposed that the C9 mutations reported here 
were not involved in CD59 binding; rather form a ‘Super MAC’ that caused increased 
cell lysis or increased sublytic signalling. It was also noted that there were no other rare 
variants, segregating with disease in genes encoding other components of MAC such as 
C5, C6, C7 and C8A/B/G, with the hypothesis that they could also lead to enhanced 
MAC formation. Further analysis of these C9 sequence variants is needed to determine 
whether or not these variants are functionally significant.  
5.9. Other gene candidates in literature 
There have been other gene candidates reported in the literature, to be associated with 
aHUS. This includes CFB (Goicoechea de Jorge et al., 2007), MMACHC (Lerner-Ellis 
et al., 2006) and THBD (Delvaeye et al., 2009). Screening of familial cases for rare and 
segregating sequence variants in these genes was negative, as described in 4.7. 
There have also been sequence variants were reported in Fukutin related protein (FKRP) 
in a Japanese familial case of aHUS (Watanabe et al., 2014). These variants were 
inherited in an autosomal dominant pattern, with affected individuals having disease 
onset in infancy. Autosomal recessive FKRP mutations have previously been associated 
with congenital muscular dystrophy (Hewitt, 2009), where mutant FKRP was unable to 
process dystroglycan (Esapa et al., 2002). The association of FKRP to a muscle 
phenotype suggested that the variants described by Watanabe et al. were less likely to 
be a cause of aHUS. Despite this, the families in this project were screened for sequence 
variants within FKRP. However this analysis yielded no rare candidate variants that 
segregated with disease.  
Bu et al. (2014) reported several rare sequence variants in coagulation genes, within the 
American aHUS cohort. These genes included coagulation factor XII (F12), 
plasminogen (PLG) and VWF. However no rare sequence variants that segregated with 
disease were found in the families analysed in this project (shown in Supplementary 
data). 
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A homozygous family originating from North Africa was described to have aHUS, with 
onset in adolescence (Lemaire, 2015). WES analysis identified a homozygous change in 
all affected offspring in a gene ST3GAL1, p.G288D. ST3GAL1 is a sialyltransferase 
that regulates the expression of sialic acid-containing carbohydrates and is highly 
expressed in the kidney (Kitagawa and Paulson, 1994). The removal of sialic acid 
components has been demonstrated to lead to reduced FH binding (Ram et al., 1998). 
The mechanism of disease in these patients was thought to be that loss of ST3GAL1’s 
sialyltransferase activity would lead to reduced cell surface expression of sialic acid-
containing carbohydrates. This would then reduce the amount of FH that can bind, 
decreasing complement regulation at the cell surface (Lemaire, 2015). Screening of 
exome data for all families in this study did not reveal any rare sequence variants in 
ST3GAL1 that segregated with disease. 
5.10. Families with no genetic candidates 
There were 19 families that did not have a genetic cause for disease before analysis 
using the exome candidate pipeline. After the discovery of novel disease candidates 
DGKE, INF2 and C9, the number of families with no known genetic cause of disease 
was reduced to 13. Therefore of the 28 families that were analysed in total, 54% had 
their genetic cause of disease identified. However this assumes that the novel genes are 
functionally demonstrated to be causative of disease, which has yet to be carried out.  
There were several reasons why no genetic candidate could be found in all the families 
tested. In some cases there was a lack of clinical data, which meant that some family 
members may have been treated as affected when they were not, for example the father 
in family 7 did not have TTP. There is also the possibility that there was consanguinity 
that was not known or disclosed. To try and avoid this multiple analyses were carried 
out using each mode of inheritance (autosomal dominant, autosomal recessive and 
compound heterozygous). Detailed clinical data was also critical in helping to further 
reduce the number of candidate sequence variants. For example family 16 had a very 
detailed phenotype, consisting of a combined renal and neurological phenotype, which 
identified INF2 as a good candidate for disease.  
Many families within this project only had DNA available for testing in one individual. 
This makes the analysis more difficult, because the final number of variants after 
filtering is higher, shown in Table 20. In addition the majority of the samples sent for 
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WES were affected family members. In the future it might be beneficial to undertake 
WES in unaffected family members, to identify variants that are restricted to affected 
individuals.  
For some samples the quality of the DNA was very poor, in some cases requiring WGA 
prior to WES. This has been demonstrated previously to lead to accurate sequencing 
(Hollegaard et al., 2013, Hasmats et al., 2014). However from the coverage data shown 
in Table 18, the percentage of the exome covered was much lower than in non-
amplified samples. This may result in candidate sequence variants being missed. 
There were also limitations to the technology used, for example WES only covers 1% of 
the genome; therefore disease-causing mutations outside of exome would not be 
detected. WES poorly sequences CG-rich or highly repetitive regions (Meynert et al., 
2014), which might result in loss of candidate sequence variants. In addition the capture 
step can introduce bias, preferentially capturing wild type alleles, which may lead to 
low coverage of candidate variants (Meynert et al., 2014). Finally in this project 
INDELs were removed from the analysis, due to their low detection accuracy (Fang et 
al., 2014). Therefore there is the possibility that this step has removed candidate 
variants, as was seen in family 13 for a sequence variant in DGKE. 
5.11. Discussion 
WES is a highly beneficial technology as it widens the search for genetic causes of 
disease. This is crucial as many patients do not present with ‘classical’ symptoms or in 
cases where diseases have overlapping phenotypes, patients might have been 
misdiagnosed. However it can generate large quantities of data that can make 
identification of disease candidates very difficult. In addition it only interrogates 
approximately 1% of genome; therefore it is possible that disease-causing variants have 
been missed.  
This is a very rare disease, which meant that there were few large recessive pedigrees in 
the Newcastle cohort, available for testing. 1359 genes were identified with rare 
sequence variants that segregated with 1 family. This makes it very difficult to 
differentiate sequence variants that directly cause aHUS from those that do not. One 
method of overcoming this could be to combine the WES data from the Newcastle 
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cohort with the data of other international and European cohorts. A larger sample size 
may allow for the detection of novel gene candidates for aHUS. 
The candidate pipeline used in this project was basic with scope for evolution, with the 
aim to discover the most obvious candidates for disease. In the future a more stringent 
approach to variant calling could be used. For example reducing the MAF threshold to 
0.1% in 1000g and ESP6500 or keeping variants that are classed as deleterious by more 
than one prediction program. This would further reduce the final number of candidate 
variants in the analyses, aiding candidate gene discovery.  
In silico tools were used to try and identify variants that may cause disease. They use 
various methods to assess the impact a variant may have on the protein structure and 
function; thus predicting whether or not it may be disease-causing. The detailed in silico 
results for known disease-causing variants, identified in this project, were shown in 
Appendix I and summarised below, in Table 32. In total, 6 variants occurring in the 
genes MCP, CFI and ADAMTS13 had been previously reported to be pathogenic. 5 of 
these variants were missense and had predictions from 6 in silico tools, whilst one was 
splice site variant and had one prediction score. Overall, none of the variants were 
predicted to be pathogenic by all 6 programs. PolyPhen-2 HDIV predicted all 5 
missense variants to be deleterious, Mutation Taster predicted 5/6 variants to be 
damaging and PolyPhen-2 predicted 4/5 variants to be detrimental to the protein. 
RadialSVM predicted 2 variants to be pathogenic, with Mutation Assessor and 
FATHMM only predicting one variant to be deleterious. The lack of agreement between 
the predictions of Mutation Assessor and FATHMM, with the in vitro data may suggest 
they were less accurate, although only a small number of variants were analysed. 
Overall these observations are similar to those found by Marinozzi et al. (2014), who 
previously used in silico tools to assess the pathogenicity of CFB sequence variants. 
They found that the predictions only corresponded with in vitro data for a third of 
variants analysed. However studies have shown that some in silico tools, such as 
PolyPhen-2, produce more accurate predictions for loss-of-function variants compared 
to gain-of-function (Leong et al., 2015), which is the case of CFB variants. It still 
remains that to fully understand how these sequence variants may cause aHUS, further 
in vitro or in vivo analysis is required. 
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Gene 
Sequence 
Variant 
Reference 
Deleterious in silico 
prediction scores 
MCP 
Y189D 
Fremeaux-Bacchi et al. 
(2006) 
4/6 
c.286+2T>G 
Fremeaux-Bacchi et al. 
(2006) 
1/1 
CFI I416L Bienaime et al. (2009) 4/6 
ADAMTS13 
I673F Matsumoto et al (2004) 3/6 
R1060W Camilleri et al. (2008) 3/6 
R507Q Veyradier et al. (2004) 3/6 
Table 32 In silico predictions of known disease-causing variants. 
This table shows sequence variants that have previously been shown to cause disease and the 
number of in silico tools that have predicted them to be deleterious. In silico tools assessed were 
PolyPhen-2 (HDIV and HVAR), Mutation Taster, Mutation Assessor, FATHMM and Radial 
SVM.  An in silico prediction for a splice site change was only available using Mutation Taster. 
In this project INDELs were actively selected against, due to detection inaccuracies. 
These can occur due to the PCR amplification of the library, particularly in regions of 
repetitive sequences, which can cause polymerase slippage (Krawitz et al., 2010). They 
can also occurring when there is an error during read alignment to the reference genome 
(Li, 2014). In the future it would be important to reanalyse data, specifically looking at 
INDELs. This is particularly true as technology improves and bioinformatic tools 
become more sensitive, rerunning samples may lead to more accurate variant calls, 
aiding discovery of pathogenic mutations. 
The occurrence of CNVs was investigated in the RCA cluster, however there is the 
possibility that they have occurred elsewhere in the genome. It is possible to utilise 
WES data to look for CNVs, by comparing the read depth between a sample and an 
unrelated control (Plagnol et al., 2012). This was not investigated here, but would be 
important to consider in the remaining families with no genetic cause of disease. 
Alternatively array comparative genomic hybridisation (CGH) could be carried out.  
Overall WES identified 3 genes that are predicted to be novel genetic causes for disease, 
based on in silico analysis. Firstly sequence variants were identified in DGKE. This is 
involved in the regulation of the PI signalling pathway. Sequence variants were 
identified in homozygosity or compound heterozygosity, suggesting complete absence 
of functional DGKε was necessary to lead to disease onset. Patients were noted to 
develop disease in infancy and had disease recurrence whilst on eculizumab treatment. 
Other studies have identified similar findings, supporting the hypothesis that this was a 
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disease-associated gene. Loss of DGKε was hypothesised to cause increased PKC 
signalling, leading to the formation of a prothrombotic environment in the glomerulus. 
However the exact mechanism of disease has yet to be elucidated and functional 
validation of the variants identified is required.  
The second novel genetic cause of disease was INF2. Several patients were identified to 
have sequence variants in this gene, which has been associated with renal and 
neurological pathologies. INF2 is involved in actin cytoskeletal regulation and genetic 
defects have been demonstrated to disrupt this, leading to podocyte dysfunction. R177H 
had previously been demonstrated to be functionally significant and V102D was 
positioned close to the DAD binding site so was hypothesised to be pathogenic. This 
was supported by the observation of a neurological phenotype in the affected family 
members. The combination of limited clinical information and lack of functional data 
meant that the pathogenicity variant R950W was unknown. One hypothesis is that INF2 
may be a pleiotropic gene, causing both renal phenotypes (FSGS and aHUS). Although 
cases of FSGS have been seen in association with aHUS, no mutations in INF2 have 
been reported in patients with the concomitant features. Admittedly the relatively recent 
discovery of INF2 mutations in FSGS may account for this. An alternative hypothesis is 
that aHUS may be occurring as a secondary phenomenon. The kidney damage caused 
by the INF2 defect in addition to complement risk SNPs was proposed to predispose 
these patients to a TMA. However there are other post-surgical complications that can 
lead to TMA post transplantation, which have to be considered. Functional work is 
required to determine the role of these sequence variants in disease pathogenesis. 
Finally rare sequence variants were identified in C9. These were hypothesised to lead to 
the formation of a ‘super MAC’ as a result of either enhanced C9 polymerisation or 
increased resistance to breakdown. The exact mechanism has yet to be elucidated in the 
context of aHUS; however the combination of these effects could create a 
prothrombotic environment in the glomerulus. Due to the association of the variant 
P167S with AMD, also mediated by complement over activation, it was hypothesised 
that it could play a role in the pathogenesis of aHUS. Whether P167S has a direct effect 
on disease onset or whether the presence of additional genetic factors are responsible for 
disease, has yet to be elucidated. Further interrogation of the WES data is needed to 
look for other sequence variants that may influence disease pathogenesis. The aHUS 
cohort could be screened for the remaining C9 exons, which may identify additional 
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candidate variants. The C9 sequence variants identified here require functional analysis 
to establish whether or not they are causative of aHUS.  
Overall there were 13 families remaining with no genetic candidate for disease. This 
may be due to limited clinical information, poor quality DNA, filtering out INDELs, the 
occurrence of a pathogenic sequence outside of the exome or problems with the 
technology. There had been other novel gene candidates reported in the literature as 
being associated with aHUS. This included FKRP, ST3GAL1 and coagulation genes 
F12, PLG, and VWF. However in this project no rare variants that segregated with 
disease were found in these patients. 
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Chapter 6: Discussion and Future work 
6.1. Summary 
The aim of this project was to elucidate the genetic cause of disease in aHUS patients, 
in whom no genetic cause had previously been identified.  
6.2. Hybrid CFH/CFHR3 gene causes aHUS 
A patient was found to have a deletion of the C-terminal exons of CFH, which was 
hypothesised to have occurred as a result of MMEJ. This led to aberrant splicing of 
CFH, where exons of CFHR3 were incorporated. This was confirmed in patient gDNA 
and evident in cDNA. Analysis of the serum identified a hybrid protein and a hybrid 
degradation product. Mass spectrometry confirmed the hybrid protein contained 
peptides that were identical to the FH/FHR3 reference sequence. Functional analysis of 
the patient purified FH mixture produced results that were consistent with a cell surface-
binding defect. This was predicted to be the result of the loss of the C-terminal domains 
of FH, which prevented FH from binding to GAGs on the cell surface. However it may 
also be in part due to the propensity for the protein to break down, as demonstrated by 
western blotting. 
6.3. High prevalence of genetic abnormalities in CFH and CFHRs 
Studies have identified that CFH is the most frequently observed gene defect, occurring 
in approximately 30% of aHUS cases (Kavanagh et al., 2013, Maga et al., 2010, 
Fremeaux-Bacchi et al., 2013, Noris et al., 2010). Review of all patients in the 
Newcastle aHUS cohort with a rare CFH defect (n=95), identified 36.8% had a genomic 
rearrangement or conversion between CFH and a CFHR. This most commonly occurred 
between CFH and CFHR1, which was thought to be due to the high sequence homology 
shared between the two genes. Gene rearrangements were the result of NAHR, with the 
exception of two hybrid genes occurring between CFH and CFHR3, which were the 
result of MMEJ. The high prevalence of gene conversions and rearrangements in this 
gene cluster, emphasised the importance of undertaking CNV analysis in aHUS patients, 
as gene rearrangements were not detected by Sanger sequencing. 
Approximately 41% of point mutations and INDELs were located in CCPs19-20 of 
CFH, an area critical for cell surface binding (Ferreira et al., 2009). This demonstrated 
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the importance of complement regulation at the cell surface in preventing onset of 
aHUS. Sequence variants occurring in CCPs 1-18 were high impact mutations, with 
57.7% comprising of nonsense, INDELs or affecting splice sites. Finally the majority of 
the sequence variants observed were heterozygous (96.8%), supporting previous 
evidence of CFH haploinsufficiency (Kavanagh et al., 2013, Maga et al., 2010, 
Fremeaux-Bacchi et al., 2013, Noris et al., 2010).  
6.4. Known genetic causes of TMA were identified 
28 familial cases with no known genetic cause of disease were analysed using a 
combination of Sanger sequencing and WES. In total 7 families had sequence variants 
in genes known to be associated with aHUS, which were CFH, MCP and CFI. All 
variants were observed in heterozygosity except for one family with a homozygous 
MCP sequence variant. All variants were rare and predicted to be deleterious by in 
silico tools.  
Two families were demonstrated to have compound heterozygous mutations in 
ADAMTS13 that were known to be functionally significant. Further detailed discussion 
with clinicians looking after these families, revealed a clinical phenotype in keeping 
TTP. The screening of familial aHUS cases yielded no rare sequence variants that 
segregated with disease in CFB, although rare, functionally significant sequence 
variants have been identified in the sporadic cohort. Screening of THBD in familial and 
sporadic cases did not identify rare variants that segregated with disease. Therefore no 
evidence was found in this cohort that supported THBD as being associated with disease. 
Finally no sequence variants were identified in MMACHC in either the familial or 
sporadic cohort, which might be due to the distinctive phenotype, which means that 
clinicians are not referring these patients to the national aHUS service. 
6.5. Novel gene candidates identified as disease-causing 
WES was used to look for novel genetic causes of disease in the remaining 19 families, 
with an unknown genetic aetiology. A filtering pipeline was used to reduce the number 
of candidate variants, in order to identify the most obvious candidates for disease. 
However there were caveats that may have led to the removal of candidate sequence 
variants. 
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DGKE was the first novel candidate gene proposed in this project. It was observed in 
multiple pedigrees, inherited in an autosomal recessive and compound heterozygous 
mode of inheritance. All variants were very rare and predicted to be deleterious by in 
silico tools. Loss of DGKε functional activity was proposed to lead to increased PKC 
signalling which would lead to formation of a prothrombotic environment and thus 
onset of disease. This gene has since been identified as a candidate gene for disease in 
other cohorts, supporting the findings reported here. Further functional work is required 
to demonstrate whether the variants identified in this study contribute to disease. 
INF2 has previously been demonstrated to cause FSGS with CMT or FSGS alone. Rare 
variants in INF2, which were predicted to be deleterious, were found to segregate in 3 
families with aHUS. Two variants were located in a mutation hot spot, one of which has 
been demonstrated to be functionally significant. The third variant arose in another 
region of the protein, which has not been functionally described and we cannot be 
definitive about its functional significance. This could be an example of genetic 
pleiotropy, where mutations in a single gene may lead to different phenotypes. However 
there is no evidence in the literature of patients with INF2 changes having a TMA 
phenotype. It was then hypothesised that the TMA was a secondary event occurring 
after the FSGS-related kidney damage, potentially due to concomitant presence of CFH 
and MCP risk haplotypes. However it is possible that aHUS was the result of post-
transplant milieu. Further analysis of the variants identified is required to establish 
whether they are causative of aHUS. 
Sequence variants were identified in C9 in 1 familial and 2 sporadic cases. All variants 
were rare and predicted to be deleterious by in silico tools. These variants were 
hypothesised to cause enhanced MAC formation, leading to increased cell lysis or 
increased sublytic signalling. One variant was previously associated as a risk variant in 
AMD, another disease caused by complement over activation. No other rare variants 
were seen in other components of MAC, such as C5, C6, C7 and C8A/B/G, with the 
hypothesis that they could also lead to enhanced MAC formation. However it is yet to 
be established as to whether these variants are involved in disease pathogenesis. 
6.6. Remaining families with an unknown genetic aetiology 
The genetic analysis carried out in this project did not identify candidate sequence 
variants in all families tested. There may several reasons why a candidate gene was not 
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identified, firstly a causal intronic variant would not be detected by WES. Secondly 
families are referred to the National aHUS service as having a clinical diagnosis of 
aHUS; however the lack of clinical data available may lead to the possibility that there 
are additional phenotypes that may indicate an alternative diagnosis. There are also 
technical issues with the technology used that may lead to loss of candidate variants, for 
example low sequencing coverage of regions that are GC-rich or contain repetitive 
sequences. Finally, screening of novel genes reported in the literature as being 
associated with aHUS, such as coagulation genes (F12, PLG and VWF) (Bu et al., 
2014), FKRP (Watanabe et al., 2014) and ST3GAL1 (Lemaire, 2015), revealed no rare 
sequence variants that segregated with disease. 
6.7. Final remarks 
In this project 28 families with an unknown genetic aetiology were analysed and in total, 
54% had their genetic cause of disease identified. However this assumes that all families 
in whom a novel candidate gene was identified, are functionally significant. The overall 
percentage of familial aHUS cases with no genetic cause of disease was reduced from 
55% in 2010, before the project commenced, to 27%, after completion of the project, 
shown in Figure 6-1. The discovery of novel disease candidates DGKE, INF2 and C9, 
comprised of 11% of the cohort, although this is subject to functional validation. Known 
TMA-associated gene ADAMTS13 was observed in 4% of the cohort. 
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Figure 6-1 Genetic cause of disease in 2010 and 2015. 
Pie charts showing the genetic cause of disease in familial aHUS cohort. The results are shown 
for the cohort in 2010 (before) and 2015 (after) completion of this project. This assumes that all 
sequence variants identified in novel genes are confirmed to be functionally significant. 
6.8. Future work 
In Chapter 3 functional analysis of the hybrid FH/FHR3 protein was performed using a 
haemolytic assay. This was carried out using OX24-purified FH species from control 
and patient. If more patient serum could be obtained, it would be interesting to perform 
the haemolytic assay using pure FH/FHR3 protein, rather than using a mixture of wild 
type and hybrid protein. The FH/FHR3 protein could be isolated using immunoaffinity 
chromatography, using the antibody specific to the CFH 402Y SNP, which was shown 
to be specific to the FH/FHR3 protein. 
Patients with sequence variants in known disease-causing genes, described in chapter 4, 
should have functional analysis performed to determine their effect on protein. This 
includes testing for changes to protein expression in patient samples. The function of 
mutations could also be tested in vitro, for example using techniques such as surface 
plasmon resonance to detect alterations in binding affinity and haemolytic assays to 
detect changes to complement regulation at the cell surface. 
Patients with DGKE sequence variants could be tested for absence of DGKε expression. 
For example Lemaire et al. (2013) used an immunohistochemistry method to stain 
kidney tissue with antibodies specific to DGKε. If kidney tissue was available from 
affected patients in this project, it would be interesting to examine any changes in 
DGKε staining in endothelial cells and podocytes. Further work should also be 
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undertaken to try and elucidate the mechanism in which DGKε deficiency causes aHUS 
and the functional significance of the sequence variants identified here. 
Three INF2 sequence variants observed in this project, one of which has been 
functionally analysed (R177H) (Boyer et al., 2011b). It would be important to perform 
functional analysis on V102D and R950W to test their ability to regulate the actin 
cytoskeleton and to see whether they have a comparable defect to R177H. This is 
particularly true for R950W, which occurs in a different region of the protein. In 
addition it is important to try and determine the mechanism that causes TMA and 
disease recurrence post transplantation in these patients.  
Sequence variants were observed in C9 that were predicted to lead to either enhanced 
MAC formation or increased sublytic signalling. An aHUS panel was screened for exon 
5 of C9; this should be extended to all other exons, as it may lead to the identification of 
further candidate sequence variants. It would be interesting to see if these patients have 
altered terminal complement activity. This could be tested for using patient sera, 
isolating patient C9 and testing it in a haemolytic assay. This would confirm if the 
mutant MAC alters the amount of cell lysis. Recombinantly expressed mutant C9 could 
be tested in vitro on a glomerular endothelial cell line to see if mutant MAC alters 
sublytic signalling, which may modify expression of prothrombotic and 
proinflammatory molecules or cell survival. Finally, it would be interesting to examine 
the remaining aHUS cohort for rare variants occurring in other components of MAC, 
such as C5, C6, C7 and C8, with the hypothesis that they also lead to enhance MAC 
formation.  
The remaining families with no genetic candidate for disease could be tested for array 
comparative genomic hybridization (CGH) or WGS, to look for potential intronic causal 
variants. However initially, further interrogation of the WES data is necessary to look 
for other sequence variants that may mediate disease pathogenesis. This includes 
analysis of INDELs and CNVs, which was not carried out in this project. The analysis 
of these families might become easier as more families with aHUS are recruited, 
increasing the sample size. 
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Chapter 7: Appendices 
7.1. Appendix A 
The following figures were reprinted from Challis et al. (2015), with permission from 
the publisher. The manuscript can be seen in Appendix J. 
Figure 3-2 Histological sections of patient renal biopsy. 
Figure 3-3 MLPA screening results 
Figure 3-4 Sequencing chromatogram of break point. 
Figure 3-5 Breakpoint sequence homology. 
Figure 3-8 Confirmation of CFH/CFHR3 cDNA product. 
Figure 3-10 Binding sites for anti-FH antibodies. 
Figure 3-11 Western blotting results of sera from proband and control. 
Figure 3-12 Mass spectrometry results. 
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7.2. Appendix B 
7.2.1. In house Sanger sequencing primer sequences 
Gene Exon Forward Sequence (5’  3’) Reverse Sequence (5’  3’) 
Annealing 
temperature (°C) 
Product size 
(bp) 
ADAMTS13 
1 CCCTGAACTGCAACCATCTT CAGCTAGCTCAGAATA 55 316 
6 CTGTTTTCTCTCACCGAGG TCAGCTCCTTGCCAGATC 55 210 
12 TACTGTAGGGTGCCATGTA CCAGAGCCTGAACCACTTTG 55 336 
13 CCCAGATGCAAAGGATGAAG ACTGCAGCTCCATCA 55 341 
17 TGGCCATGACAGTGACCCT GTGCTGTGGATGAGCCTTC 55 228 
21 CACACACGCCACTTCCTG CCACGTGTTCCCATATAGTCTG 55 360 
24 GGCTCAGTGGCTGCACTTTCC TCCAGCGTCCCCAAACCTAAG 55 576 
29 AAGGCTTCCGTGAGTGCTA AAGCCAGGTCTGGACAGCTTA 55 538 
C9 
4 GATACCTCACCTCCAGGGTTA CACCTATGTCCCTCGCACAAA 60 352 
5 GTGTTGTGGTATTTCCACTTCTG TCCAAACTACATCGCCTCTTC 60 330 
MCP 
5 TTGTGTACACCACCTCCA TTATACAGGAGGAGGAAGCA 55 306 
2 GAAGCTATGGAGCTCATTGG ATGCATTGTTATCTTGAACCTC 55 289 
CFH 12 CTCACTTTATTGTGGCATATGT CATGTATTGAGTACTGAATACCTGAG 55 417 
DGKE 
c.888+
40A>G 
CAGATGAAGGAAAATGTTGGA GGATGGCTTGAACCTGAGAA 60 398 
INF2 
2 TGGTGGCCAGGAGGACA CTGAAGCCTCATACCAGGTC 55 524 
3/4 TGCACAGGCATGGGAAG ATGCACTGGCCAAGAGGC 55 466 
5.1 CTCTGGGTGGCAGAAGTGA CCTTGTTCTAGTGGGCCTG 63 570 
5.2 GGACGCAAGATGGAGACA ACCTGAATGAACTGCATG 55 550 
6 TGGTACACTGGCGCTGAC CCCAGCCTCTGGACCTCA 60 300 
7 CACAGTCCTTAGTCCACCA GACCTCAGTGTCTGCCCA 60 260 
8.1 CTTCTCCCTTGACCCTGGA CCAGGCCTGGCAGGGGTG 60 448 
8.2 TAAGGCCCTCCCAACAGCA TCTCCCCAGCAGAGACCAG 60 448 
9/10 ACATCCTTTAGACCCTCT CCCAAGTCAGAAGGCTCA 55 464 
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Gene Exon Forward Sequence (5’  3’) Reverse Sequence (5’  3’) 
Annealing 
temperature (°C) 
Product size 
(bp) 
11 CTCGACTGTTCTGTGTCC CCTGTGGCTCACGGTTCA 60 377 
12 TGAACCGTGAGCCACAGG TTGGCACAGCCTCTTCTC 55 305 
13 CAGAGCCCTGTGCTGAGT CAGCCATTATGATACTGGC 55 284 
14/15 GCTCCGAACCAAGAGCCC ATGGGGGTATGGCCTCTAC 60 379 
16 GACCTTAATTGCTAAGGG TGCGCTGCAGCTGTGAGA 55 282 
17 TCAGAGTACAGCCTGCAGG AGACAGCACAGCCACTCG 60 320 
18 CTCTCACGGGACTGTCA AAAGGTGCCTCTGCCCAT 60 291 
19/20 CGACACAGCCATGTGGGC GACCATGAGGAGGCAGTG 60 546 
21.1 GGGCGTTCAGGTAGACAG CTCGTCCTCGTCCTCATC 55 582 
21.2 GAGGCCGACAGCACAAGTG TCCTGGGTGCCGCTGGAAC 55 371 
22 GAGTCAGGGTTGCTTCTG AGAAGCCAGGTTAGTGTC 55 217 
Table 33 In house Sanger sequencing primer sequences 
Primers were tagged with sequences specific for sequencing primers. The sequences for the forward and reverse primers were ‘GTAGCGCGACGGCCAGT’ and 
‘CAGGGCGCAGCGATGAC’ respectively. 
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7.2.2. Diagnostic lab Sanger sequencing primer sequences 
Gene Exon Forward Sequence (5’  3’) Reverse Sequence (5’  3’) 
Annealing 
temperature (°C) 
Product 
size (bp) 
CFH 
1 GGAGTGCAGTGAGAATTGGG CAACAATGTCAAAAGCCACTC 60 458 
2 CCTGTGACTGTCTAGGCATTTTT TTTTGTATTTGACTGGCAATAGTGA 60 434 
3 CCTTACATTCAATCTGTCTTC CCATCATAGTTAAACTTTCAGG 60 399 
4 GACACTCAGAATGGCATCGAG GATCAGGCTGCATTCGTTTTTG 60 390 
5 CCTCCAATCTTATCCTGAGGATG GCTGATATTCCTTAGAATGAACG 60 411 
6 CCTGATGGAAACAACATTTCTG CATAAATTAGCACTCTACTTTTG 60 409 
7 GCCATTTTGTATTATGCTAAGG CTTACTTTGTATATACAATAAGAC 60 442 
8 TTTCTTTCTGGAGAGCCTTCAT TTTGGTCACTTTGCTTGAACA 60 658 
9 TTAGTAACTTTAGTTCGTCTTCAG GGTCCATTGGTAAAACAAGGTG 60 486 
11 GGTTTTCAGTTACAAATGACTC GAAATTATATCAGCCCCCAC 60 417 
12 GCTTTTTCTTCTTAGAATGGG CAACATTCCTTAACAATTCCTC 60 395 
13 TCTGATGCCCCTCTGTATGACC CTTATTTCAGCAATTGTAAGATAAG 60 358 
14 GAAGAAAATCTTTCCATTTTACTG AAAATACAAAAGTTTTGACAAG 60 350 
15 ACTTGTCAAAACTTTTGTATTTTG GGAAATGTTGAGGCATATCTG 60 405 
16 GATTAAGTCATAATTTTACCATGC CACACATACCTATTACTTTTCC 60 392 
17 
GTGATAATTTATGAAACAGTTATTGATCTTT
C 
GTGATTGATTAATGTGCCTAGGTC 60 424 
18 GTATTTTATTTGTTTTTAACCCTTTGA CCTCACTTTGATAACAAGAGATTATTT 60 340 
19 GTGATGTCATAGTAGCTCCTG CTAGAGTCCCTGTTTACTTTC 60 419 
20 CGCTATTTTAGAATCCATTACATG GGCCTCCCAAAGTGCTGGG 60 379 
21 GTAACTGTTATCAGTTGATTTGC TAACCCTGCTATACTCCCCC 60 332 
22 TTCTTCCAGGACTCATTTCTTTC GTGAGTATTTTGTTACAAACAGTG 60 439 
23 CCTAATTCTCATACATTAAACATCG GACACAACCGTTAGTTTTCCAGGA 60 653 
CFI 
1 GGAAACAAGTTCCTATTGGTC CTTGTTCAGTTCAATGCCTCT 60 565 
2 AACACCATCCTCATCTGTACT TCTGATAGAAAGTATGGCATAC 60 495 
3 CGTCATGATGTTCAAAGCTCAC GGAAATTAATACACAGAAAGGTTAGG 60 395 
4 GTTTCTTACCTGCTACAGTAG TATTATTGCCTCTGTGACTGG 60 403 
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5/6 TCATGCCACCACTCCATAAA TTTACCTAAAGAAAAGTTTCAGAATCC 60 525 
7 CAGCTAGACATCCTACAATTC CATTAAAATATAAGACCAAAGAAC 60 307 
8 ACATGCCTTGGGGATTTTGTA GCTTGAATCAATTATATATATGCAAATG 60 307 
9 TACTAATGATTCCAGCCTGTC CTTATAATTACATCATCCTCCTGC 60 356 
10 GTCTTGCCATGGAAATATCTTAG GCTTTATCATCTGCCACAATC 60 297 
11 AAAGTGAAGTGTCAGAATTCCTATTTA GATGTTATGCTTCTCTCTGAGTGCT 60 553 
12 AAACACGCTAAGGAAGAGTTC ATTAGAGGAAGAAACCTGAGC 60 464 
13 TTGTTAAATGCCATGGAGGAG CGTTTTATTTCCATTAAATGGAACTC 60 403 
MCP 
1 CCGCCCTGGTGACTCGACGCACTT GTCCCCGCATTCCCCGCCACATAC 60 493 
2 AATCTTGCCAAGGGCCTTTCTG GTAGTGGAATATGTACCCCAAAATGTA 60 416 
3 TATATTCCCACCCATTCAAAAGA GAAAGCAAAATTAAGTTTACAGGAAT 60 334 
4 GTTTAAGAAACCACCCCCTCAAAC CTTAAAGTGTAAAGGGTGTAAAGGA 60 326 
5 AGAAACCCTATATTGACAAATTTATTG AGGAAGCACATACACCTGCTTTG 60 433 
6 CATTCCTTGTCTCTGTTCACACTG TTGTTTCTTTTCAGTTATTTTGTATGAC 60 428 
7/8 GTTCTTAGCACGTTATGTAC ATGGCTATACAAATGTCCTC 60 583 
9 ACACCCATCCTCACATTACTTTCA CTGGGGGAGGGATAGCATTAG 60 533 
10 CACAGAATGTTGTCACAGAAAATG GGATCCTATGTTTGGGCACCTC 60 413 
11 AATTGCGATTCAAGATGAGATT AAAAGCACATTTGGGAAGC 60 480 
12 ATTATGGGGAGTTGGATTTAGAT TGTTTTTATGTTGCAGTGATGTTA 60 473 
13 GAACCTAATTCTCAGCTTTC CCTCTTTGATATTTACTGCC 60 365 
C3 
1 GATAAAAAGCCAGCTCCAGC CACCCTGAATTCTACAGGGAC 60 290 
2 CACATCCGTGGAATGACAA GCTTAGAAAGGGAGAAGACAGA 60 373 
3/4 GGGACCCAGCCCAAGATC TTCCGGTGTGTCTTTCTCTG 60 526 
5/6 GAGAATGTCCAGACACAGGTC GGAGAGATGGCGTTGGT 60 489 
7 GGAGTCAGTGCCCAGAAC TCCCTCACCTGGCTCTT 60 229 
8/9 GTCTTCAGCACAGGCAGGAG ACCCCACTTTCACTCTGAGC 60 556 
10/11 TCTGAGGGAGGAGGTCTAAT CTGTACCGTCTTCCCAGTG 60 514 
12 GATTCGGGTGTGGGTATCC GGGATGGGGGAAGGAGTC 60 381 
13 GATCCCTCCCTGCGTTC AGAGAGAGAGAGAGAGGAGTAG 60 365 
14 TCTCCCAGGGCTGACTT GCCTCCGCCTCTTCTCA 60 279 
15 GGATCCCAATTGTCAGCCT GTGGAGGTGCTGTCTGT 60 268 
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16/17 GGAACACCCCCACCTCACAC TCCCTCCTCAGACAGGAGT 60 610 
18/19 CATGAGCCATGGCAACTG ATGACACTCAGACACCCT 60 604 
20/21 CCTGGCCTTGTCCACTC AGTACGAAGACCAGGAGC 60 603 
22/23 TCTGTGTGTCTGTCTGTTCTT GTTAAACACCTCCAGAATGAGAT 60 461 
24 AGTCCTCGCCTGTCCCTAAC TCAAATGAGGGGAGTGGCTA 60 494 
25 TCCACCTCCTCGTTCTGATC TGGACTCTGCAGGTCCAGG 60 423 
26 CATGGCAGTCTCTGGATCT TCGTGTTCATCCTGCGAG 60 315 
27 CACCTAGAAGAGACTCAGCC GACTGCAGTGATGTCTGTTATTG 60 379 
28 CAATGCCCACATGACCG TTCAGCCATGCATCTCCC 60 276 
29 ATGCATCTCTTTCTGAGCTTTC GGGCCTCAGTGTCTTCTCTA 60 366 
30/31 TCCCAGCTCTGATTTGAACC CCACCTGGTAAGATGGGAGA 60 620 
32/33 GGAACAGAAACCCACACCTG CTTGGAAAGTACTGAATATCATGGA 60 515 
34/35 TGCTGCTATGTGGGAATCAG CCAGAGACAAAAGCTGAAAGG 60 534 
36 GAGGGATCTGAGGGGTTGAAG TGAAGCCACACCATGACAAC 60 475 
37/38 GGAGGGAGGCCCTTATC ACAATTGGACACACACAGC 60 507 
39/40 CCCTCATGGTCAACCTAGC GGCGTGACAATGGTGTG 60 465 
41 CCACACCATTGTCACGC CTGGGGATTTCAGCCTCT 60 339 
CFB 
1 GCAGGGGAAGGGAATGTGA AAAGGCCAAGGAGGGAT 60 284 
2 TGCCTGATGCCCTTTATCT CACCCTAAAACTGCTCCTAC 60 522 
3 TACACCTAAGGCAGCCTTTC CGTCAGGGAGACAGCAA 60 319 
4 CTCTCTACCTTGCTCACGG GGAGAGAAGACAGTAGGATGG 60 333 
5/6 CCTGACACTCCCAGACAT GAAGATCAGCGAGATTCCATT 60 468 
7 GAAATCTCCCAATCACAGTATTCTAT TCCACCCTGAACCTCCT 60 393 
8 GGTCAAAGGGAAGTCCGTG GGAGAGATGAACAGCCAGCTA 60 439 
9/10 CCTTCCTCAACTTGCTCAC GGTGTAGAGGAAGAATGAATTACT 60 519 
11/12 ATCCCGTGGTCTTTCCCTTTC AGGATGGGTGGAGTGTAGGA 60 600 
13/14 TCCTACACTCCACCCATCCT CCCCTAAGCCCTTCTAGAGC 60 630 
15/16 CTGGCCCAGAACCTAGCTC CCAGAATCACCTGCAAGGAG 60 641 
17 GTTGTGCTACAAGTGCCCAAG CATGCTGACCACTTGGCATC 60 194 
18 GCCATGCTTCCAGGATTAG CCCAAAAGGATCTGGAACAC 60 328 
THBD 1.1 CTGTGCCCCTCTGCTCC TGGTGTTGTTGTCTCCCGTA 60 526 
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1.2 TCATTTCCTTGCTACTGAACG CACGCTGCAGTCCCAAG 60 582 
1.3 GCTCCCCTCGGCTTACAG CGTCCACCAGGTCGTAGTTAG 60 413 
1.4 ATACTGGAGCCCAGTCCGTG GTCACAGTCGGTGCCAATG 60 580 
1.5 GCACGGACATCGACGAG TTTGGTAGCAAAGCTGGGG 60 576 
DGKE 
2.1 AGCGGAGCCACCTTCACT GTCCAGGACCTTGGTGTCAT 60 522 
2.2 GTTCAGCCAGCCCACCTACT GCAGGCCTCTACACCACTCT 60 374 
3 TGCCAAATGTTATGGTAAGTAGTGA TTCCTGGCACCAATTCTTCT 60 420 
4 TCAAGGCATGGAAAATGTG CAGGTGATTAGTGACTTGAAGCAT 60 310 
5 CAGATGAAGGAAAATGTTGGA GGATGGCTTGAACCTGAGAA 60 430 
6 GCACAAGCTTTAGCAAAACAA TGGCACATTTCATCTACACAAG 60 414 
7 TTTGCATGCTCATATACGTGTG GTGCCGTATCTTGTGCAATG 60 272 
8 TGACTCAAGCTTAGGTGGAACC AAAACAGAGCAGGTAAATATTTCTGTA 60 330 
9 GGGAGCTTTGATACAGCGTATTT AGCATTTCTGTTTAAAAAGTCTTCA 60 275 
10 ATGAGAGGCCCTGAGTGAGA GAAAATTTGAGGAAAAATGTTAAAGTC 60 401 
11 AAGTTGATGGTCCAACTGTGTT GCTTAGAATTGGATTGGGACA 60 291 
12 GGTTAAGGGATTGTGGATGGT GCTGGTTTGGGGATGCTAT 60 459 
Table 34 Diagnostic Lab Sanger sequencing primers. 
Primers were tagged with sequences specific for sequencing primers. The sequences for the forward and reverse primers were ‘GTAGCGCGACGGCCAGT’ and 
‘CAGGGCGCAGCGATGAC’ respectively. 
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7.3. Appendix C 
7.3.1. In house MLPA primer sequences 
Gene Exon Left Primer (5’  3’) Right Primer (5’  3’) 
CFH 1 CACAATTCTTGGAAGAGGAGAACTG GACGTTGTGAACAGAGTTAGCTGG 
2 TGACAGGTTCCTGGTCTGACCAA ACATATCCAGAAGGCACCCAGGCT 
3 CGTTTTAGAAAGGCCCTGTGGACATCCTGGA GATACTCCTTTTGGTACTTTTACCCTTACAGGAGG 
4 GGTATCAATTGCTAGGTGAGATTAATTACCGTGA 
ATGTGACACAGATGGATGGACCAATGATATTCCTATATGTG
AAGG 
TAG 
5 GTGCAATGGAACCAGATCGGGAATA CCATTTTGGACAAGCAGTACGGTTTG 
6 CATGGGTTATGAATACAGTGAAAGAGGAGA TGCTGTATGCACTGAATCTGGATGGCGTCCGTTGCCT 
7 
GGTGACTACTCACCTTTAAGGATTAAACACAGAACTGGA
GATGAAATCACGTAC 
CAGTGTAGAAATGGTTTTTATCCTGCAACCCGGGGAAATAC
AGC 
8 CACATTCATTGCACACAAGATGGA TGGTCGCCAGCAGTACCATGCCTC 
9 GTACAGGGTAAATCTATAGAC GTTGCCTGCCATCCTGGCTACG 
10 
CAGAATGGGAAATGCTAATTCAGCTCCTCCAGGCAGCC
CAATGGG GCTGGTGGCTTTGAGATTATTAAACTCTTTCTCTGCTGC 
11 TGAAACATCAGGATCAATTACATGTGG GAAAGATGGATGGTCAGCTCAACC 
12 GAATGCCAGAACTAAAAATGACTTCACATGGTTTAAG CTGAATGACACATTGGACTATGAATGCCATGATGG 
13 ACCTAATTCCGTTCAGTGCTACC ACTTTGGATTGTCTCCTGACCTCC 
14 CAGTGAAGTGGTGGAATATTATTGCAATC CTAGATTTCTAATGAAGGGACC 
15 
GGAGGAGAGTACCTGTGGAGATATACCTGAACTTGAAC
ATGG CTGGGCCCAGCTTTCTTCCCCTCCTTATTACTATGG 
16 GGAAAAGAAGGATGGATACACACAGTCTG CATAAATGGAAGATGGGATCCAGAAGTGAACTGC 
17 GGCACAAATACAATTATGCCCACCTCCACCTCAGATTCC  CAATTCTCACAATATGACAACCACACTGAATTATCG 
  
 
1
8
0
  
18 CCATGTTCACAACCACCTCAGATAGAACAC GGAACCATTAATTCATCCAGGTCTTCAC 
19 GGAATTGATGGGCCTGCAATTGCAAAATGCTTAG GAGAAAAATGGTCTCACCCTCCATCATGC 
20 GGATGGAGCCAGTAATGTAACATG CATTAATAGCAGATGGACAGGAAGGC 
21 
CTTATATAGTGTCGAGACAGATGAGTAAATATCCATCTG
GTGAG 
AGAGTACGTTATCAATGTAGGAGC 
CCTTATGAAATGTTTGGGGATGAAGAAGTGATGTGTTTAAAT
GGA 
AACTGGACGGAAC 
22 CGTAAGTACTTTAATATTCACGTGGCTG GAAAAATCTCTGTGATGAGTCTGATATTTCACTGTTTG 
23 GGACAGCCAAACAGAAGCTTTATTC GAGAACAGGTGAATCAGTTGAATTTGTG 
CFHR5 1 GAGACTACCAAGCATGTTGCTCTTATTCAGTGTAATC CTAATCTCATGGGTATCCACTGTTGGGGGAGAAGG 
2 CCCAGGAACACTTTGTGATTTTCCAAAAATACACCATG GATTTCTGTATGATGAAGAAGATTATAACCC 
3 CAAATTATTTGCAACACAGGATACAGC CTTCAAAACAATGAGAAAAACATTTCGTGTG 
4 GTCATGTTCCAATTTTAGAAG CCAATGTAGATGCTCAGCC 
5 CCACCTCCTCAACTCTCCAATGGTGAAGTTAAG GAGATAAGAAAAGAGGAATATGGACAC 
6 
GGATACATACCTGAACTCGAGTACGGTTATGTTCAGCCG
TCTGTC CCTCCCTATCAACATGGAGTTTCAGTCGAGGTGAATTGC 
7 CAGATGTTCAGACATCTTCAGATACAG GCACTCAGTCTGTATAAACGGG 
8 
GGGAACAATTCTGCCCACCGCCACCTCAGATACCTAAT
G CTCAGAATATGACAACCACAGTGAATTATCAGGATGG 
9 
CCCATTATCAGTATATCCTCCAGGGTCAACAGTGACGTA
CCGTTGC 
CAGTCCTTCTATAAACTCCAGGGCTCTGTAACTGTAACATG
C 
10 GCTGTTGAATTCCAGTGTAAATTCC CACATAAAGCGATGATATCATCACCACC 
Table 35 In house MLPA probe hybridisation sequences for CFH and CFHR5. 
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7.4. Appendix D 
7.4.1. Diagnostic Lab MLPA primer sequences 
7.4.1.1. CFH, CFHR1, CFHR2, CFHR3 and CFHR5 
Gene Exon Left Primer (5’  3’) Right primer (5’  3’) 
CFH 
1 GAGTCTCTTTTAATCTTACCTTCTGCTACACAA 
ATAGCCCATAACATAAGGCAAATAATCTTTGCTAGAAGTC
TCATTTTTTGGATCT 
2 TCTGACAGGTTCCTGGTCTGACCA 
AACATATCCAGAAGGCACCCAGGCTATCTATAAATGCCG
CCCT 
3 TGGACATCCTGGAGATACTCCTTTTGGT 
ACTTTTACCCTTACAGGAGGAAATGTGTTTGAATATGGTG
TAAAAGCTGTG 
4 GGTATCAATTGCTAGGTGAGATTAATTACCGTGA 
ATGTGACACAGATGGATGGACCAATGATATTCCTATATGT
GAAGGTAGA 
6 CATGGGTTATGAATACAGTGAAAGAGGAGA TGCTGTATGCACTGAATCTGGATGGCGTCCGTTGCCT 
9 
CCTGTTATTTTCCTTATTTGGAAAATGGATATAATCAA
AATC 
ATGGAAGAAAGTTTGTACAGGGTAAATCTATAGACGTTG
CCTGCCATCCTGG 
Intron 10 GAAAGAAGCTGGTGCAGATAGGTAGTCA 
TATTTGGAACATCCAGAAAGTCAGTGACAAGTATGACTAA
CAGAAAATGCT 
Intron12 GCTTTGCAACTTTTGACTTGGACACATT 
ATGATTGAGTCGCCAATGGAAAATCAAAACTGGATATGT
GAAGTGTGGA 
13 CTGCAAACCAGGATTTACAATAGTTGGACCT 
AATTCCGTTCAGTGCTACCACTTTGGATTGTCTCCTGACC
TCCCA 
Intron15 CCCTCTACATCAGTGGTATAGCTGAGTGA 
CATGAGGTAGTCAGGGACTGAGTCAGGACGTAAATCTCA
TTGAC 
18 CACCTCAGATAGAACACGGAACCATTA 
ATTCATCCAGGTCTTCACAAGAAAGTTATGCACATGGGA
CTAAATTGAG 
23 TCAATACATAAATGCACCAAAAGTGATATCAATACATA 
AATGCACCAAAACTGATGAAATGTAGATACTTCTACAAGA
TG 
Down- GGAATAAGACAGACAAAACCACATGATTGCACTTATA TGCAATCCGTTGTAAAATATGGTGACTTTAGTTAAC 
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stream CA 
CFHR1 
Intron 1 CAGTAAAATATATTTCCCTCTGTTGAAGGATAATTCA 
ATTGAAATGGGAATTCCTCCATTTTAATGACCTTTAAAATT
TAAATGATCAAATCTAGG 
3 GCTGAACAATGCAAAATTCATCAGAGAGTTTCAG 
GTCCATGTGTAGTGATAATAGACTATAGCAATGCTTCTCA
CACAGAAGTGT 
5 CATTCAGCAGAATGGTTGTTCAATAATCTGTGAT 
TATTTTGTTACCAACAGCAAAATATCAGACTCATCACACT
GATTTTTCCAG 
6 CCAAATTCAGCTGATTCACCTGTTCTCA 
AATAAAGCTTCTGTTTGGCTGTCCACCTTAATGCTATGTT
ATAATTTTCCAT 
6 CCGAACTGGACACAACAGTTAGTTTTCCAAGT 
TTTAATATGGTGCTTTTAAGAAGAGAGCCACCGGTCTCA
GCTTA 
CFHR2 
Intron 1 
CACCAAGGTCTAGGATACTAATTAAACTATGTCTGTA
CT 
TGGAGTTTCGATCATTATGCTTTACCCTTTGATTTCCAAA
AAGTT 
2 GAGAAGGATATGCCAGACAAGATCATAAA CACTTGATAATCACAGGAGCAGTGACCAGAGGAGCTGG 
3 GAAGATAATCCCTTGAAGTTTAAGTAATACCTGTG 
TGTGGTTTATAGTATCGGGTTAGTTGACAAGAAATGGTTA
CAAAACTGAT 
4 TCATTCCTGTTGTCAGTATATGCTCCAGG 
TTCATCAGTTGAGTACCAGTGCCAGAACTTGTATCAACTT
GAGGGTA 
CFHR3 Up-
stream GTTTTCTTATGATTGCAGGATATTTAGTCCGAGGT AGAAAGGGACATAAACTAAAGGAAATCATTTAAATC 
Up-
stream 
TTCATTTCTAAGTTCTAGGATATTCAGGGTGGTAATC
T 
TGGCTCTCAGTGGTTGCTTTTAAGTTTCTGTAGGAGGGA
GAGAA 
1 TGGGTTTCCTGTGCTAATGGACAAGGTAAGTTA 
AAAGAGATCTAAACACTCAGCTTCCCTCTTAAATGTAACT
TCATGTAATATCTAG 
2 
CGAGATAAATTTTGATATCACCTTCTCTCAAACATTTT
CTTG 
TGGAATTACAGCAACCATAACTAGTTTCCTGATCCTGACC
TCT 
3 CATGTCTTTCTAAGTAACACGGACGACAG 
TCTCAGACTTGTCTATATTAACTGTGGCAAAATGTTTTTG
TCAACTTGTT 
Intron 4 CAATGTTATCATGAGTTTTGGGGGTTATATG 
AATTCCTACATTTCTAGAATACTGTTTTCAATTTCTATACT
TATCAAGGGCTCTGTG 
6 TAATAAGTTCAGTTGCACTTCCCCAACA TCACAGCAGAGATCATCAGGTGAGGTGATAAACGTGAAC 
6 TCTGGGGTATTCCACTATCCCTTCCCG ACACACTGCTTGAAATGATAGAATTGATGTATTTGCATTA
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TATCCCAA 
CFHR5 
1 CAGTGTAATCCTAATCTCATGGGTATCCA 
CTGTTGGGGGAGAAGGTAAGTTGAAAACAGATCCGAATA
TTTTA 
2 
CCAAAATACACCATGGATTTCTGTATGATGAAGAAGA
T 
TATAACCCTTTTTCCCAAGTTCCTACAGGGGAAGTTTTCT
ATTACTCCTGT 
3 GAAAAATGGTCATTCTGAATCTTCAGGACT 
AATACATCTGGAAGGTGATACTGTACAAATTATTTGCAAC
ACAGGATACAGC 
Table 36 Diagnostic lab CFH, CFHR1, CFHR2, CFHR3 and CFHR5 MLPA probe hybridisation sequences.  
SALSA MLPA probemix P236-A1 ARMD (MRC Holland). 
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7.4.1.2. MCP and CFI 
Gene Exon Left Primer (5’  3’) Right primer (5’  3’) 
MCP 1 CCAATTCGGCTCTTGCCACGCCCACCTGTCCTGCA GCACTGGATGCTTTGTGAGTTGGGGATTGTTGCGTCCCA 
Intron 1 GAGCAAAGGCACCAAGATGTGACACTA CTGGACTGCCAAGCTATTCAGTGTGGCAGAGTAGGGC 
3 CCTGCAAATGGGACTTACGAGTTT 
GGTTATCAGATGCACTTTATTTGTAATGAGGGGTAAGTTG
CTCCTTAGA 
5 GTCGTGCTGCTCCAGAGTGTAAAGGTA 
GTGTTTCAATTTATTTCCTTCTTCATTTGTAAATACTATGGA
AACATTT 
6 GATATCTGTTTTCCATTTTCGACTACTGGA 
AATCGACATTTGACCACTGGAAAATTAGAGAAACCTCAGA
ATTAATGGA 
7 CTGCTGCCTCCATCTAGTACAAAACCTCCAGCT 
TTGAGTCATTCAGGTTTAGTAGCTTCTTCCTTATATGTCTT
CTTCCT 
8 TGAGGCACTGGACGCTGGAGATT 
TTGTAGTGGAAGAAGTCGACACTGGAAAACAAAATAATAA
TGTA 
9 CAGAGTGTGGTGAGCATTCTTGTACATA 
CATCTTACATACTTGTGCAAATATATATGTAGGTTAAATTCT
AAGATGTGG 
10 CGTGTAGGTAATTAGTTTTTATGAGGTGCCCA 
AACATAGGATCCTTGGTAGGGTAAGATAACTTTCTTAAATG
CTGTGT 
11 CTCAGATGTTTGGGTCATTGCTGTGAT 
TGTTATTGCCATAGGTAAGTATCACAAATTTTGACACCACT
TAAGT 
12 TGCAGTAATTTGTGTTGTCCCGTACAGATA 
TCTTCAAAGGAGGAAGAAGAAAGGGTAAATTAAAGCATGT
TTCT 
13 CTTCTCTGTGGGTCTCATCAGTTAGGT 
ATGTGCTGAACAGAGGAAGAGAAAACGGCTGAATAAAATA
GTGACTTCA 
14 CATAAGAAGTGAGAGGACTCTGACAGCCA 
TAACAGGAGTGCCACTTCATGGTGCGAAGTGAACACTGTA
GTCTTGT 
CFI 
1 TACGGTAAATCTCTCTGGATTTCAGCCAA 
ATTCTTTCAGAGTTCAAAAGTACAAAGCTCTTTAGGAGGTT
TGTTCT 
Intron 1 GAACCTACTCAGACAAGGAAACTAGGGGA 
TTCAGAAAAGATGGAAAAGAAACCCATAGCACAGTGGGAG
TGGCTGC 
2 GAATGGCACTGCAGTGTGTGCAACTA ACAGGAGAAGCTTCCCAACATACTGTCAACAAAAGAGTTT
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GGAATGTCTT 
3 CATGCTCCAGCTGCTTTTGCATATGA 
ACATTGTCTTATCTTGGTCCACAAGTTTTACTTCAACTATT
CCCTCTGAATCT 
4 GTCTACATGTGCATTGCCGAGGAT 
TAGAGACCAGTTTGGCTGAATGTACTTTTACTAAGAGAAG
AACTATGGG 
5 GATGACTTCTTTCAGTGTGTGAATGGGA 
AATACATTTCTCAGATGAAAGCCTGTGATGGTATCAATGAT
TGTGGAG 
6 CAAGGCAAAGGCTTCCATTGCA 
AATCGGGTGTTTGCATTCCAAGCCAGTATCAATGCAATGG
TG 
9 CAGTGCCTGGACATGTGGCA 
TCCTTTATCAGCTAGAGGCTGGTAAATGTTTAACCTCTTGG
CCAGCC 
10 TGGTGGCTGTTGGATTCTGACTGCT 
GCACATTGTCTCAGGTAAAAGATGTCTTCAGTAAATTTTAG
ATTTCCC 
11 CCAGCCAGAAACGATGCATGTA 
TCATTAGGTTGGAATAGGTAAGGAGACCAGGGGACACAG
GCA 
12 CTGATGTGGTGGGAGGAGATGT 
TTGATAGGGGAAATACATACATCTTGACATCTTGGATAAAC
CACTTGG 
13 CACCTGGGAACTCTGGTTTTCCACAGT TTTCCCCCCAACTCACAACACCCCAGACATAAGTCACATT 
Table 37 Diagnostic lab MCP and CFI MLPA probe hybridisation sequences.  
SALSA MLPA probemix P296-A2 (MRC Holland). 
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7.5. Appendix E 
7.5.1. WES raw data 
7.5.1.1. Non-amplified samples 
Family ID Affected 
Mean 
coverage 
Total number 
of reads 
received 
Total number of 
reads mapped to 
reference 
genome (after 
removal of 
duplicates) 
Percentage of exome covered 
1x 
coverage 
5x 
coverage 
10x 
coverage 
20x 
coverage 
40x 
coverage 
1 
II:1 Y 77.5 114974982 98586935 97.3 95.9 94.3 89.1 68.3 
II:2 Y 85.4 134872396 114981021 97.1 95.9 94.6 91.0 75.4 
2 II:2 Y 76.3 112217406 95704007 97.1 95.6 93.6 87.4 65.5 
3 
II:3 Y 70.4 124133766 104459515 97.0 95.5 93.7 87.3 63.9 
II:4 Y 76.8 130534982 109001220 97.1 95.7 94.0 88.6 68.3 
4 
I:1 Y 73.7 121353664 101385367 97.1 95.5 93.5 87.0 64.3 
II:1 Y 68.7 117968364 98693616 97.1 95.6 93.7 87.1 62.3 
5 
I:1 N 88.9 139361596 133479064 97.4 96.3 95.2 91.7 76.6 
I:2 N 82.6 121274658 116839474 97.0 95.8 94.6 90.7 73.5 
II:1 N 73.4 123569540 102987732 97.1 95.6 93.8 87.6 65.1 
II:2 Y 75.7 122146926 102046946 97.0 95.5 93.6 87.8 66.8 
II:3 Y 103.3 147386324 131463134 97.4 96.5 95.6 91.6 73.5 
II:4 N 101.5 142635116 126757457 97.0 96.2 95.2 90.8 70.7 
6 II:1 Y 94.5 146038316 140311887 97.1 96.0 95.1 92.4 79.9 
7 
II:2 Y 87.1 134261126 128957859 97.4 96.3 95.3 91.8 75.4 
III:1 Y 82.0 124410752 119676674 97.0 95.8 94.7 90.9 73.5 
8 
II:2 Y 70.3 132421462 110974674 97.1 95.7 94.4 89.5 66.4 
III:1 N 78.2 136685376 113887522 96.9 95.7 94.4 89.9 70.2 
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9 
II:1 Y 79.7 141398536 118269985 97.4 96.2 95.0 90.7 71.6 
II:2 Y 70.9 126935304 105904339 97.3 96.1 94.6 89.1 65.5 
10 
II:1 Y 61.6 66099336 64971496 99.0 96.2 90.4 73.3 39.5 
II:2 Y 94.1 126630412 114746149 96.9 96.0 94.9 90.2 68.2 
III:1 Y 93.1 127921188 116003397 96.9 96.0 94.8 89.7 66.6 
III:2 Y 86.4 119136342 108482050 97.3 96.3 94.8 87.9 61.7 
11 VII:2 Y 100.7 139157236 125564757 97.4 96.5 95.3 90.4 69.9 
12 
II:2 Y 97.3 135221320 118392192 96.9 96.0 94.9 90.3 69.5 
III:1 Y 94.8 128595444 117158024 97.0 96.0 94.9 89.4 66.1 
15 
I:2 N 53.0 46400618 44141371 98.3 96.8 93.3 79.0 42.2 
II:1 Y 57.4 50080940 47759460 98.6 97.1 93.8 80.8 46.7 
16 
I:2 Y 57.9 63413530 62311388 99.0 95.9 89.5 70.9 36.2 
II:1 Y 67.6 70865504 69500893 99.1 96.7 91.7 76.9 44.4 
17 II:1 Y 57.2 62877906 61710104 99.3 95.8 88.8 69.8 35.6 
18 
II:2 Y 63.7 70540038 69139986 99.1 96.4 90.8 74.5 41.1 
II:1 Y 60.2 68329296 67192618 99.4 97.0 91.5 74.1 38.9 
19 
II:1 Y 58.7 63293332 62185955 99.0 95.5 89.0 70.6 36.8 
II:2 Y 61.2 54735214 52129022 98.3 97.0 94.4 83.4 50.6 
20 
II:1 Y 63.9 70205374 68717548 99.2 96.5 91.0 75.2 42.1 
II:2 Y 54.8 62194670 61247621 99.3 96.1 89.1 69.5 34.5 
21 
II:2 Y 61.2 60207124 59064387 99.0 96.3 90.8 74.7 40.8 
II:1 Y 61.7 61956088 60824939 99.0 96.8 91.7 75.9 41.5 
22 II:1 Y 58.8 58152316 57132907 99.4 96.9 91.4 74.5 39.3 
23 II:1 Y 51.1 50865124 49916523 99.1 94.6 86.5 65.9 31.7 
24 
II:2 Y 78.5 78146778 76396557 99.2 97.6 94.3 83.8 55.0 
II:1 Y 56.4 57423640 56404657 98.9 95.8 89.5 71.3 36.3 
25 I:2 Y 18.0 29944902 29976323 93.3 71.4 46.7 19.4 4.5 
27 II:2 Y 73.1 70287754 67909660 98.4 95.2 89.7 78.3 53.5 
Average 73.0 99723087.4 90507574.2 97.8 95.6 92.0 82.0 56.3 
Standard Deviation 16.7 35933194.4 29725819.4 1.2 3.7 7.2 12.4 16.6 
Table 38 WES raw data for non-amplified samples. 
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Y=Yes, N= No. 
7.5.1.2. Whole Genome Amplified samples 
Family ID Affected 
Mean 
coverage (x) 
Number of 
reads 
received 
Number of 
reads mapped 
to reference 
genome (after 
removal of 
duplicates) 
Percentage of exome covered 
1x 
coverage 
5x 
coverage 
10x 
coverage 
20x 
coverage 
40x 
coverage 
5 II:5 Y 35.4 42842532 42795642 47.8 23.4 18.6 14.3 10.2 
11 VI:5 Y 64.4 66501440 65676781 98.6 94.4 87.3 69.1 39.4 
13 II:7 Y 27.0 60670068 57010010 88.8 67.3 46.7 23.8 8.4 
14 II:2 Y 42.1 82457622 75375855 94.8 87.1 74.1 48.3 20.5 
Average 42.2 63117915.5 60214572 82.5 68.0 56.7 38.9 19.6 
Standard Deviation 16.0 16355994 13824960.1 23.5 31.9 30.5 24.7 14.2 
Table 39 WES raw data for Whole genome amplified samples 
Y=Yes, N= No. 
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7.5.1.3. Sporadic patients 
ID Affected 
Mean 
coverage 
(x) 
Number of 
reads 
received 
Number of 
reads mapped 
to reference 
genome (after 
removal of 
duplicates) 
Percentage of exome covered 
1x 
coverage 
5x 
coverage 
10x 
coverage 
20x 
coverage 
40x 
coverage 
Sp4 Y 62.4 61141134 58873293.0 98.3 95.5 90.6 80.2 55.3 
Sp6 Y 72.8 72516930 67704185.0 98.4 96.2 91.9 83.2 62.9 
Average 67.6 66829032.0 63288739.0 98.4 95.8 91.2 81.7 59.1 
Standard Deviation 7.3 8043902.5 6244383.6 0.0 0.5 1.0 2.1 5.3 
Table 40 WES raw data for sporadic patients. 
Y=Yes, N= No. 
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7.6. Appendix F 
7.6.1. Mass Spectrometry coverage data. 
7.6.1.1. 160kDa band 
MRLLAKIICLMLWAICVA EDCNELPPRRNTEILTGSWSDQTYPEGTQAIYKCRPGYRSLG 
 LEADER SEQUENCE                                      FH CCP1        
NV IMVCRKGEWVALNPLRKCQKRPCGHPGDTPFGTFTLTGGNVFEYGVKAVYTCNEGYQL 
                                               FH CCP2          
LGE INYRECDTDGWTNDIPICEVVKCLPVTAPENGKIVSSAMEPDREYHFGQAVRFVCNS 
                                                FH CCP3          
GYKIEGD EEMHCSDDGFWSKEKPKCVEISCKSPDVINGSPISQKIIYKENERFQYKCNMG 
                                                FH CCP4          
YEYS ERGDAVCTESGWRPLPSCEEKSCDNPYIPNGDYSPLRIKHRTGDEITYQCRNGFYP 
                                                FH CCP5          
AT RGNTAKCTSTGWIPAPRCTLKPCDYPDIKHGGLYHENMRRPYFPVAVGKYYSYYCDEH 
                                                FH CCP6          
FETPSGS YWDHIHCTQDGWSPAVPCLRKCYFPYLENGYNQNYGRKFVQGKSIDVACHPGY 
                                  H402Y         FH CCP7          
ALPKA QTTVTCMENGWSPTPRCIRVKTCSKSSIDIENGFISESQYTYALKEKAKYQCKLG 
                                                FH CCP8          
YVTADGE TSGSITCGKDGWSAQPTCIKSCDIPVFMNARTKNDFTWFKLNDTLDYECHDGY 
                                                FH CCP9          
ESNTGST TGSIVCGYNGWSDLPICYERECELPKIDVHLVPDRKKDQYKVGEVLKFSCKPG 
                                               FH CCP10          
FTIVGP NSVQCYHFGLSPDLPICKEQVQSCGPPPELLNGNVKEKTKEEYGHSEVVEYYCN 
                                               FH CCP11          
PRFLMKGP NKIQCVDGEWTTLPVCIVEESTCGDIPELEHGWAQLSSPPYYYGDSVEFNCS 
                                               FH CCP12          
ESFTMIGHRSI TCIHGVWTQLPQCVAIDKLKKCKSSNLIILEEHLKNKKEFDHNSNIRYR 
                                               FH CCP13          
CRGKEGWIHT VCINGRWDPEVNCSMAQIQLCPPPPQIPNSHNMTTTLNYRDGEKVSVLCQ 
                                               FH CCP14          
ENYLIQE GEEITCKDGRWQSIPLCVEKIPCSQPPQIEHGTINSSRSSQESYAHGTKLSYT 
                                               FH CCP15          
CEGGFRIS EENETTCYMGKWSSPPQCEGLPCKSPPEISHGVVAHMSDSYQYGEEVTYKCF 
                                               FH CCP16          
EGFGIDG PAIAKCLGEKWSHPPSCIKTDCLSLPSFENAIPMGEKKDVYKAGEQVTYTCAT 
                                                FH CCP17          
YYKMDGASNVTCINSRWTGRPTCR/QVKPCDFPDIKHGGLFHENMRRPYFPVAVGKYYSYY 
FHR3 CCP1 
CDEHFETPSGSYWDYIHCTQNGWSPAVPC LRKCYFPYLENGYNQNYGRKFVQGNSTEVAC 
FHR3 CCP2 
HPGYGLPKAQTTVTCTEKGWSPTPRCI RVRTCSKSDIEIENGFISESSSIYILNKEIQYK 
FHR3 CCP3 
CKPGYATADGNSSGSITCLQNGWSAQPIC INSSEKCGPPPPISNGDTTSFLLKVYVPQSR 
FHR3 CCP4 
VEYQCQPYYELQGSNYVTCSNGEWSEPPRCI HPCIITEENMNKNNIKLKGRSDRKYYAKT 
FHR3 CCP5 
GDTIEFMCKLGYNANTSILSFQAVCREGIVEYPRCE 
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7.6.1.2. 150kDa band 
7.6.1.3. 120kDa Band 
 MRLLAKIICLMLWAICVA EDCNELPPRRNTEILTGSWSDQTYPEGTQAIYKCRPGYRSLG 
 LEADER SEQUENCE                                       FH CCP1        
NV IMVCRKGEWVALNPLRKCQKRPCGHPGDTPFGTFTLTGGNVFEYGVKAVYTCNEGYQL 
                                               FH CCP2          
LGE INYRECDTDGWTNDIPICEVVKCLPVTAPENGKIVSSAMEPDREYHFGQAVRFVCNS 
                                                FH CCP3          
GYKIEGD EEMHCSDDGFWSKEKPKCVEISCKSPDVINGSPISQKIIYKENERFQYKCNMG 
                                                FH CCP4          
MRLLAKIICLMLWAICVA EDCNELPPRRNTEILTGSWSDQTYPEGTQAIYKCRPGYRSLG 
LEADER SEQUENCE                                       FH CCP1 
NV IMVCRKGEWVALNPLRKCQKRPCGHPGDTPFGTFTLTGGNVFEYGVKAVYTCNEGYQL 
                                                       FH CCP2 
LGE INYRECDTDGWTNDIPICEVVKCLPVTAPENGKIVSSAMEPDREYHFGQAVRFVCNS 
                                                       FH CCP3 
GYKIEGD EEMHCSDDGFWSKEKPKCVEISCKSPDVINGSPISQKIIYKENERFQYKCNMG 
                                                         FH CCP4 
YEYS ERGDAVCTESGWRPLPSCEEKSCDNPYIPNGDYSPLRIKHRTGDEITYQCRNGFYP 
                                                         FH CCP5 
AT RGNTAKCTSTGWIPAPRCTLKPCDYPDIKHGGLYHENMRRPYFPVAVGKYYSYYCDEH 
                                                         FH CCP6 
FETPSGS YWDHIHCTQDGWSPAVPCLRKCYFPYLENGYNQNYGRKFVQGKSIDVACHPGY 
                                        Y402H            FH CCP7 
ALPKA QTTVTCMENGWSPTPRCIRVKTCSKSSIDIENGFISESQYTYALKEKAKYQCKLG 
                                                         FH CCP8 
YVTADGE TSGSITCGKDGWSAQPTCIKSCDIPVFMNARTKNDFTWFKLNDTLDYECHDGY 
                                                       FH CCP9 
ESNTGST TGSIVCGYNGWSDLPICYERECELPKIDVHLVPDRKKDQYKVGEVLKFSCKPG 
                                                       FH CCP10 
FTIVGP NSVQCYHFGLSPDLPICKEQVQSCGPPPELLNGNVKEKTKEEYGHSEVVEYYCN 
                                                      FH CCP11 
PRFLMKGP NKIQCVDGEWTTLPVCIVEESTCGDIPELEHGWAQLSSPPYYYGDSVEFNCS 
                                                           FH CCP12 
ESFTMIGHRSI TCIHGVWTQLPQCVAIDKLKKCKSSNLIILEEHLKNKKEFDHNSNIRYR 
                                                        FH CCP13 
CRGKEGWIHT VCINGRWDPEVNCSMAQIQLCPPPPQIPNSHNMTTTLNYRDGEKVSVLCQ 
                                                        FH CCP14 
ENYLIQE GEEITCKDGRWQSIPLCVEKIPCSQPPQIEHGTINSSRSSQESYAHGTKLSYT 
                                                       FH CCP15 
CEGGFRIS EENETTCYMGKWSSPPQCEGLPCKSPPEISHGVVAHMSDSYQYGEEVTYKCF 
                                                     FH CCP16 
EGFGIDG PAIAKCLGEKWSHPPSCIKTDCLSLPSFENAIPMGEKKDVYKAGEQVTYTCAT 
                                                       FH CCP17 
YYKMDG ASNVTCINSRWTGRPTCRDTSCVNPPTVQNAYIVSRQMSKYPSGERVRYQCRSP 
                                                     FH CCP18 
YEMFG DEEVMCLNGNWTEPPQCKDSTGKCGPPPPIDNGDITSFPLSVYAPASSVEYQCQN 
                                                       FH CCP19 
LYQLEG NKRITCRNGQWSEPPKCLHPCVISREIMENYNIALRWTAKQKLYSRTGESVEFV 
                                                      FH CCP20 
 CKRGYRLSSRSHTLRTTCWDGKLEYPTCAKR 
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YEYS ERGDAVCTESGWRPLPSCEEKSCDNPYIPNGDYSPLRIKHRTGDEITYQCRNGFYP 
                                                FH CCP5          
AT RGNTAKCTSTGWIPAPRCTLKPCDYPDIKHGGLYHENMRRPYFPVAVGKYYSYYCDEH 
                                                FH CCP6          
FETPSGS YWDHIHCTQDGWSPAVPCLRKCYFPYLENGYNQNYGRKFVQGKSIDVACHPGY 
                                H402Y         FH CCP7          
ALPKA QTTVTCMENGWSPTPRCIRVKTCSKSSIDIENGFISESQYTYALKEKAKYQCKLG 
                                                FH CCP8          
YVTADGE TSGSITCGKDGWSAQPTCIKSCDIPVFMNARTKNDFTWFKLNDTLDYECHDGY 
                                                FH CCP9          
ESNTGST TGSIVCGYNGWSDLPICYERECELPKIDVHLVPDRKKDQYKVGEVLKFSCKPG 
                                               FH CCP10          
FTIVGP NSVQCYHFGLSPDLPICKEQVQSCGPPPELLNGNVKEKTKEEYGHSEVVEYYCN 
                                               FH CCP11          
PRFLMKGP NKIQCVDGEWTTLPVCIVEESTCGDIPELEHGWAQLSSPPYYYGDSVEFNCS 
                                               FH CCP12          
ESFTMIGHRSI TCIHGVWTQLPQCVAIDKLKKCKSSNLIILEEHLKNKKEFDHNSNIRYR 
                                               FH CCP13          
CRGKEGWIHT VCINGRWDPEVNCSMAQIQLCPPPPQIPNSHNMTTTLNYRDGEKVSVLCQ 
                                               FH CCP14          
ENYLIQE GEEITCKDGRWQSIPLCVEKIPCSQPPQIEHGTINSSRSSQESYAHGTKLSYT 
                                               FH CCP15          
CEGGFRIS EENETTCYMGKWSSPPQCEGLPCKSPPEISHGVVAHMSDSYQYGEEVTYKCF 
                                               FH CCP16          
EGFGIDG PAIAKCLGEKWSHPPSCIKTDCLSLPSFENAIPMGEKKDVYKAGEQVTYTCAT 
                                                FH CCP17          
  YYKMDGASNVTCINSRWTGRPTCR/QVKPCDFPDIKHGGLFHENMRRPYFPVAVGKYYSYY 
FHR3 CCP1 
 CDEHFETPSGSYWDYIHCTQNGWSPAVPC LRKCYFPYLENGYNQNYGRKFVQGNSTEVAC 
FHR3 CCP2 
 HPGYGLPKAQTTVTCTEKGWSPTPRCI RVRTCSKSDIEIENGFISESSSIYILNKEIQYK  
FHR3 CCP3 
 CKPGYATADGNSSGSITCLQNGWSAQPIC INSSEKCGPPPPISNGDTTSFLLKVYVPQSR 
FHR3 CCP4 
 VEYQCQPYYELQGSNYVTCSNGEWSEPPRCI HPCIITEENMNKNNIKLKGRSDRKYYAKT 
FHR3 CCP5 
  GDTIEFMCKLGYNANTSILSFQAVCREGIVEYPRCE 
 
 
Highlighted = Identified by mass spectrometry. ‘/’ = Break point 
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7.7. Appendix G 
7.7.1. Patient clinical data 
Family/ Sp 
Number 
ID 
C3 (0.68-
1.38 g/L) 
C4 (0.18-
0.6g/L) 
FH (0.35-
0.59 g/L) 
FI (38-
58mg/L) 
MCP FACS 
Anti-FH 
antibodies 
Genes screened Other tests 
1 
II:1 0.63 0.29 0.44 68 - Negative 
C3, MCP, CFH, CFB, 
CFI, THBD. 
AP100-N 
CH100-N 
CP100-N 
II:2 - - - - - Negative THBD - 
2 II:2 0.99 0.22 0.55/0.53 49  Negative CFI, CFB, CFH18-23 - 
3 
II:3 - - - - - - CFH 18-23 - 
II:4 - - - - - - CFH 18-23 - 
4 
I:1 - - 0.67 47 - Negative  - 
II:1 - - 0.61 46 - Negative CFH  - 
5# 
I:1 - - 0.55 53 - - - 
AP100-N 
CH100-N 
CP100-N 
I:2 0.67 - - 56 - - - 
AP100-N 
CH100-N 
CP100-N 
II:1 0.65 - - 52 - - - 
AP100-N 
CH100-N 
CP100-N 
II:2 - - - - - - CFH, CFI - 
II:3 - - - - - - CFH18-23 - 
II:4 - - 0.47 46 - - - 
AP100-N 
CH100-N 
CP100-N 
II:5 - - - - - - - - 
6 II:1 1.66 0.29 0.97 77 - - CFH18-23, MCP - 
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Family/ Sp 
Number 
ID 
C3 (0.68-
1.38 g/L) 
C4 (0.18-
0.6g/L) 
FH (0.35-
0.59 g/L) 
FI (38-
58mg/L) 
MCP FACS 
Anti-FH 
antibodies 
Genes screened Other tests 
7 
II:2 - - - - - - MCP, CFH, CFI, CFB - 
III:1 - - - - - Negative - - 
8 
II:2 1.01 0.14 0.55 57  - MCP, CFH, CFI - 
III:1 1.41 0.12 0.76 68 Normal Negative C3, CFB, CFH18-23 - 
9 
II:2 1.18 0.10 0.72 58 - Negative MCP, CFH1-17, CFI - 
II:1 0.63 - - 53 - Negative CFH - 
10 
II:1 1.63 0.55 0.77 83 - Negative - - 
II:2 0.98 0.28 0.58 39 - Negative MCP, CFH18-23 - 
III:1 1.79 0.4 0.74 61 - Negative - - 
III:2 1.71 0.53 0.87 70 - Negative - - 
11# 
VII:2  1.14 0.16 0.56 49 - - MCP, CFB, CFH, CFI - 
VI:5 - - - - - - CFH18-23 - 
12 
II:2 1.73 0.32 0.68/0.83 85 Normal Negative CFI - 
III:1 1.23 0.21 0.13/0.57 56 Normal ++ CFI - 
13# II:7 - - - - - - 
MCP, CFH, CFI, 
DGKE 
- 
14 II:2 - - - - - - CFI, CFH18-23 - 
15# 
I:2 - - - - - - - - 
II:1 - - - - - - - - 
16 
I:2 0.66 0.29 0.47 61 Normal  Negative 
C5 R885H, C3, MCP, 
CFH, CFI, CFB, DGKE 
- 
II:1 0.56 0.19 0.39 47 - Negative 
C5 R885H, C3, MCP, 
CFH, CFI, CFB, DGKE 
- 
17 II:1 - - - - - Negative  - 
18 
II:2 - - 0.70/0.68 63 - Negative CFH18-23 - 
II:1 - - 0.70 - - - CFH18-19 - 
19 
II:1 - - 0.7 - - Negative - - 
II:2 - - 0.6 - - Negative CFH18-23 - 
20 
 
II:1 - - - - - - - - 
II:2 1.25 0.33 0.57 51 Normal - - - 
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Family/ Sp 
Number 
ID 
C3 (0.68-
1.38 g/L) 
C4 (0.18-
0.6g/L) 
FH (0.35-
0.59 g/L) 
FI (38-
58mg/L) 
MCP FACS 
Anti-FH 
antibodies 
Genes screened Other tests 
21 
II:2 1.34 0.44 1.03 72 - - - - 
II:1 1.2 0.51 1.05 60 - - CFH18-23 - 
22 II:1 0.75 0.20 0.50 49 - - C3, CFH, CFI - 
23 II:1 - - - - - - CFH - 
24 
II:2 - - 0.61 - - Negative CFH18-23 - 
II:1 - - - - - Negative CFH,CFI - 
25 I:2 - - 0.56 - - Negative CFI, CFB - 
26# II:6 0.7 - - - - - - - 
27 II:2 1.33 - 0.45 - - - CFI - 
28 II:2 - 0.28 0.32 - - Negative - - 
Sp1# II:1 1.01 0.22 - - - - CFH - 
Sp2# II:1 1.64 0.81 0.72 69 Normal - CFH, CFI - 
Sp3# II:1 - - - - - - - - 
Sp4 II:1 0.97 0.26 0.50 60 - Negative 
C3, MCP, CFH, CFI, 
CFB, DGKE 
- 
Sp5 II:1 1.24 0.18 0.71 81 - - - - 
Sp6 II:1 0.67 0.19 0.46 62 Normal - 
C3, MCP, CFH, CFI, 
CFB, DGKE 
- 
Table 41 Clinical results for all patients. 
#= consanguineous. ‘-’= not available. 
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7.8. Appendix H 
7.8.1. Patient screening data 
Family/Sp 
Number 
ID 
Exome 
preparation 
In house MLPA NHS MLPA Western blot 
CFH CFHR5 CFHR1/3 CFI MCP CFH CFHR1/2, FHL CFHR4/5 
1 
II:1 1 N - 2 N N N N N 
II:2 1 N - 2 - - N N - 
2 II:2 1 N N 1 - - N - N 
3 
II:3 1 - - - N N - - - 
II:4 - - - - - - - - - 
4 
I:1 1 - - 2 - - - - - 
II:1 1 - - 2 - - N - N 
5# 
I:1 1 N N - - - N - - 
I:2 1 N N - - - N - - 
II:1 1 - - - - - N - N 
II:2 1 - N - - - - - - 
II:3 1 - N 2 N N - - - 
II:4 1 - - - - - - - - 
II:5 2*** - - - - - - - - 
6 II:1 1 N - 2 N N N - - 
7 
II:2 1 N N - - - - - - 
III:1 1 - - 1 - - N - N 
8 
II:2 1 N N - N N N - N 
III:1 1 N - 0 - - - - - 
9 
II:2 1 - N 0 N N N - N 
II:1 1 - - 1 - - N - N 
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Family/Sp 
Number 
ID 
Exome 
preparation 
In house MLPA NHS MLPA Western blot 
CFH CFHR5 CFHR1/3 CFI MCP CFH CFHR1/2, FHL CFHR4/5 
10 
II:1 2 - N 1 - - - - - 
II:2 1 - N 1 N N N - N 
III:1 1 N N 0 - - N - N 
III:2 1 N N - - - N - N 
11# 
VI:5 2** - - 2 - - - - - 
VII:2 1 N - - N N N - - 
12 
II:2 1 N N 1 - - N - N 
III:1 1 N - 0 N N - - - 
13# II:7 1* - - - - - - - - 
14 II:2 1* - - - N N - - - 
15# 
I:2 3 N - - - - - - - 
II:1 3 - N - N N - - - 
16 
I:2 2 - - - N N - - - 
II:1 2 - - - N N - - - 
17 II:1 2 - - - N N - - - 
18 
II:1 2 - - 2 - - - - - 
II:2 2 - - 2 - - N - - 
19 
II:1 2 - - - - - N - - 
II:2 3 - - - N N N - - 
20 
II:1 2 - - - N N - - - 
II:2 2 - - - - - - - - 
21 
II:2 2 - - - - - - - - 
II:1 2 - - - N N - - - 
22 II:1 2 - - 1 - - N - - 
23 II:1 2 - - 1 - - - - - 
24 
II:2 2 - - 1 - - - - - 
II:1 2 - - 1 - - - - - 
  
 
1
9
8
 
Family/Sp 
Number 
ID 
Exome 
preparation 
In house MLPA NHS MLPA Western blot 
CFH CFHR5 CFHR1/3 CFI MCP CFH CFHR1/2, FHL CFHR4/5 
25 I:2 2 - - 1 - - - - - 
26# II:6 - - - - - - - - - 
27 II:2 3 - - - - - - - - 
28 II:2 - - - - - - - - - 
Sp1# II:1 - - - - - - - - - 
Sp2# II:1 - - - - - - - - - 
Sp3# II:1 - - - - - - - - - 
Sp4 II:1 3 - - - - - - - - 
Sp5 II:1 - - - - - - - - - 
Sp6 II:1 3 - - - - - - - - 
Table 42 Screening results for all patients. 
1= Illumina TruSeq chemistry, 2= Illumina Nextera rapid capture exome, 3= Agilent SureSelect
XT
 Human all exon V5, *= WGA Sigma, **= WGA Qiagen repli-g, 
***= WGA Qiagen repli-g FFPE, #= Consanguineous, N= normal. 
 
  
 
1
9
9
 
7.9. Appendix I 
7.9.1. In silico data 
Gene 
Amino acid 
change 
Family or 
Sporadic 
number 
In silico testing 
PolyPhen-2 Mutation 
Taster 
Mutation 
Assessor 
FATHMM 
Radial
SVM 
GERP++ PhyloP 
HDIV HVAR 
CFH 
E625* 23 NA NA D NA NA NA 5.12 2.876 
C1152S 28 D D P H D NA NA 2.737 
MCP 
Y189D 4 D D N H T D 4.85 2.158 
c.286+2T>G 18 NA NA D NA NA NA 2.33 0.661 
c.286+2T>G 22 NA NA D NA NA NA 2.33 0.661 
F246I 26 D D P M T NA NA 0.729 
CFI I416L 27 D B D M D D 5.62 2.145 
ADAMTS13 
R7W 
7 
B B P N D T -6.55 -1.237 
D217H D D D L D D 4.69 2.161 
I673F D D D M T T 1.6 0.027 
A1033T D D D L T T 5.59 2.64 
R1060W D D D M T T 3.17 1.192 
Q448E 
24 
B B P N T T 4.25 0.678 
R507Q D D D M T T 5.42 2.535 
A900V B B P N T T 4.55 0.971 
DGKE 
T533P 20 D D D L T T 5.8 2.216 
R155G 
8 
B D D M D D 4.56 0.936 
L476P D D D M T T 5.36 2.15 
M1L Sp1 B B D NA T NA NA 3.313 
W322* Sp2 NA NA D NA NA NA NA 5.709 
K109E Sp3 D D D M D NA NA 4.553 
INF2 V102D 16 D D D M D D 4.76 1.777 
INF2 
R950W 9 D D D N T T 2.53 0.91 
R177H Sp4 D D D M D D 4.48 2.027 
  
 
2
0
0
 
Gene 
Amino acid 
change 
Family or 
Sporadic 
number 
In silico testing 
PolyPhen-2 Mutation 
Taster 
Mutation 
Assessor 
FATHMM 
Radial
SVM 
GERP++ PhyloP 
HDIV HVAR 
C9 
P167S 1,Sp5 D D D M T T 3.81 1.401 
G126R Sp6 D D D M D D 5.32 2.484 
Table 43 In silico predictions for sequence variants. 
Table shows the in silico predictions for the sequence variants reported in this project. Predictions could not be carried out on all variants, therefore are labelled 
NA (not available). Software is not able to calculate predictions for INDELs, so they were not included. B= Benign, D= deleterious, H= high, L= low, M= medium, 
N= neutral, P= polymorphism and T= tolerated. 
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7.10. Appendix J 
7.10.1. Known-TMA gene list 
CFH 
CFI 
MCP 
CFB 
C3 
THBD 
ADAMTS13 
MMACHC 
Table 44 List of genes known to cause TMA.  
7.10.2. CMT- associated genes 
AARS KARS 
AIF KIF1B 
AIFM1 KIF5A 
ALS11 LITAF 
AMOXAD LMNA 
AMY1 LRSAM1 
APOA2 MARS 
AT3 MED25 
BSCL2 MFN2 
C12orf65 MPZ  
CADM4 MTMR2/13 
CHM NDRG1 
DHTKD1 NEFL 
DNM2 PDK3 
DYNC1H1 PLEKHG5 
EGR2 PMP22 
FBLN5 PRPS1 
FGD4 PRX 
FIG4 RAB7 
GARS SBF1/2 
GBA SCN4A 
GDAP1 SH3TC2 
GJB1 SIMPLE 
HADHB SURF1 
HARS SMAD1 
HSP27 TRIM2 
HSPB1 TRPV4 
HSPB8 TRPVR 
INF2 YARS 
Table 45 List of genes associated with CMT. 
7.10.3. Genes associated with a renal phenotype 
ACTN4 LAMB2 
ADCK4 LMX1B 
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ADD3 MAL 
ALG1/13 MPV17 
ALMS1 MPZ 
ANLN MTTL1 
APOE MTTY 
APOL1 MYH9 
ARHGAP24 MYO1E 
ARHGDIA NPHS1/2 
CBS NEU1 
CD151  NXF5 
CD2AP PAX2 
CDC42 PDSS2 
CLCN5 PDCN 
COL4A3/4/5 PLAUR 
COQ2/6 PLCE1 
CRB2 PODXL 
CUBN PMM2 
CYP11B2 PTPRO 
DCLRE1B/C RAG1/2 
DGKE SCARB2 
E2F3 SEPT7 
EHD3 SHROOM3 
EMP2 SLC17A5 
FN1 SLC35A2 
FOXC2 SMAD7 
GLA SMARCAL1 
INF2 SYNPO 
ILK TCF21 
ITGA3 TRPC6 
ITGB4 TREX1 
JAG1 TTC21B 
JAK2 UMOD 
KAT2B WT1 
KLF6 ZMPSTE24 
Table 46 List of genes associated with a renal phenotype. 
7.10.4. Complement gene list 
C1QA C9 
C1QB CD55 
C1QBP CD59 
C1QC CFD 
C1R CFP 
C1S CLU 
C2 CPB2 
C4A CR1 
C4B CR2 
C4BPA FCN1/2/3 
C4BPB MASP1/2 
C5 MBL2 
C5AR1 SERPING1 
C6 SFTPA1/2 
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C7 SFTPB 
C8A SFTPC 
C8B SFTPD 
C8G  
Table 47 List of complement genes 
7.10.5. Coagulation gene list 
CPB2 KNG1 
F10 PF4 
F11 PLAT 
F12 PLAU 
F13A1 PLAUR 
F13B PLG 
F2 PLGRKT 
F2R PROC 
F3 PROS1 
F5 PROZ 
F7 SERPINB2 
F8 SERPINC1 
F9 SERPINE1 
FGA SERPINE2 
FGB SERPINF1 
FGG SERPINF2 
HRG TFPI 
KLK1 VWF 
KLKB1  
Table 48 List of coagulation genes. 
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7.11. Appendix J 
7.11.1. Published hybrid CFH/CFHR3 paper 
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